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Abstract 
African trypanosomes are extracellular protozoan pathogens that have evolved a complex and 
sophisticated interface with hosts to acquire nutrients and protect against the host immune 
system. The variant surface glycoprotein (VSG) forms a dense and dynamic protective coat, 
which serves to defend against the immunoglobulin-mediated host response. In addition, a 
unique set of receptors mediate uptake of host macromolecules and must comply with 
recognising ligands from a broad host range whilst also avoiding immune detection. Host 
transferrin (Tf) is acquired by trypanosomes through the expression of a transferrin receptor 
(TfR), which does not share homology with the host TfR. Multiple diverse copies of the TfR are 
present in the trypanosome genome but only one is expressed at a time. Several hypotheses 
revolve around the evolutionary advantage of multiplication and diversification of the receptor, 
falling into two main categories. Either the TfR repertoire serves to accommodate different Tfs 
from the wide vertebrate host range, or variation has arisen as part of an immune evasion 
strategy. To elucidate the complexities surrounding the receptor, two different TfRs were 
expressed as recombinant proteins to study receptor-ligand interactions at the molecular level.  
Biophysical analyses of binding interactions provided no evidence to support the hypothesis 
that the receptor repertoire had evolved to favour host promiscuity. Instead, a single receptor 
was capable of binding Tf from multiple different mammals, highlighting the lack of requisite to 
evolve species-specific receptors. Structural determination of the trypanosome TfR in 
conjunction with sequence variation mapping provided further evidence. The structure 
revealed a predominantly conserved Tf binding site, while variation and N-linked glycans 
resided in the surrounding accessible regions at the apical surface of the receptor, indicating 
that receptor evolution was likely driven by an immune evasion strategy. 
The findings presented in this thesis have served to further our understanding of the molecular 
architecture of the trypanosome cell surface by providing structural and biophysical data to 
define a complex host-parasite interaction. Therapeutic strategies have also been adapted 
through advances in our knowledge of the relationship between trypanosome and host. Finally, 
the trypanosome TfR is a remarkable example of evolutionary drift within a receptor, 
propagated by the advantage conferred by immune avoidance, and restricted by functional 
requirements of ligand uptake. Thus, the TfR repertoire has likely derived from an antigenic 
variation strategy to promote long-term persistence in the host. 
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Chapter 1      
 
Introduction 
 
 
 
1.1 African trypanosomes 
Trypanosomatidae are a family of unicellular protozoa that diverged from other eukaryotes 
approximately 500 million years ago (Lukeš et al., 2014). Within the family are the African 
trypanosomes, a group of extracellular pathogens with an interesting set of challenges, as the 
parasite must hijack nutrients from the host environment whilst also avoiding immune 
recognition. Trypanosoma brucei is the most studied group of African trypanosomes and is 
subdivided into three subspecies: Trypanosoma brucei (T. b.) gambiense, T. b. rhodesiense 
and T. b. brucei. While all three can infect vertebrates, the two former are the only primate-
infective African trypanosomes. Infection of animals causes a disease referred to as animal 
trypanosomiasis, or nagana, a wasting disease that can be lethal if left untreated. Nagana 
poses a huge economic burden in sub-Sahahran Africa due to loss of livestock. T. b. 
gambiense and T. b. rhodesiense are responsible for human African trypanosomiasis (HAT), 
commonly referred to as sleeping sickness. HAT is endemic in 36 countries in sub-Saharan 
Africa (Figure 1A).  T. b. gambiense HAT accounts for 97% of HAT cases and is predominantly 
an anthroponosis prevalent in West Africa. On the other hand, T. b. rhodesiense HAT is 
located in East Africa and is a zoonosis, with the large animal reservoir complicating reservoir 
control programs (Simarro et al., 2008). Recent efforts focussed on eliminating HAT have 
shown promising results, with fewer than 3000 cases reported to the World Health 
Organisation in 2015 (Figure 1B). The current trend of reported cases falls below the 
forecasted number of cases and suggests that imminent HAT elimination may be achievable. 
 2 
 
T. brucei is transmitted to the host via an insect vector, the tsetse fly (Glossina species). The 
parasite has adapted accordingly to proliferate in a variety of different environments such as 
the mammalian host bloodstream and tissues, and the insect vector midgut and salivary gland. 
T. brucei adopts a variety of different cell forms to maximise infectivity and survival in diverse 
settings. In its simplest form adapted for laboratory culture, the trypanosome life cycle can be 
compartmentalised into bloodstream-form cells that propagate in the mammalian host and 
procyclic-form cells that colonise the tsetse fly (Vickerman, 1985). Trypanosomes have 
evolved a sophisticated genome architecture to promote survival within the challenging 
environments. 
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Figure 1: HAT epidemiology. A, Geographical distribution of HAT cases reported in 2009 
(adapted from Kennedy, 2013). A black line depicts the separation between T. b. gambiense 
in West sub-Saharan Africa and T. b. rhodesiense in the East. B, Number of HAT cases 
reported to the World Health Organisation from 2008-2015 (from Fourth WHO report on 
neglected tropical diseases, 2017).    
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1.2 Genome architecture 
The T. brucei nuclear genome is primarily organised into 11 megabase chromosomes,  in 
addition to the lesser characterised ~5 intermediate chromosomes and more than 100 mini-
chromosomes (Berriman et al., 2005). The large number of chromosomes results in over 250 
telomeres, which were found to encode most of the variant surface glycoprotein (VSG) genes 
in sub-telomeric arrays. A small group of VSG genes are located in organised telomeric 
expression sites (Müller et al., 2018). The VSG (Mr = 50,000 – 65,000) is the major cell surface 
protein in trypanosomes, forming a dense and dynamic coat of 1x107 VSG copies (Bartossek 
et al., 2017). The inherent instability of telomere-proximal regions has resulted in multiplication 
and diversification of VSGs, with identification of more than 1500 different VSG genes 
throughout the genome. Many reside as incomplete genes, with more than 80% of the 
‘VSGnome’ composed of pseudogenes, and recombination is required to form a functional 
VSG (Cross et al., 2014). The large and diverse repertoire of VSGs underpins the success of 
antigenic variation in trypanosomes.  
Telomeric expression sites, referred to as bloodstream expression sites (BESs), encode VSG 
and a set of expression site associated genes (ESAGs) which have also arisen through 
duplication and diversification (Hertz-Fowler et al., 2008). A typical BES contains an RNA 
polymerase (pol) I promoter in proximity to the ESAG7 and ESAG6 genes, an array of other 
ESAG1-12 genes, and a VSG encoded at the 3’ end (Figure 2). DNA repeats are also present 
within intergenic regions, contributing to the instability of the telomeric region. Through 
duplication events, the set of genes has multiplied to occupy approximately 15 different BES 
with conserved architectures in the L427 isolate (Hertz-Fowler et al., 2008). Over time, the 
ESAG and VSG genes have diversified between expression sites. While the function of most 
ESAGs remain unknown, the ESAG6 and ESAG7 genes were shown to encode the two 
subunits of the trypanosome transferrin receptor (TfR) (Salmon et al., 1994) (Steverding et al., 
1994). Only one VSG and TfR are expressed at a time, governed by tight regulation at the 
transcriptional level. 
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Figure 2: Organisation of a typical BES. Schematic representation of a BES encoding VSG and ESAG1-11 genes or pseudogenes, adapted 
from Hertz-Fowler et al. (2008). At the 5’ end, 50 bp repeats are often located upstream of the RNA pol I promoter, while VSG is flanked with 70 
bp repeats at the 5’ end and telomere repeats at the 3’ end. Interspersed between promoter and VSG are the ESAG genes, which can range 
from ESAG1 to ESAG12.  
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1.2.1 Dynamics orchestrated at the transcriptional level 
Chromosome internal protein coding genes are transcribed by RNA pol II, while the ~15 BESs 
are transcribed by RNA pol I (Kooter & Borst, 1984) (Günzl et al., 2003), a polymerase usually 
reserved for transcription of ribosomal DNA in eukaryotes. In trypanosomes, RNA pol I is 
localised in a discrete extranucleolar structure, named the expression site (ES) body (Navarro 
& Gull, 2001). The ES body imposes stringent restrictions on expression, with only one BES 
expressed at a time to maintain mono-allelic VSG expression. Recent studies have shown 
that under antibiotic selection, two BESs can occupy the same ES body, yet this process is 
reversible once the selective pressure is removed (Budzak et al., 2019). The factors controlling 
allelic exclusion of other BESs under normal conditions remain unclear. The active BES is 
transcribed as a polycistronic unit and subsequently trans spliced and polyadenylated to 
produce mature mRNA transcripts (reviewed by Vanhamme and Pays, 1995). VSG and 
ESAGs are constitutively transcribed as polycistronic units, yet expression levels of the 
different proteins vary dramatically, which prompted an investigation into post-transcriptional 
regulation in trypanosomes. 
 
1.2.2 Dynamics orchestrated at the post-transcriptional level 
The VSG accounts for more than 90% of T. brucei cell surface proteins (Grünfelder et al., 
2002), yet it is transcribed at the same rate as other less represented proteins such as the 
TfR. This raises an interesting question of how trypanosomes achieve different levels of 
protein expression given that regulation is not controlled by transcription. Cis-acting elements 
that affect mRNA stability and translation have been identified in the 3’ untranslated region 
(UTR) (Furger et al., 1997) (Webb et al., 2005). In addition, a codon bias in which certain 
codons favour mRNA stability has been reported (Nascimento et al., 2018) (Jeacock et al., 
2018). Together, these findings explain some of the differences observed in protein expression 
levels, although the entire process is still yet to be resolved.  
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1.3  Innate immunity 
1.3.1 Primate resistance to T. b. brucei infection 
Some primates have evolved to combat T. b. brucei infection through the assembly of two 
innate immune complexes, trypanosome lytic factor 1 (TLF1) and TLF2. The complexes 
contain two primate-specific proteins, apolipoprotein L1 (apoL1) and haptoglobin-related 
protein (Hpr), associated with high density lipoprotein (HDL) particles in TLF1, and IgM in 
TLF2 (Raper et al., 1999). While initial studies suggested that Hpr may be the trypanolytic 
component (Smith et al., 1995), it was later found that Hpr mediated specificity by targeting 
TLF to the T. brucei haptoblobin-haemoglobin receptor (TbHpHbR) (Vanhollebeke et al., 
2008). Hpr shares 91% amino acid identity with haptoglobin (Maeda, 1985) and associates 
with haemoglobin (Nielsen et al., 2006). Molecular mimicry results in uptake of TLF via 
TbHpHbR-mediated endocytosis (Vanhollebeke et al., 2008). The trypanolytic factor was 
identified as apoL1 (Vanhamme et al., 2003), a pore-forming protein owing to the lytic capacity 
of TLFs. It was originally suggested that insertion of ApoL1 in the endosomal membrane 
resulted in the formation of an anion-selective pore which triggered osmotic swelling of 
lysosomal compartments, followed by cell lysis (Pérez-Morga et al., 2005). However, more 
recent work has shown that the pores are cation-selective and pH-dependent (Thomson & 
Finkelstein, 2015). At acidic pH, apoL1 is inserted into endocytic vesicle membranes, forming 
a low conductance pore. As the endosome is recycled to the cell surface, neutral pH increases 
the conductance of the pore by 3000-fold, resulting in an influx of cations, cytoplasm swelling 
and cell lysis (Thomson & Finkelstein, 2015). While the route of TLF1 uptake is largely 
understood to rely upon TbHpHbR, loss of the receptor showed that TLF2 uptake was reduced 
but not abolished (Bullard et al., 2012). TbHpHbR-independent uptake suggested an 
alternative route of TLF2 entry into trypanosomes although the pathway remains unknown.      
 
1.3.2 Evolution of a unique serum resistance associated gene in T. 
b. rhodesiense 
In response to host innate immunity, T. b. rhodesiense has co-evolved to suppress a TLF-
mediated attack through expression of a serum resistance associated (SRA) gene. A unique 
copy of the SRA gene is encoded in a single T. b rhodesiense VSG expression site (Xong et 
al., 1998). The SRA protein had a predicted GPI-anchor addition site and was shown to 
localise to membranes of endocytic compartments (Vanhamme et al., 2003). Resistance was 
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mediated by an interaction between N-terminus of SRA and the C-terminus of ApoL1 
(Vanhamme et al., 2003), neutralising the pore-forming activity of ApoL1. Structural studies 
revealed that SRA adopts a similar fold to other trypanosome cell surface proteins, with a 
characteristic three-helix bundle maintaining the core fold of the protein (Zoll et al., 2018). In 
particular, the structural resemblance to the VSG N-terminus is striking and suggests that SRA 
has evolved from a VSG, with a loss of the multiple flexible loops that form the apical surface 
of the VSG, instead replaced by a single disordered loop (Zoll et al., 2018). The array of loops 
at the membrane distal surface of the VSG are involved in antigenic variation, and the absence 
of loops in SRA is likely due to a lack of selective pressure to generate diverse loops due to 
the intracellular location. Ectopic expression of the SRA gene in T. b. brucei conferred 
resistance to human serum (Xong et al., 1998), demonstrating that SRA was both necessary 
and sufficient in mediating human serum resistance.  
 
1.3.3 Evolution of multiple resistance strategies in T. b. gambiense 
T. b. gambiense can be separated into two genetically different groups (Balmer et al., 2011). 
Group 1 has constitutive resistance to human serum while group 2 resistance is less well-
defined (Capewell et al., 2011). T. b. gambiense does not express SRA and instead has 
evolved several strategies to promote resistance to human serum. The strategies adopted by 
the well-characterised group 1 population will be discussed. First, T. b. gambiense was shown 
to express fewer HpHbR copies on the cell surface. A reported 20-fold reduction of expression 
compared to T. b. brucei was associated with a decrease in Hpr binding sites led to reduction 
in TLF1 uptake (Kieft et al., 2010). Second, a single amino acid substitution was identified in 
the T. b. gambiense HpHbR (Symula et al., 2012). The replacement of leucine with serine at 
position 210 led to a dramatic reduction of TLF1 uptake, further promoting TLF1 resistance in 
T. b. gambiense (DeJesus et al., 2013). Finally, a T. b. gambiense-specific glycoprotein 
(TgsGP) was identified and shown to mediate resistance to TLF2 (Uzureau et al., 2013) 
(Capewell et al., 2013). In contrast to the SRA gene which relied upon VSG expression site 
activation for SRA expression, TgsGP was constitutively expressed. The combination of these 
evolutionary measures has led to human serum resistance in group 1 T. b. gambiense.  
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1.4 Adaptive immunity 
1.4.1 Hydrodynamic flow  
The high density of VSG at the cell surface confers immunogenicity, with immunoglobulin (Ig) 
capable of binding the accessible N-terminal membrane distal domain of the VSG while the 
C-terminal domain is shielded (Schwede et al., 2011). At low antibody titre, Ig-VSG complexes 
were shown to migrate to the posterior pole of the cell (Engstler et al., 2007). Concomitant 
movement of the trypanosome and hydrodynamic forces applied to macromolecules 
protruding at the cell surface resulted in sorting of Ig-VSG complexes towards the flagellar 
pocket. As the junction between cell body and flagellum, the flagellar pocket forms a site of 
rapid endocytosis at the surface of trypanosomes (reviewed by Field and Carrington, 2009). 
Ig-VSG complexes were endocytosed, providing antibody clearance to prevent opsonisation. 
While this mechanism is effective during the initial stages of an emerging antibody response, 
hydrodynamic flow-mediated strategies cannot cope with the high antibody titres that develop 
with long-term infection (McLintock et al., 1993). 
 
1.4.2 Antigenic variation 
To promote long-term persistence in the host and address immunogenicity associated with 
the VSG, T. brucei has evolved a VSG repertoire containing more than 1500 diverse genes in 
the genome (Berriman et al., 2005). Allelic exclusion ensures that only a single VSG gene is 
expressed at a time within a cell (Navarro & Gull, 2001). However, the process is reversible, 
and a VSG switch event can occur to produce monoallelic expression of a different VSG. The 
switch usually occurs in two forms, often linked to the stage of infection. During early infection, 
a switch in expression site is predominantly observed. With the number of expression sites 
limited to approximately 15 BESs, antigenic variation using this method is rapidly exhausted. 
As the infection progresses, trypanosomes rely upon homologous recombination to insert 
archived VSGs from silenced genomic regions into the active expression site. The BES VSG 
gene is flanked by 70 base pair repeats at the 5’ end of the gene and telomere repeats at the 
3’ end. The repetitive sequences facilitate DNA rearrangements through homologous 
recombination. The dynamics of antigenic variation within the host were studied by Mugnier 
et al. (2015). Four mice were infected with trypanosomes each expressing a different VSG, 
and parasites were isolated at different stages of the infection to perform RNA-seq specifically 
targeted to the VSG by cDNA amplification using primers targeting conserved 5’ and 3’ 
regions. Studies of VSG expression in mice showed that the population was rich in VSG 
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diversity, with expression of an average of 28 different VSGs at any time point during the first 
30 days (Figure 3). Some VSG variants appear transiently and are rapidly cleared whereas 
others are dominant in the population. Certain VSGs were dominant in several mice, 
suggesting there may be a VSG expression hierarchy, whereas in other mice the dominant 
VSGs were merely transient, highlighting that there may be differences between humoral 
responses in mice (Mugnier et al., 2015). The findings highlighted that VSG expression was 
highly dynamic and suggested the presence of a VSG hierarchy. Investigation of the 
determinants that may be ascribed to VSG hierarchy revealed that both VSG length and 
genome organisation may be involved. Regarding VSG length, studies demonstrated 
preferential expression of shorter VSGs during infection, leading to faster growth and an 
energetically favourable recourse (Liu et al., 2018). Histone variants and genome architecture 
were shown to be intimately linked with VSG expression, with chromatin configurations 
favouring accessibility of certain expression sites which may dictate an antigenic variation 
hierarchy (Müller et al., 2018) and affect VSG switching (Povelones et al., 2012).  
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Figure 3: In vivo dynamics of VSG expression during early infection. Each different VSG 
population is represented by a coloured line, from Mugnier et al. (2015). 
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1.5 Molecular architecture of the cell surface 
1.5.1 Structure of the variant surface glycoprotein 
In addition to Ig-VSG endocytosis and antigenic variation, the VSG also provides protection 
by forming a physical barrier to shield invariant proteins. VSG molecules form homodimers 
and can be separated into an N-terminal and C-terminal domain. Different types of VSG have 
been identified and classified based on disulphide bond conservation (Carrington et al., 1991). 
The N-terminal domains were separated into three classes, type A, B and C, while C-terminal 
domains formed four classes, type I, II, III and IV. The membrane-proximal C-terminal domain 
has a glycosylphosphatidylinositol (GPI) anchor to mediate membrane attachment. The VSG 
coat was originally observed by electron microscopy in bloodstream-form trypanosomes 
(Vickerman, 1969), forming a dense layer with a thickness of 12 – 15 nm. Several VSGs have 
since been investigated by X-ray crystallography. In 1990, Freymann et al. reported a 2.9 Å 
structure of a type A VSG N-terminal domain, VSG MITat1.2 (Protein data bank (PDB): 1VSG). 
The core fold of the protein was formed of two long alpha helices and a third truncated alpha 
helix (Figure 4A). The apical surface of the structure was arranged in an array of flexible loops, 
which formed exposed epitopes eliciting an Ig-mediated response. The structure of a second 
type A VSG, ILTat1.24, was determined and revealed striking structural homology despite a 
lack of sequence homology (Blum et al., 1993) (PDB: 2VSG). The three-helix bundle formed 
the core fold of each monomer which showed remarkable structural conservation despite 
considerable sequence divergence (Figure 4A, B), with only 16% amino acid identity between 
the structure sequences. Thus, it was postulated that a structural motif common to VSGs was 
likely necessary for function and that variation of epitopes was the result of smaller structural 
modifications rather that overall structural rearrangements (Blum et al., 1993).  
The structure of an intact VSG with both N- and C-terminal domains remained elusive. In 2017, 
Bartossek et al. focussed their research on elucidating the stucture of an entire VSG. First, a 
third N-terminal type A VSG structure was determined by X-ray crystallography, again 
confirming structural homology and the presence of a conserve three-helix bundle motif 
(MITat1.1; PDB: 5LY9) (Figure 4A). In parallel, a high-resolution structure of a VSG type II C-
terminal domain was determined by Bartossek et al. using nuclear magnetic resonance (NMR) 
(PDB: 5M4T). To complement the findings, small angle X-ray scattering (SAXS) was 
performed with a complete VSG containing the N- and C-terminal domains. The previously 
solved structures were used to fit the low-resolution molecular envelope generated by SAXS. 
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For the first time, the structure of an intact VSG could be visualised in solution and two 
predominant conformations were observed for the C-terminal domain. Furthermore, the two 
distinct conformations were observed in lipid bilayers, confirming that the flexibility was not an 
artefact induced by the lack of constraints in solution. Finally, another VSG containing a type 
I C-terminal domain, ILTat1.24, was also studied and the same finding were observed, 
confirming that the flexible nature of the C-terminal domain could be extended to other VSGs. 
The findings were used to model intact VSG conformations within the membrane and 
demonstrated the nuanced density of VSG layer (Figure 5). While the VSG coat can be 
compact, the C-terminus confers flexibility, allowing modulable VSG cell surface coverage, 
which can be adapted in response to receptor accessibility requirements or immunoglobulin-
mediated attack (Bartossek et al., 2017).  
A wealth of data was available relating to VSG type A N-terminal domains, yet other VSG 
types were neglected. Pinger et al. (2018) focused their efforts on elucidating the structure of 
a type B VSG, MITat1.3, which revealed several striking findings. First, despite considerable 
sequence divergence (Figure 4B), the type B N-terminus also adopted a similar tertiary 
structure centred around the three-helix bundle motif (Figure 4A), suggesting that this fold was 
ubiquitous across VSG classes. Second, the type B VSG did not form the quaternary structure 
observed amongst type A VSGs. Rather than assembling as homodimers, the type B structure 
was monomeric in solution and the crystal packing revealed a trimer. Although the native 
oligomerisation status was not evident, it was likely that type B quaternary architecture had 
diverged from type A VSGs. Finally, an O-linked glycosylation was identified at the membrane-
distal surface of the VSG. The finding represented the first discovery of an O-linked 
glycosylation in T. brucei. Furthermore, the glycosylation conferred virulence when infections 
of trypanosomes expressing glycosylated and mutant non-glycosylated type B VSG were 
compared in mice (Pinger et al., 2018). The findings demonstrated that antigenic variation and 
immune evasion were not solely governed by sequence diversity between VSGs, highlighting 
that post-translational modifications may also play an important role.  
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Figure 4: Comparison of the structures and sequences of VSGs. A, Structures of the N-
terminal domains of three type A VSGs (MITat1.2, ILTat1.24 and MITat1.1) and one type B 
VSG (MITat1.3). The type A N-terminal domains are shown as homodimers while type B is 
represented as a monomer. C-terminal domains are illustrated as springs of various sizes to 
represent flexibility within the domain. B, Alignment of the protein sequences of the four VSGs, 
with conserved similarity shown in white and non-conserved residues coloured in grey. 
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Figure 5: Nuanced density of the VSG coat. The C-terminal domain of the VSG confers flexibility and allows the VSG coat to adopt compact 
(left) or relaxed (right) configurations in response to other cell surface protein requirements (from Bartossek et al. 2017).  
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1.5.2 Invariant surface proteins 
A less-characterised family of glycoproteins is the invariant surface glycoproteins (ISGs). Two 
of the most studied ISGs are ISG65 and ISG75, named to reflect their apparent molecular 
weight. While little is known regarding their function, a few observations have been reported. 
First, ISGs are present in high copy numbers, with 70,000 copies for ISG65 and 50,000 for 
ISG75 in T. brucei (Ziegelbauer & Overath, 1992). Second, ISGs rely on a transmembrane 
domain for membrane insertion (Carrington & Boothroyd, 1996), which distinguishes the family 
from GPI-anchored proteins that adopt a conserved three-helix bundle. Finally, ISG75 has 
been implicated in the uptake of suramin (Alsford et al., 2012), a compound commonly used 
to treat early stage HAT. Although the structures of ISGs remain elusive, conserved cysteines 
suggest that the extracellular domains adopt a VSG type A fold (Carrington & Boothroyd, 
1996). 
The recently identified factor H receptor (FHR) is an example of an invariant receptor. Factor 
H protects host cells against the downstream consequences of C3b deposition and is exploited 
by trypanosomes. By recruiting factor H to the cell surface of trypanosomes, the receptor 
enables inactivation of complement factor C3b through the inhibitory interactions of factor H. 
The FHR structure has recently been determined and the invariant receptor adopts the 
characteristic three-helix bundle fold (Macleod et al., 2020). The receptor was shown to be 
upregulated in stumpy bloodstream form trypanosomes which are capable of infecting tsetse 
flies. Furthermore, knockdown of the FHR significantly reduced the infection rate of tsetse fly 
midguts by more than 2.5-fold. Together, the findings provide valuable evidence to 
demonstrate that the T. brucei FHR has evolved to increase parasite transmission to tsetse 
flies (Macleod et al., 2020).  
 
1.5.3 Evolution of the haptoglobin-haemoglobin receptor 
The HpHbR is a well-characterised invariant receptor expressed in trypanosomes to fulfil haem 
requirements (Vanhollebeke et al., 2008). The structure of the HpHbR of T. congolense, a 
trypanosome that commonly infects livestock in sub-Saharan Africa, was determined by 
Higgins et al. (2013). The structure revealed a monomeric three-helix bundle (PDB: 4E40), 
sharing structural homology with the VSG. Subsequent structural determination of the T. brucei 
HpHbR (TbHpHbR) provided insights into the evolution of the receptor (Lane-Serff et al., 2014). 
The core TbHpHbR fold was formed of the characteristic three-helix bundle motif, similar to 
the T. congolense receptor. However, the TbHpHbR had evolved several strategies to increase 
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uptake of HpHb. First, the T. brucei receptor had evolved longer helices, allowing protrusion 
from the dense VSG coat (Higgins et al., 2013). Second, the receptor had adopted a rigid 50° 
kink which would facilitate separation of VSG molecules and augment ligand accessibility 
through the display of a large ligand binding platform. Finally, the altered conformation 
promoted interaction of two TbHpHbR molecules with a dimeric HpHb ligand, producing a 
bivalent binding model with improved avidity. Monovalent binding of TbHpHbR to dimeric HpHb 
produced a dissociation constant (KD) of 1 µM, while bivalent binding of two receptor molecules 
to dimeric HpHb resulted in an increased binding response, with a reported KD of 4.5 nM 
(Higgins et al., 2013) (Lane-Serff et al., 2014). The accessible and invariant properties of the 
receptor raised an interesting question regarding immunogenicity. However, the low copy 
number of the receptor (~200 - 400 copies per cell) (Vanhollebeke et al., 2008) may reduce 
the likelihood of an Ig-mediated response.  
While the receptors discussed thus far are invariant, the receptor responsible for transferrin 
(Tf) uptake presents a peculiarity as it is encoded in each of the telomeric expression sites, 
and multiple variants have been identified (Hertz-Fowler et al., 2008). 
 
1.6 The trypanosome transferrin receptor 
1.6.1 ESAG6 and ESAG7 form the transferrin receptor 
The trypanosome transferrin receptor (TfR) is arguably the most highly studied yet poorly 
understood trypanosome receptor. The complexities began in 1991 when the discovery of a 
transferrin-binding protein was made (Schell et al., 1991a). The receptor was identified as a 
heterodimer formed of the proteins encoded by the ESAG6 and ESAG7 genes (Salmon et al., 
1994) (Steverding et al., 1994). Initial reports of a receptor dimer most likely binding two 
molecules of transferrin (Salmon et al., 1994) were dispelled when it was revealed that an 
ESAG6 (Mr = 50,000 – 60,000) and ESAG7 (Mr = 40,000 – 42,000) heterodimer bound a single 
molecule of transferrin (Mr = 75,000 – 80,000) (Steverding et al., 1995). Studies demonstrated 
that ESAG6 or ESAG7 homodimers failed to support binding of transferrin, and despite their 
high degree of shared sequence identity, only ESAG6/7 heterodimers formed a functional 
transferrin-binding receptor (Salmon et al., 1994). However, ESAG6 and ESAG7 homodimers 
can readily associate and the predisposition to form ESAG6/7 heterodimers is yet to be 
demonstrated. 
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The location of conserved cysteines revealed that ESAG6 and ESAG7 were likely to adopt a 
VSG N-terminus type A fold, suggesting that these genes have evolved from a common 
ancestor (Carrington & Boothroyd, 1996). Construction of a VSG-TfR fusion protein containing 
the VSG N-terminus with the ESAG6 or ESAG7 Tf-binding site produced a functional receptor 
with similar binding efficiency compared to the native TfR, further indicating a common origin 
for TfRs and VSGs (Salmon et al., 1997).  
 
1.6.2 The transferrin receptor mediates iron acquisition 
Vertebrates have evolved to sequester iron within the serum transporter glycoprotein 
transferrin. The transporter is formed of two lobes, referred to as N-lobe and C-lobe. Each lobe 
coordinates an iron ion in the Fe(III) state. The trypanosome TfR binds host Tf through an 
interaction with both the N- and C-lobes of Tf  (Steverding et al., 2012). Studies have 
demonstrated that the receptor is located in the flagellar pocket (Steverding et al., 1994) 
(Tiengwe et al., 2017), containing approximately 3000 receptors per cell (Steverding et al., 
1995). The TfR-Tf complex is endoytosed via clathrin-mediated endocytosis (Coppens et al., 
1987), but the fate of ligand and iron thereafter lacks clarity and will be further discussed in 
chapter 5.  
To understand the requirements for Tf, several studies were performed. First, Schell et al. 
(1991) attempted to grow trypanosomes in serum depleted of Tf. Cell growth was arrested 
after 24 hours, and they concluded that Tf was an essential growth factor for trypanosomes. 
Next, studies were centred on the receptor itself. TfR knockout studies were difficult to achieve 
due to the multiplicity of ESAG6 and ESAG7 genes in the genome. Tiengwe et al. (2016) 
developed a method for pan-specific knockdown of TfRs by targeting common ORF sequences 
and 5’UTR sequences by RNAi. TfR silencing led to arrested growth in trypanosomes, and 
proved lethal after three days, with survival during the first 48 hours attributed to iron reserves 
(Taylor & Kelly, 2010). Together, the findings suggested that TfR-mediated endocytosis of Tf 
was essential in trypanosomes.   
 
1.6.3 Identification of a collection of transferrin receptor sequences 
The advances in DNA sequencing facilitated an analysis of the T. brucei genome (Berriman et 
al., 2005). However, the initial studies did not include the VSG expression sites. Efforts were 
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subsequently focussed on the telomeric expression sites, and isolation of these regions was 
achieved by transformation-associated recombination (TAR) cloning in yeast (Becker et al., 
2004), followed by sequence determination and assembly (Hertz-Fowler et al., 2008). For the 
first time, all the telomeres of the T. b. brucei Lister 427 (L427) isolate could be assembled and 
the presence of one or multiple copies of ESAG6 and ESAG7 in each bloodstream expression 
sites (BES) was confirmed. The different ESAG6 and ESAG7 genes showed diversity within 
each gene family, yet only a single TfR is expressed at a time. Furthermore, the polymorphisms 
did not appear to be the result of stochastic mutations, with variation residing in hotspots 
referred to as hypervariable sites (Salmon et al., 1997). The findings prompted an interesting 
question, what is the function of TfR multiplication and diversification?  
 
1.6.4 Function of the transferrin receptor repertoire 
One hypothesis relating to TfR diversity stemmed from the broad host range of trypanosomes. 
The proposed theory was that a TfR repertoire may be required to accommodate the different 
Tfs from vertebrates (Bitter et al., 1998) (Isobe et al., 2003). Studies found that a single TfR 
had varying affinities for Tfs from different species, with differences of several orders of 
magnitude (Bitter et al., 1998) (Gerrits et al., 2002) (Salmon et al., 2005). Perhaps more 
convincingly, Bitter et al. (1998) demonstrated that trypanosomes could switch TfR depending 
on the host serum. In their study, trypanosomes displaying a TfR expressed from BES1 
showed normal growth in bovine serum. Upon transfer of the cells to canine serum, 
trypanosome proliferation was reduced for almost 200 hours. Once normal proliferation had 
resumed, an outgrowing population of trypanosomes expressing from BES2 was identified, 
suggesting that the change in host Tf had induced a switch in TfR expression (Bitter et al., 
1998). While the previous study did not isolate the specific role of Tf in switch induction, Gerrits 
et al. (2002) performed a similar study in which BES1-expressing cells grown in canine serum 
prevented switching when supplemented with bovine Tf. However, upon transfer of BES1-
expressing trypanosomes to horse serum, the addition of bovine Tf did not prevent switching 
to BES2, indicating that other factors may be responsible for the observed switching events. 
Furthermore, it was noted that different batches of serum led to considerably variable results, 
with switching from BES1 to BES2 only observed in certain batches of canine serum (Gerrits 
et al., 2002). In 2003, Isobe et al. observed an interesting correlation between host range and 
TfR diversity. T. equiperdum is a species of trypanosome restricted to equines and had less 
diversity in the predicted TfR binding site compared to T. brucei (Isobe et al., 2003), providing 
further evidence to suggest that T. brucei TfR diversification was the result of adaptation to a 
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larger host range.  In contrast, the TfR repertoire was also proposed to mediate an immune 
evasion strategy. Similar to the VSG repertoire, it was speculated that the TfR could alter its 
identity to avoid host immune detection (Borst, 1991). Due to the confusion surrounding the 
role of the transferrin receptor repertoire, further investigations would be performed in this work 
to elucidate the origin of TfR diversification.  
 
1.7 Clinical manifestation 
T. b. gambiense and T. b. rhodesiense are resistant to human serum and can cause a severe 
disease in humans, referred to as human African trypanosomiasis (HAT). The early stage 
infection, termed haemolymphatic, is characterised by waves of parasitemia which were 
historically correlated with changes in temperature and intermittent fever (Ross & Thomson, 
1910). The non-specific nature of the symptoms, which include waves of fever, pruritis, 
headaches and lymphadenopathy, makes diagnosis reliant upon laboratory testing (Brun et 
al., 2010). Techniques for diagnosis were developed in the late 1970s and are based on 
antibody detection using a card-agglutination trypanosomiasis test (CATT) (Magnus et al., 
1978). However, the low sensitivity and specificity of the test make early diagnosis a 
challenging feat (Bonnet et al., 2015). Breach of the blood brain barrier and parasite invasion 
of the central nervous system (CNS) marks the advancement to late stage neurological or 
meningoencephalitic trypanosomiasis. The ensuing deregulation of the host circadian rhythm, 
characterised by diurnal somnolence and nocturnal insomnia, lends itself to the name sleeping 
sickness. In addition, motor weaknesses, tremors, fasciculations and paralysis of limbs can 
occur, with aggressive or irritable behaviour and psychotic reactions also reported (Brun et al., 
2010). T. b. rhodesiense produces an acute infection, with rapid progression to coma and 
death in under 6 months in most cases, if left untreated (Odiit et al., 1997). T. b. gambiense is 
responsible for a less aggressive infection, typically described as chronic, which lasts 
approximately three years if untreated (Checchi et al., 2008).  
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1.8 Therapeutics 
1.8.1 Current therapeutic landscape 
The current treatment regimen for HAT relies predominantly on non-specific chemotherapeutic 
compounds associated with nocive side effects. The first-line treatment for early stage HAT is 
typically pentamidine and suramin for T. b. gambiense and T. b. rhodesiense, respectively 
(Brun et al., 2010). Both are delivered by injection, intramuscular for pentamidine and 
intravenous for suramin, requiring administration by a healthcare professional. Pentamidine 
can cause gastrointestinal adverse effects, while suramin can result in liver and kidney damage 
(Fevre et al., 2008). For the advanced, neurological stage of T. b. rhodesiense, the arsenic 
derivative melarsoprol can be administere, but not without risk. Encephalopathic syndrome is 
an often fatal adverse reaction to melarsoprol, occurring in 5 – 18% of cases (Sutherland et 
al., 2015). Late stage T. b. gambiense is treated with a Nifurtimox and Eflornithine combination 
therapy (NECT). Melarsoprol and Eflornithine are both delivered by intravenous injection, while 
Nifurtimox is an oral drug. The nature of the treatments, which require administration by a 
healthcare professional and clinical surveillance, is a drawback for those who do not have 
access to healthcare infrastructures. Until recently, there has been little advance in novel 
treatment approval for HAT, which led to its classification as a neglected tropical disease by 
the World Health Organisation.  
 
1.8.2 Recent advances in therapeutic strategy 
In 2018, Fexinidazole was approved for the treatment of both early and late stages of T. b. 
gambiense (Mesu et al., 2018). The orally administered drug, which was effective and safe for 
the treatment of both stages, provided a breakthrough as determination of disease progression 
and stage was not required and therapy could be home-based. In recent years, advances in 
specific delivery of toxins via antibody-based technologies have shown promising results. The 
remarkable endocytic capacities of trypanosomes can offer a rapid entry route for a toxin-
conjugated vector. Nanobody therapeutics have gathered attention due to their small size 
which facilitates accessibility to invariant surface targets and favours penetration of the blood-
brain barrier (reviewed by Stijlemans et al., 2017). However, these camelid-derived 
therapeutics raise the concern of immunogenicity and whether repeated injections may elicit a 
host immune response. Recently, MacGregor, Gonzalez-Muñoz et al. (2019) developed a 
toxin-conjugated human antibody targeting the T. brucei haptoglobin-haemoglobin receptor. 
They demonstrated that a single dose of the antibody, raised in vitro by phage display, was 
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effective in clearing a peripheral infection in mice. The promising findings raised the question 
of whether other trypanosome cell surface proteins could be targeted in the same manner. 
 
1.9 Project foundations 
1.9.1 Limitations in our understanding of the trypanosome 
transferrin receptor 
As extracellular pathogens, trypanosomes have developed remarkable cell surfaces that 
mediate key functions such as nutrient uptake and protection against host immune effectors. 
Studies to elucidate the molecular architecture of the cell surface have been heavily biased 
towards the VSG. To date, the only well-characterised cell surface protein involved in receptor-
mediated endocytosis is the HpHbR, which prompted an interest in characterisation of another 
trypanosome receptor. Furthermore, studies of telomeric expression sites have been centred 
around VSG research, while the study of other proximal genes has been overlooked in 
comparison, with the function of some ESAGs still unidentified. The study of two important 
ESAGs, ESAG6 and ESAG7, would further our understanding of the unusual genome 
organisation and the role of expression of multiple genes from telomeric expression sites. The 
project originated from several broad questions which remained poorly understood. 
Why has a diverse TfR repertoire evolved? 
How do two different TfRs bind Tfs from different mammals? 
Can a low affinity TfR support trypanosome growth? 
Previous studies of the TfR had investigated receptor-ligand interactions in the context of the 
trypanosome cell membrane. However, this can produce inaccuracies during determination of 
kinetic parameters due to variations in TfR copy numbers and detection methods. To study 
receptor-ligand interactions at the molecular level and obtain robust kinetic data, strategies for 
TfR isolation were explored. Due to low copy numbers of TfR at the trypanosome cell surface 
and the challenges associated with isolation of membrane proteins, expression and purification 
of recombinant TfR was preferential and would form the basis of the study. 
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1.9.2 Selection of expression system 
The choice of expression system was influenced by the presence of disulphide bonds and 
glycans. Three disulphide bonds were present in ESAG6 and four in ESAG7, which would 
result in unfavourable folding conditions in the reducing environment of E. coli cytoplasm 
(Stewart et al., 1998). Furthermore, the trypanosome TfR is a glycoprotein with five predicted 
N-linked glycosylation sites in ESAG6 and three in ESAG7, based on the consensus that 
glycosylations can be linked to asparigines located within the N-X-S/T motif where X is any 
amino acid except proline (Gavel & Heijne, 1990), and confirmed by findings from Mehlert et 
al.  (2012). It was not entirely clear which role glycans play and how the receptor would fold in 
the absence of endoplasmic reticulum (ER) processing. In previous studies, recombinant TfR 
had been produced in insect cells in the presence of tunicamycin to study to the involvement 
of glycosylation in receptor function (Maier & Steverding, 2008). Tunicamycin inhibits N-linked 
glycosylation and non-glycosylated TfR was produced to study ESAG6/7 heterodimerisation 
and Tf binding. The non-glycosylated receptor retained heterodimerisation and Tf-binding 
capacities, indicating that TfR glycans were not essential for receptor function (Maier & 
Steverding, 2008). As the role of glycans remained unknown, a eukaryotic expression system 
was deemed favourable. A mammalian expression system was yet to be tested for 
trypanosome TfR expression and could provide a lysis-free technique through the use of signal 
peptides to target proteins towards the cell surface.  
 
1.10 Objectives 
In contrast to other characterised receptors that bind host HpHb or Factor H and are present 
as a single copy in the genome, the ESAG6 and ESAG7 genes represented in multiple different 
copies due to their localisation in each of the ~15 BESs, yet the motives were unclear. Given 
the complexities that surround the receptor, this work aimed to clarify some of the ambiguities 
through exploration of the TfR-Tf interaction at the molecular level. By elucidating the binding 
mechanism, the goal was to uncover the selective pressure responsible for driving the 
multiplication and diversification of TfRs within the trypanosome genome. 
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1.10.1 Outline of the study 
The overall aims of the thesis were:  
1.  To further investigate claims that the trypanosome TfR repertoire arose from requirements 
for species specificity; 
2.  Determine the structure of the trypanosome TfR; 
3.  Gain insight into iron uptake in trypanosomes; 
4.  Assess the viability of an anti-TfR antibody therapeutic. 
First, two of the most genetically distant TfRs from different Lister 427 BESs were selected by 
phylogenetic analysis. The TfRs were expressed recombinantly in mammalian cells and 
receptor-ligand interactions were investigated at the molecular level. In addition, the growth of 
BES1-expressing trypanosomes in different sera was monitored, as the alleged Tf-induced 
switches observed in previous sera studies (Bitter et al., 1998) (Gerrits et al., 2002) and the 
alarming serum batch-dependant  discrepancies (Gerrits et al., 2002) warranted further 
investigation. While the measurement of growth rates and the kinetic parameters of receptor-
ligand binding provided valuable data, analysis of the receptor-ligand interaction at the atomic 
level using X-ray crystallography produced a wealth of additional information. Although the 
structure provided a snapshot of a single archetype from the TfR repertoire, the sequences of 
other TfRs could be mapped to identify hypervariable regions, resolving many profound 
complexities relating to TfR diversification. Next, the role of iron and the effects of pH on 
receptor-ligand interactions were investigated in a bid to understand the fate of the internalised 
complex and whether the parasite receptor mimics the native mammalian TfR. Finally, efforts 
were focussed towards determining whether the trypanosome TfR could be exploited as a 
target for a toxin-conjugated antibody therapy. 
 
1.10.2 Study outcomes 
The work presented in this thesis has provided further evidence regarding the complex 
interactions between trypanosome and host. Through the curation of a repertoire of receptors, 
trypanosomes have evolved to hijack host iron while avoiding immune recognition. A small 
piece of the puzzle has been solved in the quest to elucidate the molecular architecture of the 
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trypanosome cell surface, and the majority of the findings have been presented in a journal 
publication (Trevor et al., 2019). Finally, the viability of an antibody-drug conjugate (ADC) 
therapy targeting the TfR has been assessed and will provide insights into the design of future 
therapeutics.  
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Chapter 2   
 
 
Materials and methods 
 
 
2.1 Production of recombinant transferrin receptor 
2.1.1 Transferrin receptor cloning 
Recombinant transferrin receptors (TfRs) were produced by modification of ESAG6 and 
ESAG7 open reading frames. In the case of BES1 ESAG6 (BES1e6) and Bn2 ESAG6 
(Bn2e6), the native signal peptides and glycosylphosphatidylinositol (GPI) anchor addition 
sites were removed. The genes (residues 20-377 for BES1 and 18-375 for Bn2) were codon 
optimised for mammalian expression and synthesised (GeneArt). Genes were subcloned into 
the pDest12 mammalian expression vector, containing a cytomegalovirus (CMV) promoter 
and a CD33 signal peptide for protein expression and direction towards the secretary pathway. 
At the C-terminus, a (GS)3 linker, an AviTag and a decahistidine tag were included. For BES1 
ESAG7 (BES1e7) and Bn2 ESAG7 (Bn2e7), the signal peptides were removed and the genes 
(residues 20-338 for BES1 and 18-337 for Bn2) were codon optimised, synthesised and 
subcloned into pDest12 under the CMV promoter. The CD33 signal peptide was included at 
the N-terminus and a (GS)3 linker and StrepII-tag (Iba Life Sciences) at the C-terminus 
(Appendices 1 and 2).  
A Bn2-TfR mutant, with all N-linked glycosylation sites mutated and tags removed, was 
produced for crystallisation trials. Non-glycosylated TfR was obtained by site-directed 
mutagenesis of predicted N-linked glycosylation sites. Asparagine was converted to aspartic 
acid using the QuikChange multi site-directed mutagenesis kit (Agilent Technologies, 
200514), following manufacturer’s protocol. For Bn2 ESAG6, five mutations (N26D, N110D, 
N235D, N250D, N360D) were performed and the C-terminal linker and tags were removed. 
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The AviTag and decahistidine tag were relocated to the N-terminus with the addition of a 
tobacco etch virus (TEV) protease cleavage site for tag removal. For Bn2 ESAG7, three 
mutations (N26D, N110D and N234D) were performed and the N-terminal linker and StrepII-
tag were deleted. The genes were expressed from the CMV promoter with a CD33 signal 
peptide (Appendices 3 and 12).  
BES1-TfR mutants were produced using the QuikChange Lightening site-directed 
mutagenesis kit (Agilent Technologies, 210519), as per the manufacturer’s protocol. In BES1 
ESAG6, glycine 139 was mutated to arginine (numbering was based on the Bn2 protein 
sequence to align with the crystal structure). In BES1 ESAG7, three mutations (I229V, C233R, 
and S246Y) were performed. The genes were expressed from the CMV promoter with a CD33 
signal peptide and C-terminal tags as described for recombinant TfR production (Appendices 
1 and 12).  
 
2.1.2 Transferrin receptor expression  
For individual expression of ESAG6 and ESAG7 proteins, Chinese hamster ovary (CHO) G22 
cells developed by AstraZeneca (Daramola et al., 2014) were grown in 500 ml of serum-free 
CCM8 medium (Sigma-Aldrich), to a density of 2x106 cells/ml. Cells were transfected with 
either the Bn2e6, Bn2e7, BES1e6 or BES1e7 plasmid. DNA (0.5 µg per ml of cell culture) was 
added to 150 mM NaCl to a final volume of 1/80 of cell culture volume. PEI max 
(Polyethylenimine max; Polysciences, 24765) was added to 150 mM NaCl to a final volume of 
1/80 of cell culture volume, then mixed with DNA at a 1:8 mass ratio of DNA:PEI max and 
added to cells. Flasks were incubated overnight at 37⁰C, shaking at 140 rpm with 5% CO2 
and 80% humidity. Cells were supplemented with F9 and F10 media (AstraZeneca proprietary 
medium supplements) on days 1, 3 and 6 post-transfection. Cells were harvested on day 8 by 
centrifugation at 3000 rpm for 30 minutes at 4⁰C. The aqueous phase containing secreted 
protein was recovered after centrifugation and filtered using a 0.22 µm SteriCup filter. 
For BES1-TfR production, CHO G22 cells were cultured as described above and co-
transfected with BES1e6 and BES1e7 plasmids in equal mass ratio. For Bn2-TfR production, 
Bn2e6 and Bn2e7 plasmids were co-transfected in equal mass ratio. The Bn2-TfR glycan 
mutant was expressed in the same way. To produce TfR chimeras, BES1e6 was co-
transfected with Bn2e7 (BES1e6-Bn2e7) in equal mass ratio and Bn2e6 was co-transfected 
with BES1e7 (Bn2e6-BES1e7) in equal mass ratio. BES1-TfR mutants were produced in four 
forms. First, BES1e6 with a G139R mutation was co-transfected with BES1e7 wild type (WT) 
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to produce the BES1 e6 G139R mutant. Second, BES1e7 with I229V and S246Y mutations 
was co-transfected with BES1e6 WT to produce the BES1 e7 I229V S246Y mutant. Next, 
BES1e6 G139R and BES1e7 I229V and S246Y were co-transfected to form the BES1 e6 
G139R e7 I229V S246Y. Finally, BES1mut was produced by co-transfection of BES1e6 
G139R and BES1e7 with I229V, S446Y and C233R mutations. All proteins were expressed 
and recovered as described above.  
To produce glycosylated TfR used for structural determination, Bn2e6 and Bn2e7 were co-
transfected into CHO cells supplemented with 5 µM Kifunensine (Sigma-Aldrich, K1140), an 
α-mannosidase I inhibitor, to generate mannose-rich glycans (Yu et al., 2011). The aqueous 
phase containing expressed protein was recovered as described above. 
 
2.1.3 Protein purification 
ESAG6 subunits (Bn2e6 or BES1e6) were purified by nickel affinity chromatography using a 
His Trap EXCEL 5ml column (GE Healthcare, 17-5248-01) connected to AKTA Pure fast 
protein liquid chromatography (FPLC) system (GE Healthcare). The column was equilibrated 
with PBS (Dulbecco’s Phosphate Buffered Saline, Sigma-Aldrich) and the aqueous phase was 
loaded onto column at 5 mL/min. A wash step was performed with five column volumes of 20 
mM imidazole in PBS, pH7.4. ESAG6 was eluted with 400 mM imidazole in PBS, pH7.4. 
Fractions containing ESAG6 were dialysed into PBS. 
ESAG7 subunits (Bn2e7 or BES1e7) were purified by streptactin affinity chromatography. The 
aqueous phase containing expressed ESAG7 was dialysed into PBS to remove free biotin 
present in the medium that would interact with streptactin. the dialysed aqueous phase was 
injected at 1 ml/min over a StrepTrap HP 1 ml column (GE Healthcare) using Akta Pure FPLC 
system (GE Healthcare). Following a wash step with five column volumes of PBS, ESAG7 
was eluted with 250 µM desthiobiotin. Fractions containing ESAG7 were dialysed into PBS to 
remove desthiobiotin.  
All TfRs including chimeras and mutants were purified by nickel affinity chromatography as 
stated above and fractions containing TfR (ESAG6 and ESAG7) were dialysed into PBS. 
Elution fractions were incubated for 10 minutes at 70°C in the presence of NuPAGE lithium 
dodecyl sulphate (LDS) sample buffer (Invitrogen, NP0007) and NuPAGE reducing agent 
(Invitrogen, NP0004). Samples were analysed by sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS-PAGE) using 4-12% Bis-Tris NuPAGE pre-cast gels (Invitrogen, 
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NP0322BOX) with NuPAGE 2-(N-morpholino)ethanesulfonic acid (MES) running buffer 
(Invitrogen, NP000202). Proteins were separated at 200 V for 50 minutes and stained with 
InstantBlue Coomassie (Expedeon, ISB1L). SDS-PAGE was performed in this manner 
throughout, unless stated otherwise. Pooled fractions were dialysed into PBS and 
concentrated for subsequent biotinylation. 
 
2.1.4 Size exclusion chromatography 
Size exclusion chromatography (SEC) was performed by Gareth Rees (AstraZeneca, 
Cambridge) using a high-performance liquid chromatography (HPLC) system. A Superdex 
200 10/300 column (GE Healthcare) was equilibrated in PBS at 0.5 ml/min flow rate using an 
Agilent HP1100 HPLC. Bn2e6 at 0.9 mg/ml was injected at a volume of 10 µl with 95 µl of 
PBS. Bn2e7 at 0.2 mg/ml was injected at a volume of 70 µl with 35 µl of PBS. 20 µl of Bn2e6 
at 0.9 mg/ml was mixed with 90 µl of Bn2e7 at 0.2 mg/ml and incubated for 24 hours prior to 
injection. Peaks were detected using the 280 nm signal from a diode array detector (DAD). 
 
2.1.5 Differential scanning calorimetry  
Differential scanning calorimetry (DSC) was performed by David Staunton, Department of 
Biochemistry, University of Oxford. Samples of purified BES1 ESAG6, BES1-TfR, Bn2 ESAG6 
and Bn2-TfR were heated and the heat capacity was measured. The endothermic peak was 
used to determine the melting temperature (Tm).  
 
2.2 Analysis of receptor-ligand interactions 
2.2.1 Biotinylation of transferrin receptors 
The AviTag provided a recognition site for BirA biotin ligase, resulting in the biotinylation of a 
single lysine within the AviTag sequence (Fairhead & Howarth, 2015). Biotinylation specifically 
at the C-terminus of ESAG6 dictated the orientation of the receptor at the surface of the 
streptavidin chip, mimicking attachment to the cell surface by a GPI-anchor. E. coli BL21 (DE3) 
pRIPL cells (genotype: F– ompT hsdSB(rB– mB–) dcm
+ Tetr gal λ(DE3) endA Hte [argU proL 
Camr] [argU ileY leuW Strep/Specr]) were transformed with a plasmid encoding BirA 
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containing an N-terminal glutathione S-transferase (GST) tag (kind gift of Matthew Higgins, 
University of Oxford). Cells in mid-logarithmic phase were induced with 0.02% IPTG (Isopropyl 
β-D-1-thiogalactopyranoside). Following overnight expression of GST-BirA at 18°C, cells were 
lysed using an EmulsiFlex-C5 (Avestin). Following centrifugation, the soluble fraction was 
incubated with Glutathione Sepharose 4B resin (GE Healthcare, 17-0756-01). A wash step 
was performed with PBS and GST-BirA was eluted with PBS containing 20 mM reduced 
glutathione. GST-BirA was dialysed into PBS and used for subsequent biotinylation reactions. 
Biotinylations were performed in a 1 ml reaction volume containing 30 μM purified TfR, 0.4 μM 
purified BirA, 0.3 mM biotin and 5 mM ATP. Reactions were performed at 25°C for 16 hours, 
followed by removal of GST-BirA using Glutathione Magnetic Beads (Pierce). Western blots 
to verify biotinylation were performed by separating proteins by SDS-PAGE. Proteins were 
transferred to a polyvinylidene fluoride (PVDF) membrane (Invitrogen, IB401001) using an 
iBlot transfer device (Thermo Fisher Scientific). The membrane was blocked with Odyssey 
blocking buffer (Licor, 927-40000), then incubated with IRDye 680LT Streptavidin (Licor, 926-
68031) diluted 1:5000 in blocking buffer. After washing with PBS containing 0.05% Tween, 
the membrane was visualised at 700 nm wavelength using the Odyssey imaging system and 
its associated software. 
 
2.2.2 Surface plasmon resonance using neat serum 
Surface plasmon resonance (SPR) was performed using a Biacore T200 instrument (GE 
Healthcare) with a Series S Streptavidin (SA) chip (GE Healthcare, BR100531). Biotinylated 
TfR was immobilised on flow path 2, while flow path 1 remained without receptor to serve as 
a blank reference. Experiments were performed at 25°C in running buffer containing 10 mM 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) pH 7.4, 150 mM NaCl, 0.005 % 
Tween-20. Sera from cow (Sigma-Aldrich, B9433), horse (Sigma-Aldrich, H1270), mouse 
(Sigma-Aldrich, M5905), rabbit (Thermo Fisher Scientific, 16120099), goat (Thermo Fisher 
Scientific, 16210064), rat (Thermo Fisher Scientific, 10710C) and human (donor) were used. 
A starting concentration of neat serum diluted 1:5 into running buffer was used, and four 
additional two-fold serial dilutions were performed. Between each injection of diluted serum, a 
regeneration step was performed using 100 mM glycine pH 3. Signals observed in the blank 
reference flow path were subtracted to remove non-specific signals and sensorgrams were 
produced using the Biacore T200 evaluation software. 
 
 31 
 
2.2.3 Native transferrin isolation 
Native transferrins for SPR analysis were purified from serum using transferrin receptor affinity 
chromatography. Cow (Sigma-Aldrich, B9433), horse (Sigma-Aldrich, H1270), pig (Sigma-
Aldrich, P9783), mouse (Sigma-Aldrich, M5905), rabbit (Thermo Fisher Scientific, 16120099), 
goat (Thermo Fisher Scientific, 16210064), rat (Thermo Fisher Scientific, 10710C) and human 
(donor) were used. Due to limited volumes of donor serum, human holo-transferrin (Sigma-
Aldrich, T4132) was also used after no significant differences in binding kinetics were 
confirmed by SPR. Bn2-TfR was immobilised via amine coupling to a 1 ml HiTrap NHS-
activated HP column (GE Healthcare, 17071601) following the manufacturer’s protocol. 
Serum was passed over the column and washed with PBS. Transferrin was eluted with 100 
mM citrate pH 3.5 and dialysed into PBS. Transferrins were loaded with iron using a four-fold 
molar excess of ammonium iron (III) sulphate in the presence of 5 mM sodium bicarbonate 
(Yang, Zhang, Wang, Hao, & Sun, 2012). Free iron was removed by dialysis into 10 mM 
HEPES pH7.4, 150 mM NaCl. Human apo-transferrin (Sigma-Aldrich, T1147) was prepared 
by dialysis in the presence of 10 mM ethylenediaminetetraacetic acid (EDTA) into 10 mM 
HEPES pH7.4, 150 mM NaCl for 15 hours to remove any traces of free iron by iron chelation.  
 
2.2.4 Surface plasmon resonance using purified transferrin 
SPR was performed using a Biacore T200 instrument (GE Healthcare) with the Biotin CAPture 
kit (GE Healthcare, 28920234). The dextran-coated chip surface was functionalised with 
single-stranded oligonucleotide deoxyribonucleic acid (DNA) which hybridised with CAPture 
reagent (GE Healthcare, 28920234) containing complementary DNA covalently linked to 
streptavidin. The methodology based on DNA hybridisation enabled reversible capture of 
biotinylated proteins with regeneration after each cycle using CAPture regeneration solution 
(GE Healthcare, 28920234). A biotin CAPture chip (GE Healthcare, 28920234) prepared with 
CAPture reagent was used to immobilise biotinylated TfR onto flow path 2 to a total of ~500RU. 
Flow path 1 was left without immobilised receptor and served as a blank reference. All 
experiments were performed at 25°C as described previously. Running buffer containing 
10mM HEPES pH 7.4, 150mM NaCl, 0.005% Tween-20 was used for most experiments. 
However, the pH assay was performed using a phosphate-citrate buffer system to achieve a 
broad pH range that represented progression through the endocytic pathway. Solutions 
containing 50mM citric acid, 150mM NaCl, 0.005% Tween-20 and 50mM Na2HPO4, 150mM 
NaCl, 0.005% Tween-20 were mixed to achieve running buffers at pH 6.5, 5.5 and 4.8. Each 
concentration series of purified transferrin was prepared by two-fold serial dilution into running 
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buffer to achieve a concentration range from 1 µM to 1 nM. Each dilution was injected over 
flow paths 1 and 2 for 240s to measure association kinetics, followed by injection of running 
buffer for 500s to measure dissociation. Sensorgrams were produced following subtraction of 
non-specific signals as described in 2.2.2. Sensorgrams were fitted to a 1:1 interaction model 
and kinetic parameters were determined using the Biacore T200 evaluation software. 
 
2.2.5 Pull-down assay 
Bn2-TfR and BES1-TfR were covalently linked to cyanogen bromide-activated (CNBr-
activated) sepharose 4B (Sigma-Aldrich), following manufacturer’s recommendation. 
Receptor-coupled sepharose was incubated with bovine, goat, horse, pig and rabbit sera 
followed by a brief wash step with PBS. Bound ligand was eluted with 0.1 M citrate pH 3 and 
analysed by SDS-PAGE.  
 
2.2.6 Biolayer interferometry 
Biolayer interferometry was performed using an Octet RED384 instrument (ForteBio). 
Biotinylated BES1-TfR was immobilised onto streptavidin (SA) biosensors (ForteBio, 18-
5021). Assay buffers were prepared at four different pH values to represent extracellular and 
endocytic conditions. For physiological pH, a buffer containing 10 mM HEPES pH7.4, 150 mM 
NaCl, 0.1% bovine serum albumin (BSA), 0.05% Tween-20 was used. For endocytic pH, a 
phosphate-citrate buffer system was performed by mixing 50 mM citric acid, 150 mM NaCl, 
0.1% BSA, 0.05% Tween-20 and 50 mM Na2HPO4, 150 mM NaCl, 0.1% BSA, 0.05% Tween-
20 to achieve pH 6.5, 5.5 and 4.8. Bovine holo-transferrin (Sigma-Aldrich, T1408) and bovine 
apo-transferrin (Sigma-Aldrich, T1428) were two-fold serially diluted into the different pH 
buffers to achieve concentrations ranging from 1 µM to 62.5 nM. Receptor-conjugated 
biosensors were dipped into each dilution of Tf for 240s, followed by dissociation in assay 
buffer for 500s. A regeneration step using 0.1 M citrate pH 3 and assay buffer was performed 
between each dilution. Sensorgrams were produced using ForteBio analysis software.  
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2.3 Identification of the expressed transferrin 
receptor in trypanosomes 
2.3.1 Growth rates of BES1-expressing cells  
In vitro cultures were performed using the Lister 427 isolate expressing the BES1 VSG 
expression site. All sera were heat-inactivated by incubation at 56°C for two hours. Cells were 
cultured at 37°C, 5% CO2 in HMI-9 salts (Hirumi & Hirumi, 1989) supplemented with 10% 
foetal calf serum (FCS; Gibco, 10270106). Trypanosomes were passaged daily to 1x105 
cells/ml and initially grown for 72 hours to ensure a steady growth rate. Cells were then washed 
with serum-free HMI-9 and 1 x 105 cells/ml were resuspended in HMI-9 containing 10% horse 
(Gibco, 16050130), rabbit (Gibco, 16120099), pig (Gibco, 26250084) or FCS. Trypanosomes 
were cultured for an additional 309 hours in two independent flasks for each condition.  Cell 
counts were performed manually in duplicate using a haemocytometer. 
 
2.3.2 Reverse transcription PCR 
RNA was isolated at three time points (72, 191 and 381 hours) from the cultures used to 
determine growth rates. A RNeasy mini kit (Qiagen, 74104) was used, following 
manufacturer’s protocol. RNA was treated with DNase to remove residual DNA using Turbo 
DNA-free kit (Invitrogen). Reverse transcription of RNA was performed using random 
oligomers and SuperScript II reverse transcriptase kit (Invitrogen) to generate complementary 
DNA (cDNA). PCR was performed using the cDNA template with ESAG6 or ESAG7-specific 
primers (Appendix 12). Amplified PCR products corresponding to ESAG6 and ESAG7 mRNAs 
from cells grown in foetal calf, horse, rabbit and pig sera were sequenced using the same 
primers. 
 
2.4 X-ray crystallography 
2.4.1 Enzymatic glycan and tag removal 
Initial deglycosylation trials were performed using peptide:N-glycosidase F (PNGase F; NEB, 
P0704). Glycan cleavage was preformed using 10 µg of Bn2-TfR in PBS, following the 
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manufacturer’s protocol. After incubation for either 4 hours or 24 hours, samples were 
compared to an untreated control sample of Bn2-TfR by SDS-PAGE to visualise glycan 
removal. BES1-TfR and Bn2-TfR were also treated with endoglycosidase Hf (Endo Hf, NEB, 
P0703) following the manufacturer’s protocol and glycan removal was monitored by SDS-
PAGE. BES1-TfR and Bn2-TfR were incubated with carboxypeptidase B (Roche, 
10103233001) following manufacturer’s protocol. The efficiency of carboxypeptidase peptide 
bond hydrolysis was analysed at various time points by western blot analysis. Western blots 
were performed as described in 2.2.1, and probed with a 1:4000 dilution of mouse anti-
polyhistidine (Sigma-Aldrich, A7058) primary antibody and a 1:15000 dilution of goat anti-
mouse IRDye 680RD (Licor, 926-68070) secondary antibody.  
 
2.4.2 Initial crystallisation trials 
Bn2-TfR expressed in the presence of kifunesine was incubated with a 1.1-fold molar excess 
of human holo-transferrin (Sigma-Aldrich, T4132) in the presence of carboxypetidase B, Endo 
Hf and PNGase F (following manufacturer’s recommendation) for 20 hours at 37°C. BES1-
TfR expressed with kifunensine was incubated with a 1.1-fold molar excess of bovine holo-
transferrin (Sigma-Aldrich, T1408) and the same enzymes for 20 hours at 37°C. Receptor-
ligand complexes were isolated by size exclusion chromatography (SEC) using a Superdex 
200 16/60 column (GE Healthcare) with running buffer containing 10 mM Tris pH 8, 150 mM 
NaCl. Peak fractions were collected and analysed by SDS-PAGE. Fractions containing Bn2-
TfR in complex with human Tf were concentrated to 13.7 mg/ml, and fractions containing 
BES1-TfR with bovine Tf were concentrated to 14 mg/ml. Initial crystallisation trials were 
performed by sitting drop vapour diffusion using pre-filled SwissSci 96-well plates with four 
condition screens (ProPlex, Morpheus, JCSG Plus and Midas Plus). Drops were formed by 
mixing 100 nl of reservoir solution with 100 nl of concentrated protein complex. Plates were 
sealed and incubated at 18°C and 4°C. Small crystals of Bn2-TfR in complex with human Tf 
were fished from three conditions: 
 i) 10% w/v polyethylene glycol (PEG) 5000 molomethyl ether (MME), 12% v/v 1-Propanol, 
0.1 M MES, pH 6.5 
ii) 0.1 M sodium chloride, 25% v/v pentaerythritol propoxylate, 10% v/v dimethyl sulfoxide 
iii) 20% PEG 6000, 0.1 M Tris, pH 8.5. 
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Crystals were washed in reservoir solution to remove residual soluble protein present in the 
drop, then solubilised in NuPAGE LDS loading buffer and NuPAGE reducing agent. Samples 
were incubated at 70°C for 10 minutes and proteins were separated by SDS-PAGE. Gel 
staining was performed using a SilverQuest silver stain kit (Invitrogen, LC6070).  
 
2.4.3 Crystal optimisation 
Bn2-TfR N-linked glycan mutant was incubated with a 1.1-fold molar excess of human holo-
transferrin. TEV protease (Invitrogen, 12575015) was added for cleavage of N-terminal tags 
present on Bn2 ESAG6, and PNGase F was added to remove transferrin glycans. Following 
a 16 hour incubation at 37°C, the TfR-Tf complex was isolated by SEC, as described in 2.4.2, 
and eluted complex was concentrated to 15.5 mg/ml. Complex containing the glycan-lacking 
mutant and the previously isolated complex containing glycosylated Bn2-TfR expressed in 
kifunensine were prepared for crystallisation in optimised conditions based on the conditions 
which produced small crystals. Crystals were obtained in 12% (w/v) PEG 5000 MME, 12% 2-
methyl-2,4-pentanediol, 0.1 M MES, pH 6.5 at 18°C for both the glycan-lacking TfR mutant in 
complex with human Tf and the glycosylated TfR in complex with human Tf. Crystals were 
fished and cryo-cooled by Matthew Higgins (Department of Biochemistry, University of 
Oxford).  
 
2.4.4 Structure determination 
Data were collected from the Diamond Light Source by Matthew Higgins. Crystals of the TfR 
glycan mutant in complex with human Tf diffracted to 2.75Å resolution. Molecular replacement 
using Phaser (McCoy et al., 2007) was initially performed using human Tf as a template. Each 
lobe of human Tf was interrogated separately using structure 4X1B (Wang et al., 2015) from 
the protein data bank (PDB) for molecular replacement. Next, the structure of a type A variant 
surface glycoprotein (VSG) N-terminus (PDB: 2VSG) (Blum et al., 1993) was used for 
molecular replacement of ESAG6 and ESAG7 based on predicted structural homology 
between the TfR and VSG (Salmon et al., 1997). Restricted regions of the VSG alpha helices 
were used (residues 7-112 and 239-251). Refinement was performed by Matthew Higgins 
using Buster (Blanc et al., 2004), and model building was performed alongside Matthew 
Higgins using Coot (Emsley et al., 2010). 
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Bn2-TfR expressed in the presence of kifunensine and treated with Endo Hf crystallised in 
complex with human Tf in the same conditions as the glycan-lacking TfR. Crystals diffracted 
to 3.6Å resolution and molecular replacement was performed with Phaser using the previously 
solved structure of Bn2-TfR in complex with human Tf. During sample preparation in 2.4.2, 
glycan removal using Endo Hf resulted in a residual N-acetylglucosamine (GlcNac). Glycans 
were modelled using the electron density of the residual sugars and the TfR glycan models 
generated by Mehlert et al. (2012). Sequence entropy was determined by Matthew Higgins 
using the Shannon Entropy-One program with all available T. b. brucei ESAG6/7 sequences 
from the Lister 427 isolate (Hertz-Fowler et al., 2008) (Berriman et al., 2002) and the EATRO 
2340 isolate (Young et al., 2008) (Appendix 4). 
 
2.5 Iron quantification 
Iron quantification was performed by microbeam focussed particle induced X-ray emission 
(microPIXE). The experiment was performed by Peter Woodcock, Elspeth Garman and 
Matthew Higgins (Department of Biochemistry, University of Oxford). The differences in iron 
stoichiometries were measured over a range of pH conditions that mimicked endosomal 
progression. Bn2-TfR used in this assay was expressed in the presence of kifunensine and 
contained mannose-rich glycans which would not interfere with Tf binding as shown in the 
crystallography data. Bn2-TfR was incubated with human holo-Tf (Sigma Aldrich) and the 
receptor-ligand complex was injected over a Superdex 200 15/300 size exclusion 
chromatography (SEC) column (GE Healthcare) in various pH conditions to investigate the 
effects of pH on iron release. Human holo-Tf (Sigma-Aldrich) was studied under the same pH 
conditions to serve as a control and to concomitantly compare the effects of pH and receptor 
binding on iron retention. SEC was performed using the following buffers and, to avoid the use 
of chloride ions which would interfere with the microPIXE analysis, the pH was adjusted using 
citric acid: 
(i) 50mM sodium citrate pH 4.8, 150 mM NaBr 
(ii) 50mM sodium citrate pH 5.5, 150 mM NaBr 
(iii) 50mM Bis-Tris pH 6.5, 150 mM NaBr  
(iv) 50mM Bis-Tris pH 7.5, 150 mM NaBr.  
 37 
 
Protein samples were subsequently concentrated to 1 mg/ml and microPIXE was performed 
to measure the retained iron. Measurements were performed at the Ion Beam Centre, 
University of Surrey. X-ray emissions from dried protein droplets (volume per droplet = 0.1 µl) 
were generated by a 2.5 MeV proton beam (diameter = 2.0 µm) and measured using a 
detector. The characteristic X-ray emission for each element allowed identification and 
quantification of atoms present in each sample. Sulphur was used as in internal standard as 
the number of sulphur atoms per molecule can be determined based on the number of 
methionines and cysteines present. Quantities of sulphur and iron were compared and the 
relative number of iron ions per protein sample was determined.  
 
2.6 Growth rates in transferrin-depleted conditions 
FCS (Gibco, 10270106) was depleted of Tf using a Bn2-TfR column. Bn2-TfR was covalently 
linked to a 5 ml HiTrap NHS-activated HP column (GE Healthcare, 17071701) following the 
manufacturer’s protocol. Heat-inactivated FCS (25 ml) was passed over the column 
repeatedly until Tf was not detectable by western blot. After each cycle, bound Tf was removed 
from the column using 0.1 M citrate pH 3. Western blots were performed as described in 2.2.1, 
and probed using a 1:500 dilution of polyclonal rabbit anti-bovine transferrin antibody (Bethyl 
Laboratories, A10-114), followed by a 1:15000 dilution of goat anti-rabbit IRDye 680LT (Licor, 
926-68071). A sample of 10% FCS depleted of Tf was analysed by western blot. Samples 
containing 10% FCS and 10% Tf-depleted FCS supplemented with 3 µM Tf were also 
compared. FCS was serially diluted to determine the antibody detection limit. The 
concentrations reported were based on the assumption that mammalian serum contained ~30 
µM Tf (Dietmar Steverding, 2003).  
Trypanosomes expressing BES1-TfR were cultured in vitro as described in 2.3.1, in HMI-9 
medium containing 10% FCS or 10% Tf-depleted FCS. Cells were cultured for 200 hours and 
cell counts were performed manually in duplicate for two independent flasks. 
2.7 Phage display 
2.7.1 Media 
Tryptone yeast medium (2TY) was prepared with 16 g tryptone, 10 g yeast extract and 5 g 
NaCl per litre of medium. E. coli TG1 cells (genotype: K-12 supE thi-1 Δ(lac-proAB) Δ(mcrB-
hsdSM)5, (rK
-mK
-) F' [traD36 proAB+ lacIq lacZΔM15]) were used throughout the phage display 
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process as they can read through the amber stop codon and integrate a glutamine in normal 
conditions but recognise the stop codon in the presence of IPTG, allowing for modulable 
expression of fusion proteins.  
 
2.7.2 Soluble selections 
An aliquot of 5x1011 phage from each of the bone marrow Vaughan (BMV) library (Vaughan 
et al., 1996) and the combined spleen (CS) library (Lloyd et al., 2009) were mixed to form an 
input BMV/CS library of 1x1012 phage. The BMV/CS library was then used for soluble 
selections against the BES1-TfR and Bn2-TfR targets. To reduce non-specific interactions, 
several blocking steps were performed using 3% milk powder (Marvel) in phosphate-buffered 
saline (PBS; Sigma, D8537), unless otherwise stated. All incubations were performed for one 
hour at room temperature with end-over-end rotation at 20 rpm, unless otherwise stated.  
The BMV/CS phage library and magnetic streptavidin beads (Dynabeads) were blocked with 
milk independently, then beads were added to the library to select and remove streptavidin 
binders. Streptavidin-deselected phage were incubated with 100 nM biotinylated BES1-TfR or 
100 nM biotinylated Bn2-TfR. Blocked streptavidin beads were added, and five wash steps 
were performed with PBS containing 0.1% Tween-20 (PBST) using a KingFisher magnetic 
particle processor (Thermo Fisher Scientific, 5400000). Beads were incubated with 10 µg/ml 
trypsin in 0.1 M sodium phosphate (pH 7) for 30 minutes at 37°C to mediate the release of 
bound phage. Recovered supernatant was added to 800 µl mid-logarithmic phase E. coli TG1 
cells grown in 2TY medium. Phage infection was achieved by incubation for 1 hour at 37°C 
with slow shaking at 150 rpm. Cells were plated onto 500 cm2 bioassay plates containing 2TY 
agar supplemented with 100 µg/ml ampicillin and 2% glucose (2TYAG). Diluted cells were 
plated onto petri dishes containing 2TYAG agar to determine colony forming units per ml 
(cfu/ml) for output quantification. Plates were incubated at 30°C for 16 hours and petri dish 
colonies were counted to determine the output library size. Colonies were scraped from 
bioassay plates into 2TY supplemented with 17% glycerol and stored at -80°C.  
 
2.7.3 Phage rescue 
Output library glycerol stocks were used to inoculate 25 ml of 2TYAG to achieve a starting 
optical density at 600 nm (OD600) of 0.1. Flasks were incubated at 37°C, shaking at 280 rpm 
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until mid-logarithmic phase. M13KO7trp helper phage (7.5x1010 plaque forming units; pfu) 
were added and cells were incubated at 37°C for 1 hour, shaking at 150 rpm. Cultures were 
harvested at 3200 rpm for in a Sorvall XTR centrifuge for 10 minutes and resuspended in 25 
ml 2TY supplemented with 100 µg/ml ampicillin and 50 µg/ml kanamycin. The absence of 
glucose prevents repression of the LacZ promoter, enabling expression of scFv-pIII from the 
phagemid vector. Cultures were incubated overnight at 25°C, shaking at 280 rpm. One ml of 
overnight culture was centrifuged at 13000 rpm for 5 mins using a microcentrifuge. Phage 
input titres were calculated following E. coli infection and colony counts to determine number 
of cfu. Fifty µl of phage-rich supernatant was used to perform the next round of selection in 
the same way, the only difference being a decrease in antigen during each round (50 nM for 
round 2 and 25 nM for round 3).  
 
 
2.7.4 Master plate generation 
Plates from the 221-TfR and Bn2-TfR output libraries of the third round of selection were used 
for colony picking. Forty-four colonies from each antigen output were inoculated into wells 
containing 150 µl 2TYAG medium in a 96-well master plate. Colonies from TG1 cells 
containing a phagemid vector encoding an scFv targeting an irrelevant antigen were 
inoculated to provide a negative control. Following overnight culture, a small volume of culture 
was removed for sequencing and the master plate was supplemented with 17% glycerol and 
stored at -80°C. Sequencing of the CDR3 was performed following colony PCR with primers 
to amplify the scFv (Appendix 12). PCR products were sequenced using the amplification 
primers and sequence diversity of the output library was estimated.  
 
2.7.5 Phage enzyme-linked immunosorbent assay   
To determine specificity of the enriched output library, enzyme-linked immunosorbent assays 
(ELISAs) were performed using phage extruded from E. coli colonies in the master plate. The 
master plate was replicated by inoculating 500 µl of 2TYAG medium in a 96 deep-well plate 
using a metal replica plater. Following incubation of the daughter plate (37°C, 280 rpm), 
1.5x109 pfu of M13KO7 helper phage were added to each well of exponentially growing cells. 
Cultures were incubated at 37°C for 1 hour with 150 rpm shaking. The plate was centrifuged 
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at 3200 rpm for 10 minutes in a Sorvall XTR centrifuge. Supernatants were discarded and 
cells were resuspended in 500 µl of 2TYAK medium. Cultures were incubated overnight at 
25°C, shaking at 280 rpm. Overnight cultures were incubated with 3% milk powder in PBS 
(MPBS) for 1 hour at room temperature, then centrifuged at 3200 rpm for 5 minutes. 
Supernatants containing blocked phage were transferred to 96-well assay plates coated with 
streptavidin and antigen (50 µl of 221-TfR or Bn2-TfR at 5 µg/ml) or streptavidin alone, that 
had been previously blocked with 3% MPBS for 1 hour and washed three times with PBS. 
Phage were incubated with antigen or streptavidin for 1 hour at room temperature, then wells 
were washed three times with PBST. Anti-M13-horseradish peroxidase was diluted 1:5000 in 
3% MPBS and 50 µl were added per well. Following incubation for 1 hour at room temperature, 
plates were washed with three times with PBST. 50 µl of 3,3',5,5'-tetramethylbenzidine ELISA-
substrate (Thermo Fisher Scientific, 34028) were added per well and, following colour 
development, the reaction was quenched using 50 µl of 0.5 M sulphuric acid. Absorbance at 
450 nm wavelength was detected using an EnVision plate reader (PerkinElmer) and data were 
plotted using GraphPad Prism version 8 software.  
 
2.7.6 Periplasm extraction 
The scFv-pIII fusion was encoded in a lac operon inducible expression system within the 
phagemid vector. An amber codon separating the scFv and pIII constructs allowed for 
modulation of scFv-pIII fusion expression (Vaughan et al., 1996). IPTG induction of the lacZ 
promoter resulted in reduced read-through efficiency, with 90% of transcripts terminating 
translation at the amber codon. A leader sequence mediated delivery of soluble scFv to the 
periplasmic compartment, and controlled osmotic pressure resulted in rupture of the outer 
membrane and release of the periplasm, enabling scFv recovery as described below.  
A 96 deep-well plate containing 1 ml/well of 2TY with 100 µg/ml of ampicillin and 0.1% glucose 
was inoculated with E. coli from the master plate, as described previously. Cells were 
incubated at 37°C with shaking at 280 rpm. Mid-logarithmic phase cells were induced with 
0.02 mM IPTG and incubated overnight at 30°C, shaking at 280 rpm. Overnight cultures were 
centrifuged for 15 minutes at 4600 rpm in a pre-chilled (4°C) Sorvall XTR centrifuge. 
Supernatants were discarded and cells in each well were resuspended in osmotic shock buffer 
containing 200 mM Tris-HCl, 0.5 mM ethylenediaminetetraacetic acid (EDTA) and 0.5 M 
sucrose, pH 8. Cultures were incubated for 30 minutes at 4°C and centrifuged for 15 minutes 
at 4600 rpm (4°C) to pellet cell debris and recover periplasm containing soluble scFv.  
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2.7.7 Homogenous time-resolved fluorescence 
Homogenous time-resolved fluorescence (HTRF) assay buffer was prepared using PBS 
(Sigma, D8537), 0.1% BSA (Sigma, A9576), 0.4 M potassium fluoride (VWR, 26820.236). The 
following were combined into assay buffer to achieve final concentrations of 2 nM biotinylated 
antigen (BES1-TfR or Bn2-TfR), 1 ng/ml streptavidin cryptate (CisBio, 610SAKLB), 10 nM anti-
Myc-XL665 (CisBio, 61MYCXLB) and 25% periplasm extract recovered previously, in a 10 µl 
reaction volume. Negative controls were prepared in the same way using periplasm material 
from scFv clones targeting an irrelevant antigen. Assays were performed in a 384-well plate 
and incubated for 1 hour at room temperature. Fluorescence was detected at 620 nm and 665 
nm using an EnVision plate reader. Data were analysed using the following equations:  
Ratio = (665nm/620nm)*10,000 
% Delta F = ((Ratio Sample - Ratio Negative)/Ratio Negative))*100 
The % Delta F of each sample was determined, and values were plotted using GraphPad 
Prism version 8 software.  
 
2.7.8 Fab binding analysis using surface plasmon resonance 
Fab conversions and purifications were performed by the biologics expression team at 
AstraZeneca. Surface plasmon resonance (SPR) was performed using a Biacore T100 with 
biotinylated BES1-TfR and Bn2-TfR in the glycosylated form immobilised on a biotin CAPture 
chip, as described previously. Experiments were performed at 25°C in running buffer 
containing 10 mM HEPES pH 7.4, 150 mM NaCl, 0.005% Tween-20. Purified Fabs were 
prepared in running buffer using a two-fold serial dilution from 1 uM to 62.5 nM. Data were 
analysed using Biacore T100 software, as described previously.  
 
2.7.9 Fluorescence microscopy 
2.7.9.1 Immunoglobulin G expression and labelling 
IgG1 is typically the most abundant subclass in human serum (Vidarsson, Dekkers, & Rispens, 
2014) and was the selected expression format for IgG conversion. The IgG1 framework had 
been engineered to contain a free cysteine at position 239 in the constant region of each heavy 
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chain, referred to as the IgG1-maia format. The cysteine can subsequently be used for thiol-
reactive conjugation of fluorophores and toxins. VH fragments were amplified by PCR and 
cloned into the IgG1-maia format, while VL fragments were cloned into the lambda light chain 
framework. The use of the lambda light chain as opposed to the kappa light chain was 
determined by the flanking framework of the scFv sequence. Tbru108, Tbu111 and Nip228 
were expressed in CHO cells by equimolar co-expression of heavy and light chains, as 
described previously in 2.1.2. IgGs were purified by protein A affinity chromatography using a 
5 ml HiTrap Protein A HP column (GE Healthcare, 17040301) following manufacturer’s 
protocol. AlexaFluor 488  was site-specifically conjugated to cysteine 239 of each heavy chain, 
by incubating purified IgG with a 40-fold molar excess of Tris-(2-carboxyethyl)-phosphine 
(TCEP) for three hours, followed by a 20-fold molar excess of dehydroascorbic acid (dhAA) 
for four hours, then a 10-fold molar excess of AlexaFluor 488 C5 maleimide (ThermoFisher 
Scientific, A10254) for one hour. N-acetyl-L-cysteine (NAC) was added to stop the reaction 
and labelled IgGs were buffer exchanged into PBS using a PD-10 column, following 
manufacturer’s protocol.  
 
2.7.9.2 Uptake assays 
The Lister 427 isolate expressing from BES1 was cultured as described in 2.3.1. 
Trypanosomes were washed in serum-free HMI-9 and resuspended in serum-free HMI-9 with 
0.5 mg/ml bovine serum albumin (BSA). A lysosome protease inhibitor FMK024 
(morpholinourea-phenylalanine-homophenylalanine-fluoromethyl ketone) was added to a final 
concentration of 2 μM and cells were incubated with 500 nM of Tbr108, Tbu111 or Nip228 at 
37°C for 1.5 hours, based on previous experimental conditions defined by MacGregor et al. 
(2019). As a control, 100 nM of bovine Tf, labelled with AlexaFluor 488 (ThermoFisher 
Scientific, A10235) following manufacturer’s recommendation, was added to cells in the same 
conditions. Cells were washed with HMI-9 and fixed with 1% formaldehyde. Cells were 
mounted on microscope slides and visualised at 100x magnification using identical settings 
for all samples with a Nikon Eclipse Ti widefield microscope.  
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Chapter 3  
 
 
Investigation of transferrin receptor 
species specificity 
 
 
 
3.1 Introduction 
3.1.1 The transferrin receptor: a functional heterodimer 
The trypanosome transferrin receptor (TfR) is encoded by two genes, ESAG6 and ESAG7, 
which are homologous and have evolved from a gene duplication event. ESAG6 and ESAG7 
protein sequences from the Bn2 expression site are represented in Figure 6A.  The primary 
divergence between ESAG6 and ESAG7 is the C-terminal truncation of ESAG7 and absence 
of a GPI-anchor addition site. Membrane insertion of ESAG6 and ESAG7 heterodimers is 
mediated by a single GPI anchor at the ESAG6 C-terminus. Excluding the ESAG6 C-terminus, 
the Bn2 ESAG6 and ESAG7 proteins have 82% sequence identity. ESAG6 or ESAG7 
homodimers can form but heterodimerisation is necessary for Tf binding (Salmon et al., 1994) 
(Chaudhri et al., 1994). Understanding why both subunits are required for Tf binding and how 
trypanosomes orchestrate the assembly of heterodimers over homodimers are key questions 
that will be investigated in this chapter.   
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3.1.2 The TfR: a variant receptor 
DNA sequencing of the telomeric expression sites of the T. b. brucei L427 isolate enabled a 
comprehensive analysis of the VSG and ESAG genes (Hertz-Fowler et al., 2008). ESAG6 and 
ESAG7 genes were present in one or multiple copies in each BES. Furthermore, these genes 
had diversified, and the sequence variation could be investigated. Alignments of the L427 
ESAG6 (Figure 7) and ESAG7 (Figure 8) protein sequences demonstrated that 
polymorphisms were not randomly distributed and clustered in hotspots. Thus, variation was 
restricted to a mere tenth of the amino acid sequence with more than 90% sequence identity 
between BESs. These regions of variation were common between all ESAG6 or all ESAG7 
sequences and have been described as hypervariable sites (Salmon et al., 1997). Solved VSG 
structures from Blum et al. (1993) provided clues on the location of these sites, as the TfR 
was predicted to share structural homology with the N-terminal domain of the VSG. Modelling 
of the TfR onto the VSG N-terminus revealed a membrane distal positioning within loops at 
the hypothetical ligand binding pocket of the receptor. Diversification of these residues was 
shown to produce differences in Tf affinity between variants of the TfR repertoire (Salmon et 
al., 1997). 
 
3.1.3 Species specificity hypothesis 
In 1998, Bitter et al. noted a marked difference in trypanosome proliferation depending on the 
species of serum in which the cells were cultured. In their example, trypanosomes expressing 
the 221-TfR (BES1-TfR) showed a normal growth rate in bovine serum, with rare switching 
events. When transferred to canine serum, a reduction in proliferation was observed for 200 
hours. After 200 hours, a normal growth rate was observed and the outgrowing population of 
cells had switched expression site to express the VO2-TfR (BES2-TfR) (Bitter et al., 1998). 
The proposed hypothesis was that a change in mammalian serum led to a switch in transferrin 
receptor to accommodate the different transferrin. Over the years, this hypothesis was either 
supported (Gerrits et al., 2002) (Isobe et al., 2003) (Van Luenen et al., 2005) (Cordon-Obras 
et al., 2013) or contested (Salmon et al., 2005), with some arguing that the requirement for a 
diverse TfR repertoire may be driven by immune avoidance (Borst, 1991), and others claiming 
that both host adaptation and immune components may play a role in driving receptor 
switching (Gerrits et al., 2002). 
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3.1.4 A comparative study between two TfRs 
To further disentangle the complexities surrounding the role of TfR multiplication and 
diversification, two different TfRs were chosen for comparative studies. Recombinant TfRs 
were expressed and differences in affinity for Tf from a range of mammals was investigated. 
A mammalian expression system was selected for recombinant TfR expression, due to the 
presence of glycans and disulphide bonds in both ESAG6 and ESAG7. Surface plasmon 
resonance (SPR) was be performed to measure the kinetic binding parameters. To compare 
Tf binding between the two receptors, a panel of mammalian species was selected to 
represent diverse families and differences in transferrin affinities were measured. 
 
 
3.2 Aims 
To understand how polymorphisms in the TfR repertoire may affect the affinity for Tf, my aim 
was to conduct a comparative study to identify the extent of species specificity by comparing 
kinetic measurements for Tf binding to two of the most different TfRs. SPR was performed to 
accurately determine the differences in receptor affinity for transferrin of different species 
and several questions would be addressed: 
Do ESAG6 and ESAG7 subunits preferentially heterodimerise? 
To what extent have TfRs evolved to bind Tf in a species-specific manner? 
Is a high affinity receptor necessary to support growth? 
Does BES switching occur if a low affinity receptor is expressed? 
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3.3 Results 
3.3.1 Selection of TfRs and design of recombinant constructs 
Phylogenetic trees were assembled containing all ESAG6 or ESAG7 amino acid sequences 
from expression sites in L427 genome to inform the choice of receptor (Figure 6B). As a 
starting point, the TfR encoded in BES1 was selected (also commonly referred to as the 221 
expression site) based on reports that switching had been observed in cells expressing BES1-
TfR (Bitter et al., 1998) (Gerrits et al., 2002).  The Bn2 expression site encoded a TfR distant 
from BES1-TfR in both the ESAG6 and ESAG7 protein sequences and was chosen for further 
investigation. The Bn2 expression site was studied during characterisation of trypanosome 
expression sites (Berriman et al., 2002) and contains an ESAG6 sequence identical to the 
BES17 ESAG6, and an ESAG7 with a difference of ten amino acids to BES17 ESAG7. While 
the BES nomenclature (Hertz-Fowler et al., 2008) was used for naming BES1-TfR, Bn2-TfR 
cannot be assigned to the BES nomenclature due to the fact that the Bn2 expression site was 
not identified in subsequent sequencing efforts, which may be the result of gene conversion 
or sequencing ambiguities. 
The ESAG6 and ESAG7 genes from BES1 (referred to as BES1e6 and BES1e7) and the 
ESAG6 and ESAG7 genes from Bn2 (Bn2e6 and Bn2e7) were codon optimised and modified 
to facilitate expression in a mammalian expression system. The native trypanosome signal 
peptide was removed and replaced with mammalian CD33 signal peptide to allow for secretion 
in a mammalian cell expression system. The GPI-anchor addition site on ESAG6 was removed 
(Figure 9A) and an AviTag for biotinylation and deca-His-tag for purification were added at the 
carboxy (C) terminus (Figure 9B). For the ESAG7 constructs, a strepII tag was added at the 
C-terminus. Genes were expressed under the cytomegalovirus (CMV) promoter in CHO cells. 
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Figure 6: Alignment of ESAG6 and ESAG7 sequences and phylogenetic analysis. A, 
Protein sequence alignment of the Bn2-TfR ESAG6 and ESAG7 sequences. A solid box 
indicates the signal peptide, a dashed box indicates the GPI-anchor addition site and variation 
is highlighted in orange. B, Protein sequences of the L427 ESAG6 and ESAG7 from the 
expression sites of the L427 strain are used to construct phylogenetic trees and inform the 
selection of evolutionarily distant TfRs indicated in red.   
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Figure 7: Alignment of the L427 ESAG6 sequences. ESAG6 amino acid sequences were 
aligned with diversity highlighted in white and conserved residues indicated in blue. 
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Figure 8: Alignment of the L427 ESAG7 sequences. ESAG7 amino acid sequences were 
aligned with diversity highlighted in white and conserved residues indicated in blue. 
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3.3.2 Recombinant ESAG6 and ESAG7 expression 
In the pilot expression test, BES1e6, BES1e7, Bn2e6 and Bn2e7 were expressed individually 
in CHO cells. BES1e6 and Bn2e6 containing His-tags were purified by nickel affinity 
chromatography. BES1e7 and Bn2e7 with strepII tags were purified by streptactin resin 
(Figure 9A, B). Each purified ESAG6 was subsequently incubated with the corresponding 
ESAG7 from the same expression site. The assembly of a heterodimeric receptor was 
assessed by size exclusion chromatography and showed no evidence of the presence of 
heterodimers (Appendix 5). The ESAGs remained as homodimers and did not reassemble as 
heterodimers. Co-expression of ESAG6 and ESAG7 from the same expression site resulted 
in the formation of heterodimers that could be isolated by nickel affinity chromatography 
(Figure 9C), resulting in the formation of BES1-TfR (Figure 9D) and Bn2-TfR (Figure 9E). 
Recombinant ESAG6 (Mr = 44,000) had an additional five predicted glycan modifications, 
producing a higher molecular weight separation by SDS-PAGE. Recombinant ESAG7 (Mr = 
37,000) had three predicted N-linked glycosylation sites. Although ESAG7 did not play a role 
in affinity chromatography, equimolar amounts of ESAG6 and ESAG7 appear to co-elute. 
Thus, the propensity for the receptor to preferentially heterodimerise was investigated.  
 51 
 
 
Figure 9: Recombinant TfR design and purification. A, Native TfR schematic depicting an 
ESAG6 and ESAG7 heterodimer. The GPI-anchor addition site in the ESAG6 C-terminus 
mediates GPI anchor attachment for membrane anchorage. B, Recombinant TfR constructs 
were made by removing the ESAG6 GPI-anchor addition site and adding a C-terminal Avitag 
for site-specific biotinylation and a His-tag for affinity chromatography. A StrepII-tag was added 
to the ESAG7 C-terminus for purification. C, Workflow for TfR characterisation by SPR. 
Recombinant TfR constructs are expressed in CHO cells, purified by nickel affinity 
chromatography and biotinylated by BirA biotin ligase in preparation for SPR. D, BES1-TfR 
nickel affinity chromatography analysis by SDS-PAGE. E, Bn2-TfR nickel affinity 
chromatography. SN = supernatant; FT = flowthrough; W1 and W2 = washes; M = protein 
marker MW ladder.  
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Figure 10: Differential scanning calorimetry (DSC) to compare melting temperatures 
(Tm) of ESAG6 homodimers and ESAG6/7 heterodimers. A, ESAG6 homodimers from 
BES1 were tested by DSC and a Tm of 75°C was measured. B, BES1 ESAG6/7 heterodimers 
recorded a Tm of 61°C. C, Bn2 ESAG6 homodimers were melted at 86°C. D, A Tm of 68°C 
was measured for Bn2 ESAG6/7 heterodimers. Tm = melting temperature; Cp = heat capacity.  
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3.3.3 Investigation of preferential heterodimerisation 
The hypothesis was that the formation of heterodimers would be more energetically favourable 
than the formation of homodimers, thereby making heterodimers more thermostable. 
Differential scanning calorimetry (DSC) was performed to compare the thermostability of 
different dimer configurations. A lower melting temperature (Tm) would indicate a less stable 
structure while a high Tm correlates with an energetically favourable and stable conformation. 
Melting temperatures of ESAG6/6 homodimers from the BES1 and Bn2 expression sites were 
compared to ESAG6/7 heterodimers from the same expression sites. The BES1 ESAG6 
homodimers denatured with a Tm of 75°C (Figure 10A) while ESAG6/7 heterodimers forming 
the BES1-TfR denatured at the lower temperature of 61°C (Figure 10B). ESAG6 homodimers 
from the Bn2 expression site produced a higher Tm of 86°C (Figure 10C) compared to its 
ESAG6/7 counterparts which denatured at 68°C (Figure 10D). ESAG6 homodimers showed 
increased thermostability for both expression sites compared to the ESAG6/7 heterodimers, 
providing the unexpected conclusion that homodimers have increased stability and require 
more energy to denature than heterodimers. The preferential formation of ESAG6/7 
heterodimers in a co-expression system, and indeed most likely within the parasite, remains 
unsolved.  
 
3.3.4 Surface plasmon resonance to investigate species specificity 
hypothesis 
3.3.4.1 Site-specific biotinylation 
TfRs were prepared for surface plasmon resonance (SPR) by site-specific biotinylation of the 
ESAG6 C-terminus. Recombinant BirA containing an N-terminal glutathione S-transferase 
(GST) tag was expressed in E. coli and purified by glutathione sepharose (Figure 11A). GST-
BirA was incubated with BES1-TfR or Bn2-TfR in the presence of biotin and ATP to mediate 
site-specific biotinylation within the AviTag motif. A western blot probed with fluorescently-
labelled streptavidin indicated biotinylation of the ESAG6 subunit in BES1-TfR and Bn2-TfR 
(Figure 11B). The corresponding Coomassie-stained SDS-PAGE confirmed the presence of 
heterodimers (Figure 11C), while the western blot demonstrated the absence of biotinylation 
prior to BirA addition, and ESAG6-specific biotinylation following BirA incubation (Figure 11B).  
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Figure 11: TfR biotinylation for surface plasmon resonance (SPR). A, GST-BirA 
expression by IPTG induction and purification by glutathione affinity chromatography. B, 
Analysis of TfR biotinylation by western blot with fluorescently-labelled streptavidin. C, 
Coomassie-stained SDS-PAGE containing samples analysed by western blot in B. D, SPR is 
performed using a streptavidin chip for biotinylated TfR immobilisation. Serum or purified 
transferrin is flowed over the chip and Tf binding is measured.  
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Figure 12: Recombinant TfR function was assessed by SPR. A, Measurement of bovine 
serum response to TfR variants by SPR. Biotinylated BES1-TfR and Bn2-TfR were 
immobilised and the binding response of bovine Tf present in serum was recorded. Serum 
was injected in the following dilution range: 1:10 (blue sensorgram); 1:20 (red); 1:40 (green); 
1:80 (violet); 1:160 (orange). B, Evolutionary tree of mammals, adapted from Graphodatsky et 
al., 2011. Species indicated in brackets were selected for further investigation to represent the 
various evolutionary diversifications within the broad mammalian host range.  
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3.3.4.2 Testing transferrin binding to recombinant TfR 
To verify recombinant TfR functionality, biotinylated receptors were prepared for SPR by 
immobilisation onto an SPR streptavidin (SA) chip and bovine serum dilutions were flowed 
over the SPR chip to screen for Tf binding (Figure 11D). A response was observed for both 
BES1-TfR and Bn2-TfR and, following subtraction of the non-specific response produced by 
serum interactions with the chip surface in the absence of receptor, the specific binding 
response was reported as a sensorgram (Figure 12A). BES1-TfR produced a lower binding 
response to bovine Tf compared to Bn2-TfR, indicating differences in affinity between receptor 
variants. An additional six mammalian species were chosen to represent the broad 
mammalian host range, informed by the mammalian phylogenetic tree (Figure 12B).  
3.3.4.3 SPR with mammalian sera 
Sera from goat, horse, human, rat, mouse and rabbit were tested to compare binding of Tf 
from different species to TfR variants. Bn2-TfR displayed evidence of high affinity binding to 
transferrins from all species tested, while BES1-TfR showed a weaker binding response to all 
sera tested (Figure 13). Crude serum produced high levels of background signals due to non-
specific binding of serum components to the chip. Following subtraction of the non-specific 
response, a negative signal was observed for BES1-TfR with human and horse sera, masking 
any TfR-specific binding. Furthermore, goat and rabbit sera produced atypical binding 
responses to BES1-TfR that are not representative of a physiological receptor-ligand 
interaction, while the horse serum response to Bn2-TfR negatively correlates with serum 
concentration. Finally, determination of receptor-ligand dissociation constants was not 
possible due to unknown concentrations of Tf in each serum. I concluded that isolation of Tf 
from serum was necessary to further investigate the kinetic binding parameters of the 
receptor-ligand interaction. 
3.3.4.4 Transferrin isolation from serum  
 To isolate transferrin from serum, affinity chromatography was performed using a TfR column. 
As a promiscuous TfR that exhibited high affinity binding to all sera tested, Bn2-TfR was 
selected to purify transferrin. After covalently linking Bn2-TfR to an N-hydroxysuccinimide 
(NHS)-activated sepharose column, serum was loaded and bound Tf ligand was eluted at low 
pH (Figure 14A). The purity of the transferrin samples obtained was testament to the high 
degree of specificity of the receptor (Figure 14B). The decrease in pH may have resulted in a 
loss of iron, with Tf transitioning from the holo-Tf iron-bound form to the apo-Tf form devoid of 
iron. Purified apo-Tf was subsequently loaded with Fe(III) ions to obtain holo-Tf.  
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Figure 13: Measurement of serum response to TfR by SPR. Biotinylated BES1-TfR and Bn2-TfR were immobilised and whole serum was 
injected in the following dilution range: 1:10 (blue sensorgram); 1:20 (red); 1:40 (green); 1:80 (violet); 1:160 (orange). 
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Figure 14: Isolation of native Tf from serum. A, Workflow for Tf purification from serum 
using a trypanosome TfR column. B, Tf from different species eluted from Bn2-TfR column. 
Bovine Tf separated into two distinct polypeptides due to cleavage of a peptide fragment (Mr 
= 6,000) (Tsuji et al., 1984).  
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3.3.4.5 SPR with purified transferrin 
The use of affinity-purified native transferrin immensely improved the quality of the SPR data 
and provided a concentration range to allow accurate determination of the dissociation 
constants of transferrin from each mammal. Whilst Bn2-TfR is a broadly promiscuous receptor 
producing a strong binding response to transferrin from every species tested, BES1-TfR 
shows moderate to low affinity for its ligand (Figure 15). Analysis of the binding kinetics 
showed that Bn2-TfR has low to medium nanomolar affinity for each transferrin, with the range 
spanning from 1 to 500 nM (Table 1). Rat transferrin had the weakest affinity for Bn2-TfR (KD 
= 500 nM) while transferrins from the other species tested produced low nanomolar affinities. 
In contrast, affinities for the BES1 receptor were lower, with KD values ranging from 80 nM to 
> 3.6 µM. For most species, the affinity was predominantly in the micromolar range, with only 
cow, goat and rat exhibiting nanomolar affinities. Horse, human and pig transferrins produced 
a low signal that could not support KD measurement within the Tf concentration range used. 
The KD of horse, human and pig was therefore approximated to a value greater than the lowest 
detectable KD of 3.6 µM. While differences in binding were observed between receptor 
variants, the data highlight that there was no emergence of species specificity, as one receptor 
had an indiscriminate high affinity for all Tfs while the other receptor had unselective moderate 
to poor binding to all. There was not any evidence of species-specific evolution in which each 
receptor had diversified to generate a high affinity for a subset of Tfs. BES1-TfR did not have 
a greater affinity than Bn2-TfR for any of the Tfs tested, suggesting that the selective pressure 
is not likely to be driven by species-specific Tf affinity.  
To ensure the absence of Bn2 receptor bias for Tfs isolated during the purification method, 
pull-downs using native sera were performed. BES1-TfR and Bn2-TfR beads were incubated 
with sera from cow, goat, horse, pig and rabbit (Figure 16A). Bound ligand was eluted at low 
pH and visualised by SDS-PAGE (Figure 16B), corroborating the results observed by SPR 
using Tf purified by Bn2-TfR (Figure 15). While cow and goat Tfs produced an SPR binding 
response to BES1-TfR and were present in the BES1-TfR pull-down elution, horse and pig 
Tfs did not produce detectable binding by SPR, which was reflected in the absence of Tf in 
the horse and pig sera elution fractions for BES1-TfR. Furthermore, rabbit Tf produced a 
weak yet detectable SPR response to BES1-TfR, which was reproduced with native serum 
in the pull-down confirming the translatability between Tf purified by Bn2-TfR and Tf present 
in native serum conditions. Bn2-TfR served as a positive control for transferrin binding and 
elution in TfR pull-downs.
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Figure 15: Measurement of purified Tf binding to TfR by SPR. Biotinylated BES1-TfR and Bn2-TfR were immobilised and purified 
transferrins were injected in a concentration series ranging from 1 µM to 1 nM.
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Figure 16: Pull-down assay between TfR variants and mammalian sera. A, 
Workflow depicting the pull-down strategy using CNBr-activated beads to mediate 
BES1-TfR or Bn2-TfR coupling. B, Following serum incubation and washing, ligands 
eluted at low pH were separated by SDS-PAGE.  
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Figure 17: Measurement of human Tf binding to TfR chimeras by SPR. 
Biotinylated Bn2-TfR, BES1-TfR and TfR chimeras (BES1e6-Bn2e7 and Bn2e6-
BES1e7) were immobilised and human Tf was injected in a concentration series 
ranging from 1 µM to 1 nM. 
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Table 1: SPR measurement of binding parameters. Kinetic values for interactions 
between immobilised BES1-TfR, Bn2-TfR or TfR chimeras and purified transferrin. 
Kinetic data for low binding responses were not determined (ND). 
TfR Transferrin KD(nM) kon(M-1s-1) koff(s-1) 
BES1 Human ND ND ND 
BES1 Rabbit 3600 5.3x104 1.9x10-1 
BES1 Mouse 350 2.6x105 9.0x10-2 
BES1 Rat 2900 1.2x105 3.6x10-1 
BES1 Cow 80 4.5x105 3.6x10-2 
BES1 Goat 240 2.8x105 6.7x10-2 
BES1 Horse  ND ND ND 
BES1 Pig ND ND ND 
Bn2 Human 13 1.6x105 2.0x10-3 
Bn2 Rabbit 15 1.8x105 2.7x10-3 
Bn2 Mouse 75 3.6x105 2.8x10-2 
Bn2 Rat 500 1.3x105 6.3x10-2 
Bn2 Cow 2.8 2.7x105 7.5x10-4 
Bn2 Goat 1.4 2.5x105 3.5x10-4 
Bn2 Horse  3.7 2.4x105 8.9x10-4 
Bn2 Pig 6.2 1.5x105 9.1x10-4 
BES1e6-Bn2e7 Human 240 1.2x105 2.8x10-2 
Bn2e6-BES1e7 Human 350 8.9x104 3.1x10-2 
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3.3.4.6 TfR chimeras 
To further investigate the differences in Tf binding between variants, I wanted to 
pinpoint whether a subunit may be responsible for mediating a low affinity or high 
affinity response. BES1-Bn2 chimeras containing an ESAG from each receptor were 
produced by co-expressing BES1-TfR ESAG6 with Bn2-TfR ESAG7 (BES1e6-Bn2e7), 
and Bn2-TfR ESAG6 with BES1-TfR ESAG7 (Bn2e6-BES1e7). SPR was performed 
using human Tf which previously showed weak binding (KD > 3.6 µM) to BES1-TfR 
(Figure 15). The addition of a Bn2-TfR subunit improved BES1-TfR binding to human 
Tf in both chimeras, demonstrating that ESAG6 and ESAG7 subunits both play a role 
in Tf binding (Figure 17). Bn2-TfR ESAG7 complementation produced the greatest 
increase in affinity, with a KD of 240 nM compared to 350 nM for ESAG6 switching 
(Table 1), suggesting that ESAG7 has a larger Tf interaction interface. While it is 
possible to improve BES1-TfR affinity through ESAG switching, my next aim was to 
determine whether the low affinity of native BES1-TfR for certain species of Tf could 
suffice to support growth. 
 
3.3.5 Investigation of TfR affinity and cell growth 
3.3.5.1 Growth rates of cells expressing a low affinity TfR 
Concentrations of transferrin in serum and tissues are high, with human transferrin 
concentrations of 30 - 40 µM in serum (Shih et al., 1990) and 15 µM in tissues 
(Steverding, 2003). These values are considerably higher than the determined Tf 
dissociation constants, allowing us to speculate that sera from species exhibiting weak 
TfR binding would support growth. To test this hypothesis, cells expressing BES1-TfR 
were grown in horse, pig or rabbit sera which all displayed a weak binding response 
by SPR (KD > 3.6 µM) (Table 1). Growth rates were compared to that of BES1-TfR 
cells in foetal calf serum (FCS) as cow transferrin displayed the highest affinity for 
BES1-TfR (KD = 80 nM) and would serve as a positive control. Adult bovine and canine 
sera were not used, despite being tested in previous studies (Bitter et al., 1998) (Gerrits 
et al., 2002) (Van Luenen et al., 2005), as I was unable to culture trypanosomes in 
these sera, indicating the presence of unidentified serum factors that compromised cell 
growth.  Cells were initially cultured for 72 hours in FCS to ensure that the growth rate 
was steady prior to passaging cells into media containing each of the four different 
sera (Figure 18).  In all four sera, growth rates remained stable and there was no 
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evidence of arrested proliferation that resembled previous observations (Bitter et al., 
1998). While growth rates were marginally reduced for horse, rabbit and pig compared 
to cow, these differences did not correlate with Tf affinities as cells grew faster in horse 
serum than rabbit serum despite having a weaker affinity for horse Tf compared to 
rabbit Tf. Furthermore, population doubling times were closely aligned, with 5.9 hours 
in FCS compared to 6.6 hours in horse serum, despite differences in affinity of more 
than 40-fold between cow and horse Tf (Table 1). Thus, even in 10% serum from 
species that expressed Tf with a low affinity for 221-TfR, growth is supported at a 
steady rate. Furthermore, mammalian serum has a high Tf concentration of ~30 µM 
(Steverding, 2003), which is far greater than the dissociation constants reported. 
Together, these findings suggested that expression of a receptor with high Tf affinity 
is not an important factor controlling trypanosome growth.  
 
3.3.5.2  Identification of the expressed TfR  
While continuous cell growth after transfer to a different serum was a good indication 
of the absence of an orchestrated switching event, verification of the predominantly 
expressed TfR was performed. Following mRNA extraction and reverse transcription, 
primers specific to ESAG6 and ESAG7 were used to amplify all transcripts encoding 
the TfR. ESAG7 sequencing reads were used to identify switching as a discrete single 
nucleotide polymorphism (SNP) distinguishes BES1 from other expression sites 
(Figure 19A). Sequencing data revealed that the expressed TfR remained largely 
unchanged with predominant BES1 ESAG7 expression (Figure 19B). Although a 
unique SNP does not differentiate ESAG6 residing in BES1 from other expression 
sites, comparison of nucleotides in several locations also revealed predominant 
expression of ESAG6 from BES1. A low rate of switching was observed over time 
although this was comparable to the rate of switching observed in the bovine positive 
control and confirmed that the assay was performed for a sufficient duration to allow 
for switching. It is entirely plausible that a basal level of switching could occur, and our 
data suggest that this is independent of transferrin affinity for the predominant TfR. 
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Figure 18: Growth of trypanosomes expressing the BES1-TfR in different sera. 
After culturing BSF cells in FCS for 72 hours to ensure a steady growth rate, cells were 
grown in FCS, horse, rabbit and pig sera. Error bars were too slight for visualisation 
on the graph. 
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Figure 19: RT-PCR sequencing reveals a lack of TfR switching. A, The ESAG7 
present in BES1 has a single nucleotide polymorphism (SNP) allowing BES1 TfR 
expression to be distinguished from TfRs in other expression sites. B, Sequencing 
chromatograms of ESAG7 RT-PCR transcripts following growth of BES1-expressing 
trypanosomes in various sera. Trypanosomes were initially grown in FCS for 72 hours 
then split into different sera. RNA transcripts from cells were analysed by RT-PCR at 
72 hours, 191 hours and 381 hours to evaluate the extent of ESAG7 switching.  
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3.4 Discussion 
3.4.1 A propensity to heterodimerise by an unknown 
mechanism 
It has previously been demonstrated that ESAG6 and ESAG7 homodimers can form 
(Salmon et al., 1994), and our data confirmed these findings. However, I have found 
that heterodimers preferentially associated when both ESAGs were co-expressed and 
that their association must occur at an early stage following translation as homodimers 
did not readily dissociate to form heterodimers. The preferential heterodimerisation in 
a co-expression system was apparent following ESAG6 isolation by nickel affinity 
chromatography, which co-eluted in apparent equimolar ratios with ESAG7. The 
evidence that ESAG6 and ESAG7 may have an inherent propensity to form 
heterodimers would be logical from an evolutionary perspective due to the energetic 
burden that would occur if homodimers were formed. ESAG7 homodimers lacking GPI 
anchor addition sites would not be trafficked to the cell surface and instead would be 
destined for degradation. ESAG6 homodimers, while capable of cell surface 
anchorage, are refractory to transferrin binding and would not form a functional 
transferrin receptor. While it is apparent that preferential heterodimerisation occurs, 
the molecular features that may favour heterodimerisation remain unknown. 
 
3.4.2 A lack of evidence to support emergence of species 
specificity 
Alignments of ESAG6 and ESAG7 sequences have shown that polymorphisms are not 
the result of stochastic mutations but rather diversification is clustered in hypervariable 
hotspots suggesting active selection. The selective pressure has been proposed as 
the requirement to bind a variety of different Tfs to accommodate the broad mammalian 
host range. However, our data do not support this hypothesis based on several 
findings. First, comparison of Tf binding to two TfR variants by SPR did not 
demonstrate the emergence of discriminate species specificity. Second, growth of 
trypanosomes expressing BES1-TfR is supported in the presence of diluted sera 
containing low affinity Tf. Finally, BES1-TfR expression persists during growth in sera 
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containing low affinity Tf, suggesting that expression of a high affinity TfR is not 
necessary to support growth. In conclusion, active selection of sequence variation 
does not appear to be driven by Tf affinity, thus indicating that a different form of 
evolutionary pressure may exist.  
As extracellular parasites, trypanosomes have evolved a specialised cell surface in 
response to host immune system exposure. While VSG switching is a well-
characterised strategy to combat immune onslaught (Mugnier et al., 2015), variation 
of trypanosome receptors for immune evasion is less studied. I have shown that two 
antigenically different TfRs can survive in sera from different species without 
deleterious effects to cell growth and survival. Thus, it is conceivable that the primary 
selection factor for TfR variation may be immune avoidance as opposed to species 
specificity. 
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Chapter 4  
 
 
Structure of the trypanosome 
transferrin receptor 
 
 
 
4.1 Introduction 
4.1.1 Previous insights into the trypanosome transferrin 
receptor structure 
Predictive studies were previously performed to provide insights into the trypanosome 
transferrin receptor (TfR) structure. Initial investigations were focused on mapping the 
ligand binding site (Salmon et al., 1997). Sequence homology between ESAG6, 
ESAG7 and some VSGs including those with known structures (Freymann et al., 1990) 
(Blum et al., 1993) allowed identification of four blocks which varied between ESAG6 
and ESAG7 sequences. These blocks aligned with the four most exposed surface 
loops of solved VSGs that formed the variant epitopes. The four variable loops in 
ESAG6 and ESAG7 were predicted to form the ligand binding site due to a potentially 
exposed localisation that would be accessible. Furthermore, sequence variation in the 
ligand binding site elucidated differences observed in Tf binding between receptor 
variants (Steverding et al., 1995). In more recent studies in 2012, Mehlert et al. 
generated a TfR homology model based on the structure of VSG MITat1.2 (Freymann 
et al., 1990). As a structure of the trypanosome TfR was yet to be obtained, efforts 
here were focussed towards determining the structure. To visualise the TfR and its 
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interactions with Tf at atomic resolution, we performed structural studies with the 
receptor-ligand complex using X-ray crystallography. 
 
4.1.2 X-ray crystallography 
X-ray crystallography is a technique that allows visualisation of protein structures at 
atomic resolution. The amalgamation of X-rays and crystals stemmed from size 
restrictions imposed by molecular structures. First, atomic bonds have an average 
length of 1.5 Å (0.15 nm) which is far smaller than visible light wavelengths of 400 – 
800 nm. X-rays have a typical wavelength of 0.01 – 10 nm, thus suitable for providing 
diffraction patterns with atomic resolution. Second, the diffraction pattern produced by 
X-rays scattered from a single molecule would be very weak. Hence, crystals were 
required to provide a homogenous array of ordered molecules to amplify the diffraction 
signal.  
The transition of soluble proteins to a crystalline solid state required precipitation whilst 
avoiding denaturation of molecules. Thus, precipitation must be slow and controlled, 
achieved by the addition of precipitant to the aqueous protein solution at sub-
precipitation concentrations. The ensuing water evaporation resulted in increased 
precipitant and protein concentrations to favour gradual protein precipitation and 
crystal nucleation. The requirement of a sweet spot in precipitant concentration without 
additional evaporation which would not be conducive to crystal growth led to the 
development of the hanging or sitting drop vapour diffusion method. Within a sealed 
environment, water could diffuse between the drop containing protein and precipitant, 
and the reservoir solution containing precipitant. Crystal nucleation occurs once 
equilibrium is achieved, with a closed environment maintaining ideal nucleation and 
growth conditions. 
 
4.1.3 A quest for protein homogeneity 
Obtaining suitable crystals is not trivial and often entails a multifactorial optimisation. 
A homogenous sample of target protein favours crystal nucleation. Heterogeneity is 
commonly introduced by the presence of contaminants, hence the necessity for 
sample purity. Furthermore, glycosylations can be heterogeneous, resulting in different 
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glycosylation profiles between molecules. Finally, flexibility within glycans and 
disordered regions can introduce heterogeneity as the orientation of molecular 
features may vary. The ESAG6 and ESAG7 constructs contained C-terminal linkers 
and tags that may adopt varied orientations. Carboxypeptidase treatment can be 
performed to remove the flexible C-terminus.   
To avoid glycan heterogeneity, removal is usually best and can be performed by 
several types of glycosidase which either cleave the entire glycan or leave a sugar 
moiety. Peptide:N-glycosidase F (PNGase F) is a promiscuous endoglycosidase that 
cleaves the glycoside bond between asparagine and N-acetylglucosamine (GlcNAc) 
through a hydrolysis reaction that transforms aspargine into aspartic acid. 
Endoglycosidase Hf (Endo Hf) is another type of endoglycosidase that selectively 
cleaves the β(1-4) glycoside bond between GlcNAc sugars of mannose-rich 
carbohydrates, requiring production of mannose-rich glycans during protein 
expression. Endo Hf can achieve more efficient deglycosylation due to accessibility as 
the base of the glycan does not have to be reached. 
 
4.2 Aims 
The multiplication and diversification of TfRs has long been a focus of discussion. It is 
either the result of a requirement for a repertoire of different binding sites to 
accommodate the range of different mammalian transferrins (Bitter et al., 1998) 
(Gerrits et al., 2002) (Isobe et al., 2003); or diversity has arisen from an immune 
evasion strategy (Borst, 1991). While work in the Chapter 3 suggested that the 
repertoire had not evolved to achieve a broader host range, the trypanosome TfR 
variation remained shrouded in complexities, requiring structural determination to 
answer key questions: 
Does the structure adhere to the same three-helix fold adopted by other trypanosome 
surface proteins? 
How does the receptor bind its ligand? 
Why do ESAG6 and ESAG7 preferentially heterodimerise? 
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Can the location of polymorphisms and glycans provide insights into the origin of a 
diverse TfR repertoire? 
 
4.3 Results 
4.3.1 Crystallisation trials 
4.3.1.1 Sample homogeneity  
BES1- and Bn2-TfRs were produced as previously described in Chapter 3, and initials 
trials to remove TfR glycans were performed with PNGase F. Complete removal of 
glycans was not successful and heterogenous glycan cleavage was apparent by SDS-
PAGE (Figure 20A). A smear pattern on the gel indicated incomplete hydrolysis, 
producing a protein sample with molecules of varying sizes depending on the cleavage 
efficiency. Complete deglycosylation was only achieved after TfR denaturation, 
indicating that unfolding favoured glycan removal and thus accessibility may be the 
factor compromising PNGase F activity in folded TfR. Endo Hf provided greater glycan 
trimming efficiency compared to PNGase F, yet complete deglycosylation was not 
achieved when compared to the denatured and fully deglycosylated TfR control (Figure 
20B). Attempts were made to remove C-terminal flexible structures by 
carboxypeptidase treatment. Enzyme efficiency was monitored by western blot probed 
with anti-polyhistidine antibody to detect a C-terminal His-tag in ESAG6 (Figure 20C). 
Longer incubations with carboxypeptidase led to increased C-terminal cleavage 
efficiency, with an overnight incubation of 20 hours drastically increasing His-tag 
trimming compared to incubations of 4 hours or less. A greater concentration of 
carboxypeptidase also led to improved cleavage for shorter incubations of 4 hours, 
although an overnight incubation produced the most favourable results in the presence 
of lower concentrations of enzyme. SDS-PAGE of the samples used for western blot 
illustrated that equal amounts of TfR were used throughout the carboxypeptidase trial 
(Figure 20D).  
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Figure 20: Preparation of homogenous TfR for crystallisation. A, Pilot test of Bn2-
TfR glycan removal using PNGase F. B, Trial removal of BES1-TfR and Bn2-TfR 
glycans using Endo Hf. ESAG6 subunits are highlighted with a yellow triangle; ESAG7 
subunits are indicated with a white circle. C, Carboxypeptidase B treatment of BES1-
TfR and Bn2-TfR, followed by western blot probed with anti-polyhistidine. D, 
Coomassie-stained SDS-PAGE of western blot samples shown in C. 
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Figure 21: Isolation of TfR-Tf complexes for crystallisation. A, Size exclusion 
chromatography (SEC) was performed to isolate the Bn2-TfR and human Tf complex. 
The absorbance at 280 nm was measured and represented as a chromatogram. B, 
Coomassie-stained SDS-PAGE depicting Bn2-TfR with human Tf samples before and 
after enzymatic treatment and SEC. Bn2-TfR with human Tf prior to enzymatic 
treatment is shown in S1. Bn2-TfR with human Tf following Endo Hf, PNGase F and 
Carboxypeptidase B treatment is shown in S2. Sample S2 was subsequently 
separated by SEC to isolate the TfR-Tf complex (Peak 1 samples) and remove free Tf 
ligand (Peak 2 samples). C, Chromatogram depicting isolation of the BES1-TfR and 
bovine Tf complex by SEC. D, Coomassie-stained SDS-PAGE of BES1-TfR and 
bovine Tf samples as described in B. AU = absorbance units. 
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4.3.1.2 Isolation of the TfR-Tf complex 
Purified Bn2-TfR was incubated with human transferrin in the presence of Endo Hf for 
removal of mannose-rich glycans present on the TfR, PNGase F for cleavage of 
glycans present on Tf and carboxypeptidase for removal of TfR C-terminal tags. 
Purified BES1-TfR was incubated with bovine Tf (KD = 80 nM) as the affinity for human 
Tf was weak (KD > 3.6 µM), in the presence of the same cocktail of enzymes. Enzyme-
treated receptor-ligand complexes were isolated by size exclusion chromatography. 
Absorbance at 280 nm was monitored and fractions from peak 1 (Figure 21A, C) 
contained the TfR-Tf complex (Figure 21B, D) while peak 2 contained unbound ligand. 
In Figure 21D, bovine Tf separated into two distinguishable polypeptides due to 
peptide cleavage that can occur (Tsuji et al., 1984). Samples were set up for 
crystallisation in a variety of conditions using the sitting drop vapour diffusion method. 
 
4.3.1.3 Initial crystals 
Following sample preparation in crystallisation plates, small crystalline formations 
appeared for Bn2-TfR in complex with human Tf. BES1-TfR in complex with bovine Tf 
did not produce any crystals. The presence of a cleavage product in bovine Tf may 
have introduced heterogeneity that hindered crystallisation.  
To verify crystallisation of the complex, crystals were solubilised and analysed by SDS-
PAGE. Following silver staining, the presence of human Tf, ESAG6 and ESAG7 within 
the crystals was confirmed (Figure 22). However, the size and quality of the crystals 
were not sufficient for X-ray diffraction and further optimisation was required. 
  
4.3.1.4 Optimisation of the TfR-Tf crystals 
The optimisation approach was two-fold and involved adjusting the crystallisation 
conditions and improving protein homogeneity. In previous samples, deglycosylation 
of human Tf produced a single product (Figure 21B), in contrast to Bn2-TfR in which 
ESAG6 and ESAG7 resolved as a smeared pattern suggesting heterogenous 
deglycosylation. To circumvent TfR glycan heterogeneity and achieve complete 
absence of N-linked oligosaccharides, site-directed mutagenesis of the expression 
constructs was performed. The five predicted N-linked sites in Bn2 ESAG6 and three 
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sites in Bn2 ESAG7 were mutated to aspartic acid to abolish glycosylation. To address 
heterogeneity introduced by flexible linkers, tags and variable carboxypeptidase 
cleavage efficiency, the ESAG6 and ESAG7 constructs were further modified. C-
terminal linkers and tags were removed, and N-terminal tags were cloned upstream of 
ESAG6 with an interposed TEV protease site for subsequent tag cleavage following 
purification. The cleavage site was inserted at the N-terminus to leave a residual 
glycine after cleavage. All tags were removed from ESAG7 as they were surplus to 
requirement, with heterodimerisation sufficient for co-elution of ESAG6 and ESAG7. 
The Bn2-TfR glycan mutant was incubated with human Tf and the receptor-ligand 
complex was isolated by size exclusion chromatography, with ESAG6 and ESAG7 
showing less heterogeneity by SDS-PAGE (Figure 23). Samples were prepared for 
crystallisation using optimised conditions based on the conditions in which small 
crystals were obtained (Figure 22). 
Crystals of the non-glycosylated Bn2-TfR mutant in complex with human Tf were 
obtained in 12% (w/v) PEG 5000 MME, 12% 2-methyl-2,4-pentanediol, 0.1 M MES, 
pH 6.5 at 18°C. Crystals diffracted to 2.75 Å resolution and molecular replacement was 
first performed using available structural data for human Tf (PDB: 4X1B) (Wang et al., 
2015). Next, the VSG (PDB: 2VSG) (Blum et al., 1993) was used as a homologous 
model for Bn2-TfR molecular replacement, followed by model building and refinement. 
In addition, crystals were obtained in the same conditions with Endo Hf-treated Bn2-
TfR in complex with human Tf. Crystals diffracted to 3.6Å resolution and were solved 
by molecular replacement using the non-glycosylated TfR structure (Appendix 6).  
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Figure 22: Visualisation of crystal protein composition by SDS-PAGE. Crystals 
were solubilised and proteins were separated by SDS-PAGE and silver stained. 
Conditions for sample A: 10% w/v polyethylene glycom (PEG) 5000 monomethyl ether 
(MME), 12% v/v 1-Propanol, 0.1 M 2-(N-morpholino)ethanesulfonic acid (MES), pH 
6.5; sample B: 0.1 M sodium chloride, 25% v/v pentaerythritol propoxylate, 10% v/v 
dimethyl sulfoxide; and sample C: 20% PEG 6000, 0.1 M Tris, pH 8.5.  
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Figure 23: Isolation of Bn2-TfR mutant in complex with human Tf. Size exclusion 
chromatogram produced by the absorbance at 280 nm, with visualisation by SDS-
PAGE of the isolated sample. AU = absorbance units. 
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4.3.2 The structure revealed a VSG-like fold  
The VSG family contains a remarkable set of proteins which have undergone 
considerable sequence diversification whilst maintaining a conserved structure (Figure 
4) (Freymann et al., 1990) (Blum et al., 1993) (Bartossek et al., 2017) (Pinger et al., 
2018). The solved TfR structure revealed that the receptor also adopted a similar fold 
to other characterised trypanosome cell surface proteins, with an elongated three-helix 
bundle that formed the core of each subunit (Figure 24 and Figure 25A). Sequence 
alignments of TfR with other structurally characterised VSGs highlighted the lack of 
conservation (Figure 25B). However, superimposition of the TfR structure on solved 
structures of the VSG N-terminal domain showed close alignment and structural 
conservation (Figure 25A). The two N-terminal alpha-helices aligned with the VSG 
helices, while the third alpha-helix, partially absent in the VSG, was full-length in the 
TfR to reinforce the core fold. At the membrane proximal side of each ESAG, a short 
helix provided a wedge between the two subunits of the heterodimer (Figure 24). This 
likely dictated adequate membrane proximal spacing between molecules within the 
dense and dynamic VSG coat (Bartossek et al., 2017). A network of intramolecular 
disulphide bridges maintained the core fold of the individual receptor subunits, whilst 
heterodimer pairing was reliant on extensive hydrogen bonding. Thirty-three residues 
at the C-terminus of ESAG6 were not resolved due to poor electron density, suggesting 
flexibility. A C-terminal GPI-anchor would mediate membrane integration. The apical 
surface of the receptor was arranged in a complex array of intertwined loops that 
formed the ligand binding surface, with both ESAG6 and ESAG7 subunits interacting 
with a single molecule of human transferrin. The receptor-ligand interface was 
restricted to the membrane distal tip of the receptor, which differed from the large 
ligand binding surfaces adopted by other structurally characterised T. b. brucei cell 
surface receptors. In the case of the haptoglobin-haemoglobin receptor (HpHbR), the 
three-helix motif adopted a rigid 50° kink to displace the compact VSG layer and 
augment the ligand binding site (Lane-Serff et al., 2014). The factor H receptor consists 
of a similar motif to HpHbR and has evolved a membrane distal binding pocket, with 
two of the three helices splayed open to accommodate factor H (Macleod et al., 2020). 
In a bid to maximise epitope occlusion in the VSG coat, the transferrin receptor has 
likely evolved an exclusively apical binding pocket allowing lateral surfaces of the 
receptor to remain embedded in the VSG coat.  
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Figure 24: Structure of the trypanosome TfR in complex with human Tf. Bn2-TfR 
is represented in dark blue (ESAG6) and cyan (ESAG7). Human Tf is shown in red 
and Fe(III) is represented as an orange sphere. 
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Figure 25: Comparison of TfR with structures and sequences of other 
trypanosome cell surface proteins. A, Superimposition of TfR structure with T. 
brucei VSG structures (MITat1.2, ILTat1.24 and MITat1.1) and the T. brucei 
haptoglobin-haemaglobin receptor (TbHpHbR). The PDB codes of the structures used 
for the overlay are listed. B, Alignment of the protein sequences used for structural 
comparison, with sequence variation highlighted in orange. The TbHpHbR sequence 
was not aligned due to greater sequence diversity. 
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Figure 26: Tf binds both subunits of TfR. A, Top view of the membrane distal tip of 
the TfR. ESAG6 is represented in dark blue and ESAG7 is shown in cyan. B, Human 
Tf, shown in red, bound to the membrane distal tip of the TfR. 
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Figure 27: Overlay of TfR subunits and VSG monomers. Structural divergence and asymmetry within the loops of ESAG6 and ESAG7 is 
compared to an overlay of VSG monomers. Structures of VSG homodimers MITat1.2, ILTat1.24 and MITat1.1 were used, with PDB codes listed.
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4.3.3 The receptor-ligand interface elucidates heterodimerisation 
requirement 
ESAG6 and ESAG7 displayed remarkable structural similarity (Figure 24) yet they are not 
interchangeable, with the presence of both subunits required for functional ligand binding 
(Salmon et al., 1994) (Chaudhri et al., 1994). Alignment of the sequences showed 80% identity 
within the structurally represented sequences (Figure 6). Initial observations of the receptor-
ligand interface provided clues for the requirement of a heterodimer, illustrating that Tf binding 
spanned across both ESAG6 and ESAG7 in an asymmetric manner, with an apparent larger 
Tf footprint spanning ESAG7 (Figure 26A, B). A greater contribution of ESAG7 in Tf binding 
corroborated previous SPR data produced using TfR chimeras (Figure 17). Superimposition 
of the ESAG6 and ESAG7 structures revealed a perfectly aligned core with structural 
divergence observed solely at the apical surface (Figure 27). On the other hand, an overlay of 
VSG monomers illustrated that the flexible loops of each molecule were aligned, suggesting 
that structural divergence at the apical surface of TfR was caused by sequence variation rather 
than flexibility and movement within the loops during crystallisation, as similar differences in 
loop structure were not observed for VSG monomers. The subtle structural variation is the 
reason both ESAGs are required for transferrin binding. Transferrin itself is formed of two 
lobes, termed N-lobe and C-lobe. Structural differences within transferrin lobes further 
elucidated the requirement for heterodimerisation. The receptor must accommodate the 
bilobal heterogeneity of the ligand by providing an asymmetric binding surface.  
 
4.3.4 Receptor-ligand interface and diversification 
A single molecule of human transferrin binds at the surface of Bn2-TfR, predominantly through 
the formation of a network of hydrogen bonds. Investigation of the binding interactions at the 
receptor-ligand interface demonstrated that the majority of the interactions were mediated by 
ESAG7 (Table 2), further corroborating the SPR data with TfR chimeras (Figure 17). While 
ESAG6 predominantly contacts the C-lobe, ESAG7 binds both N- and C-lobes (Table 2).  
Alignments of the protein sequences of Bn2-TfR and BES1-TfR demonstrated the high degree 
of conservation between receptor variants (Figure 28). The ESAG6 sequences shared 91% 
sequence identity while the ESAG7 sequences were 92% identical, despite being two of the 
most different TfRs in the L427 genome. Comparison of the Tf-binding residues with the 
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residues that vary between Bn2-TfR and BES1-TfR revealed that interacting amino acids were 
conserved. Only one variable residue within the interaction site was identified, an 
arginine/glycine polymorphism located at residue 139 in ESAG6, numbered according to the 
Bn2-TfR sequence to match numbering of the crystal structure. Site-directed mutagenesis was 
performed to investigate the variable residue involved in Tf binding. Glycine 139 was mutated 
in BES1-TfR ESAG6 to the corresponding residue in Bn2-TfR by converting to arginine. To 
investigate ESAG7, three variable residues in proximity to the Tf binding site were selected 
for site-directed mutagenesis (Figure 29A, B). In BES1-TfR, residues 229, 233 and 246 of 
ESAG7 were mutated to the corresponding residues in Bn2-TfR. SPR was performed to study 
the effects of mutations on Tf affinity. Human and rat Tf were initially tested for binding as they 
previously produced the lowest affinities for BES1-TfR and Bn2-TfR respectively. Human Tf 
showed negligible binding to BES1-TfR (KD > 3.6 µM), while rat Tf produced the weakest 
binding response to Bn2-TfR (KD = 500 nM) (Table 1). Each of the mutants tested improved 
binding for human and rat Tf (Figure 30). The greatest improvement in affinity was observed 
for human Tf and was produced by combining all four mutations, with a previous KD > 3.6 µM 
improving more than 10-fold to 300 nM (Table 3). Thus, the quadruple mutant, referred to as 
BES1mut, was tested for binding to the mammalian Tf panel. The mutations improved the 
affinity of BES1-TfR for all transferrins tested (Figure 31), with at least a two-fold increase in 
binding observed for rat, mouse and rabbit. Horse affinity improved more than 10-fold; while 
cow, goat and rabbit affinities improved more than 25-fold (Table 3 and Table 1). In conclusion, 
mutation of a small number of residues in a low affinity TfR can greatly increase Tf binding, 
indicating that Tf affinity may not drive active selection of variation.  
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Table 2: List of interactions between trypanosome TfR and human Tf. Chain A represents 
EAG6, chain B is ESAG7 and chain C corresponds to human Tf.  
Transferrin receptor Transferrin  
Chain Residue Group Chain Lobe Residue Group Type of interaction 
A R139 Side chain C N A54 Backbone CO Hydrogen bond 
A D221 Side chain C C H349 Side chain Hydrogen bond 
A T222 Side chain C C H349 Side chain Hydrogen bond 
A T222 Side chain C C E372 Side chain Hydrogen bond 
A G228 Backbone CO C C R352 Side chain Hydrogen bond 
A G228 Backbone CO C C S370 Backbone NH Hydrogen bond 
A Y248 Side chain C C H349 Side chain Aromatic stacking 
A Y266 Side chain C C H349 Side chain Hydrogen bond 
B Y18 Side chain C N T330 Side chain Hydrogen bond 
B Y18 Side chain C N R324 Side chain Cation-π 
B Y18 Side chain C N N325 Side Chain Hydrogen bond 
B E19 Side chain C N Y71 Side chain Hydrogen bond 
B E19 Side chain C N R324 Side chain Hydrogen bond 
B E19 Side chain C N K312 Side chain Hydrogen bond 
B N20 Side chain C C N383 Side chain Hydrogen bond 
B G138 Backbone CO C C R352 Side chain Hydrogen bond 
B S140 Backbone CO C C R352 Side chain Hydrogen bond 
B S140 Side chain C C S359 Side chain Hydrogen bond 
B S141 Side chain C C C368 Backbone NH Hydrogen bond 
B Q142 Side chain C C R352 Side chain Hydrogen bond 
B Q142 Side chain C C C368 Backbone CO Hydrogen bond 
B N150 Side chain C C S359 Side chain Hydrogen bond 
B N150 Side chain C C E367 Side chain Hydrogen bond 
B R213 Side chain C C E367 Side chain Hydrogen bond 
B D222 Side chain C N N76 Side chain Hydrogen bond 
B H265 Side chain C N P74 Side chain Stacking 
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Figure 28: Protein sequence alignments of Bn2-TfR and BES1-TfR. Residues that vary 
are highlighted in orange. Bn2-TfR residues that bind human Tf are indicated with a red 
asterisk and residues in BES1-TfR selected for mutagenesis are indicated with a pink triangle. 
Helices are represented by a blue cylinder, signal peptides are indicated by a black box and 
the GPI anchor addition site is shown with a dashed box. 
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Figure 29: Sequence variation between Bn2-TfR and BES1-TfR. A, Surface representation 
of Bn2-TfR with ESAG6 shown is dark blue and ESAG7 represented in cyan. Residues that 
vary between Bn2-TfR and BES1-TfR are highlighted in yellow. Pink indicates residues 
selected for mutagenesis, and human Tf is shown in red. B, Cartoon representation of Bn2-
TfR bound to human Tf with an identical colour scheme as described in A. Variable residues 
are shown in stick representation.  
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Figure 30: Measurement of human and rat Tf binding to BES1-TfR mutants by SPR. 
Biotinylated BES1-TfR mutants were immobilised and purified Tf was injected in a 
concentration series ranging from 1 µM to 1 nM. 
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Figure 31: Measurement of Tf binding to Bn2-TfR, BES1-TfR and BES1mut by SPR. 
Biotinylated TfRs were immobilised and purified Tf was injected in a concentration series 
ranging from 1 µM to 1 nM. 
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Table 3: SPR measurement of binding parameters. Kinetic values for interactions between 
immobilised BES1-TfR mutants and purified transferrin. BES1mut contains four mutations: 
G139R in ESAG6 (e6); and I229V, S246Y and C233R in ESAG7 (e7). Kinetic data for low 
binding responses were not determined (ND). 
TfR Transferrin KD(nM) kon(M-1s-1) koff(s-1) 
BES1 Human ND ND ND 
BES1 Rat 2900 1.2x105 3.6x10-1 
BES1 e6 G139R Human 2600 7.2x104 1.9x10-1 
BES1 e6 G139R Rat 2800 1.1x105 3.1x10-1 
BES1 e7 I229V S246Y Human 1200 7.3x104 8.3x10-2 
BES1 e7 I229V S246Y Rat 2100 1.3x105 2.7x10-1 
BES1 e6 G139R e7 I229V S246Y Human 410 7.2x104 2.9x10-2 
BES1 e6 G139R e7 I229V S246Y Rat 1100 1.4x105 1.6x10-1 
BES1mut Human 300 6.6x104 2.0x10-2 
BES1mut Rat 1100 1.3x105 1.4x10-1 
BES1mut Mouse 150 2.9x105 4.2x10-2 
BES1mut Rabbit 99 2.1x105 3.9x10-3 
BES1mut Cow 3.2 6.5x105 2.1x10-3 
BES1mut Goat 7.6 4.1x105 3.1x10-3 
BES1mut Horse  250 3.1x105 8.0x10-2 
BES1mut Pig 1300 9.6x104 1.2x10-1 
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4.3.5 Mapping of TfR polymorphisms 
To study the locations in which polymorphisms are clustered, T. b. brucei ESAG6 and ESAG7 
sequences from the Lister 427 and EATRO 2340 isolates were analysed. The frequency of 
variation of each residue was calculated and the entropy was mapped onto a surface 
representation of the structure using the Shannon entropy scale. Polymorphic residues were 
predominantly located at the apical tip of the receptor (Figure 32A), indicating that sequence 
variation was a result of active selection. While active selection within the TfR apex could have 
arisen through a necessity to either increase Tf affinity or avoid immune recognition, SPR data 
with BES1mut (Figure 31) suggested that the former was not a viable hypothesis as a small 
number of point mutations considerably improved the affinity of BES1-TfR for all Tfs tested. 
Furthermore, surface representations of the structure were used to compare polymorphic 
residues (Figure 32B, C) with residues that formed the Tf-binding site (Figure 32D). The 
residues interacting with transferrin (Figure 32D) aligned with conserved regions at the surface 
of the receptor (Figure 32C). The binding footprint of Tf appeared to form a negative image of 
the variable sites, illustrating that Tf binding and diversification were not aligned. Mapping of 
sequence variation provided evidence that receptor evolution was not the result of a 
requirement for species specific TfRs, as diversification did not reside in the Tf binding site.  
 
4.3.6 Glycan positioning 
Endo Hf cleaved N-linked glycans at the β(1-4) glycoside bond between two GlcNAc sugars, 
leaving a residual Glc-NAc attached to the protein. The residual sugar served as a guide for 
positioning and orienting glycosylations. Previously published predicted chemical structures 
of trypanosome N-linked glycans were used for modelling (Mehlert et al., 2012). One glycan 
in ESAG6 was not modelled as it was located in the unresolved C-terminus close to the GPI 
anchor. Resolved glycans were found in two different locations on the receptor. A single glycan 
was located in the core three-helix bundle of each ESAG within the narrowest region of the 
receptor (Figure 33A). The second glycosylated region was found at the apical surface of the 
receptor. Three glycans from ESAG6 and two glycans from ESAG7 were arranged in a ring 
formation located beneath the ligand binding site (Figure 33A, C). The structure indicated that 
the glycan ring was not directly involved in ligand binding, corroborating previous findings 
(Maier & Steverding, 2008) (Mehlert et al., 2012). In addition, comparison of glycan positioning 
with polymorphisms revealed precise positioning of glycans in less diverse regions of the 
structure (Figure 33B). Glycans were located between variable patches and appeared to serve 
as a shield for conserved epitopes. 
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Figure 32: Mapping of TfR polymorphisms. A, Surface representation of Bn2-TfR depicted 
in grey, with variable residues highlighted in yellow (Shannon sequence entropy 0.3-0.5), 
orange (0.5-0.8) and red (>0.8). B, Bn2-TfR is shown in grey, with sequence variation 
concentrated towards the apical surface that surrounds the Tf-binding site. Human Tf is shown 
as a cartoon in red. C, Top view of the TfR apical surface with polymorphisms coloured as 
described in A. D, Top view of the TfR with residues that bind Tf highlighted in blue. 
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Figure 33: Localisation of TfR glycans. A, Trypanosome TfR structure shown in blue 
(ESAG6) and cyan (ESAG7). Modelled TfR glycans are represented in green and human Tf 
is shown in red. B, Surface representation of the TfR in grey, with polymorphisms highlighted 
in yellow, orange and red. Glycans and human Tf are coloured as described in A. C, Top view 
of the TfR apical surface with glycans shown in green and variable regions highlighted in 
yellow, orange and red.  
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4.4 Discussion 
Structural characterisation of the TfR revealed that the receptor adopted a structure similar to 
other trypanosome cell surface proteins, with a three-helix bundle motif maintaining the core 
fold of the receptor. In particular, the TfR showed striking similarity to the N-terminal domain 
of type A VSGs. Despite sequence divergence between surface proteins, structural homology 
is conserved.  
The heterodimerisation interface of the receptor extends along the alpha-helix. Initial hopes 
that structural data would provide clues to solve the preferential heterodimerisation 
conundrum were not fulfilled. There were no obvious regions in which the assembly of a 
homodimer would produce an electrostatic clash or steric hinderance. Due to the 
concentration of structural differences at the apical surface of the receptor, it is likely that 
discrete variations within the folding of loops in this region would favour the formation of 
heterodimers over homodimers. Ultimately, the receptor acquired an ESAG6/7 asymmetric 
binding site to accommodate the bilobal heterogeneity of the transferrin ligand.  
Several discreet mutations provided an increase in human Tf binding affinity for BES1-TfR, 
suggesting that Tf affinity was not the driving factor for TfR variation. In addition, mapping of 
TfR sequence diversity and glycans delivered further evidence indicating that host promiscuity 
was not the origin of receptor multiplication and diversification. The location of polymorphisms 
at the surface of the receptor within exposed epitopes that were not protected by bound ligand 
and could be susceptible to immunoglobulin attack strongly suggested that variation was 
driven by an immune avoidance strategy. Furthermore, N-linked glycans were placed to shield 
conserved epitopes. Concomitantly, polymorphic clusters and glycan barriers supported the 
hypothesis that evolutionary divergence of TfRs originated from an advantage conferred by 
avoidance of the host adaptive immune system, thus promoting long term persistence.  
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Chapter 5  
 
 
Iron acquisition 
 
 
5.1 Introduction 
5.1.1 Iron acquisition in mammals 
Iron is an essential nutrient and one of the most abundant elements on Earth. The redox 
potential of iron underpins its requirement in cells, with transitions between Fe(III) and Fe(II) 
constituting an important role in electron transfer reactions. Due to the necessity of iron, 
transport and uptake of iron has shaped evolution. Vertebrates sequester Fe(III) within the 
iron transporter protein transferrin (Tf) to avoid conversion to Fe(II) and the associated toxicity. 
Thus, a cellular transferrin receptor (TfR) has evolved across vertebrates to specifically bind 
circulating Tf. Furthermore, iron sequestration serves to limit iron scavenging from invading 
pathogens, which in turn has led to pathogen adaptation in the form of sophisticated iron 
acquisition mechanisms to combat host defence strategies. Bloodstream-form trypanosomes 
have evolved a TfR which is not homologous to the human TfR but can efficiently hijack host 
Tf via receptor-mediated endocytosis (Coppens et al., 1987).  
Iron acquisition has been extensively characterised in humans. The human TfR exists in two 
forms, TfR1 and TfR2. The latter is predominantly expressed in the liver, while the TfR1 
homologue is ubiquitously expressed and will be referred to in this chapter. The homodimeric 
transmembrane receptor binds two molecules of transferrin and relies on pH changes during 
cellular trafficking to efficiently release iron and transferrin. The human TfR has a high affinity 
for iron-bound holo-Tf (KD = 1 to 10 nM) (Giannetti et al., 2003). Upon binding, the receptor-
ligand complex is internalised via clathrin-mediated endocytosis (Pearse & Robinson, 1990). 
As the complex transits through the endocytic system, it experiences a progressive decrease 
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in pH. Iron is released from the complex at between pH 6.5 and pH 5.5 (Morgan, 1979). 
Studies have shown that the receptor potentiates the release of iron at a slightly higher pH 
when compared to iron dissociation from Tf alone (Giannetti et al., 2005) (Eckenroth et al., 
2011). The human TfR retains a high affinity for iron-free apo-Tf at low pH. However, the 
receptor has a low affinity for apo-Tf at neutral pH (Morgan, 1983). Upon recycling of the 
receptor-ligand complex to the cell surface, apo-Tf is released during exposure to neutral pH. 
The receptor can now resume availability and selectively bind holo-Tf. 
 
5.1.2 Iron acquisition in trypanosomes 
Procyclic-form trypanosomes that proliferate in the tsetse fly midgut are dependent upon iron 
for many cellular processes. Procyclic-form cells rely on oxidative phosphorylation for energy 
production, in which iron-sulphur clusters play a critical role. Iron acquisition during the insect 
stage remains relatively unknown, although it has been shown that the process may involve 
uptake and reduction of ferric complexes (Mach et al., 2013). In contrast, bloodstream-form 
trypanosomes, which have evolved to express a TfR, required little iron due to the absence of 
an active respiratory chain (Hannaert et al., 2003). Previous calculations revealed that 
bloodstream-form trypanosomes required 40,000 Fe(III) atoms per generation but had the 
capacity to internalise 85 000 iron atoms (Steverding, 1998). During mammalian infection, it 
is believed that Fe(III) is required to form Fe-dependent superoxide dismutases involved in 
converting superoxide radicals to protect against oxidative stress (Kabiri & Steverding, 2001). 
Haem containing iron may also play a role in antioxidant defence in bloodstream-form 
trypanosomes (Kořený et al., 2010) and can be acquired by uptake of haptoglobin-
haemoglobin mediated by the haptoglobin-haemoglobin receptor (HpHbR) (Vanhollebeke et 
al., 2008). Whether iron can be extracted from haem is uncertain and seemingly implausible, 
as an orthologue of haem oxygenase has not been identified in trypanosomes (Taylor & Kelly, 
2010). Furthermore, various studies suggested that iron transported by Tf is essential for 
trypanosomes, based on evidence which demonstrated that Tf is required for growth (Schell 
et al., 1991b) and knockdown of TfR variants by RNAi led to trypanosome growth arrest 
(Tiengwe et al., 2017).   
There is a paucity of data relating to Tf uptake and iron release in trypanosomes. The TfR-Tf 
complex is endocytosed at the flagellar pocket (Coppens et al., 1987), which prompted 
speculation that Tf and iron release may operate in a similar manner to the human pathway. 
However, the fate of the receptor-ligand complex remained unclear, with one study showing 
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that the TfR-apoTf complex is stable from pH 8 to pH 5 (Steverding et al., 1995), while another 
study demonstrated dissociation of apo-Tf from the receptor at pH 5 (Maier & Steverding, 
1996). In this chapter, affinity measurements would be performed to clarify whether binding of 
Tf to the trypanosome TfR was altered depending on the pH and iron-bound state of the ligand.  
 
5.2 Aims 
To investigate the implication of iron and the pH-dependency of receptor-ligand interactions, 
surface plasmon resonance (SPR) was performed using holo- and apo-Tf and a pH range to 
represent progression through the endocytic pathway. Several key questions would be 
addressed: 
1. Does the trypanosome TfR mimic the human TfR regarding iron and ligand release? 
2. How do pH and the presence of iron affect ligand binding? 
3. At which stage of the endocytic pathway does iron release from the receptor-ligand complex 
occur? 
 
5.3 Results 
5.3.1 A conserved binding interface on transferrin 
Unlike the human TfR, previous studies have shown that the trypanosome TfR does not 
discriminate between iron-bound holo-Tf and iron-free apo-Tf (Steverding et al., 1995). 
However, a relation in ligand binding between the human and trypanosome receptor was 
observed. An overlay of the structure of human TfR-Tf complex with the trypanosome TfR-Tf 
complex revealed that both receptors contacted a similar surface on human Tf (Figure 34). 
Trypanosomes have likely evolved to bind the same ligand surface to prevent the possibility 
of Tf escape mutations. If escape mutants arose to avoid binding to the trypanosome receptor, 
a loss in binding to the native human TfR would also occur. Furthermore, the principle of 
minimalising escape mutants can be applied to other mammals as the TfR-Tf interface is 
almost certainly conserved in mammals. The evidence for this is: First, mammalian TfRs are 
homologous, with TfRs from each species used in this study exhibiting more than 75% amino 
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acid identity with the human TfR, and an alignment demonstrated that mammalian TfRs were 
conserved (Appendix 7). Second, an alignment of mammalian Tfs also showed homology 
(Figure 35), thus suggesting that the TfR-Tf binding site is conserved across mammalian 
species. Finally, an alignment of mammalian Tfs illustrated that the majority of human Tf 
residues interacting with the trypanosome TfR were either identical or similar in other species 
(Figure 35), demonstrating that trypanosomes would bind a similar surface on other 
mammalian Tfs. Thus, the binding strategy had evolved to limit the propagation of Tf escape 
mutants and could be extended to other mammalian hosts.  
 
5.3.2 The structure revealed monoferric transferrin bound to the 
trypanosome receptor at pH 6.5 
The crystal structure confirmed that the trypanosome TfR bound a single Tf molecule. Tf can 
be subdivided into two lobes, termed N-lobe (residues 1-330) and C-lobe (residues 340-679), 
with a hinge region separating the two lobes. The structure of the trypanosome TfR-Tf complex 
was obtained at pH 6.5 and electron density corresponding to an iron atom was only present 
in the C-lobe (Figure 36). Each lobe can coordinate an Fe(III) atom via a conserved aspartic 
acid, histidine and two tyrosines within each lobe (Figure 36, inset). A synergistic anion, 
typically carbonate, completed the coordination (Lambert et al., 2005). A lack of electron 
density at the site of iron coordination within the N-lobe indicated that Fe(III) was absent.  
Previously solved structures of human apo-transferrin lacking iron (Wally et al., 2006) and 
human holo-transferrin with iron bound in both lobes (Noinaj et al., 2012) were superimposed 
onto the structure of human transferrin bound to trypanosome TfR (Figure 37) described in 
the previous chapter. Indeed, the N-lobe aligned with the apo-transferrin structure adopting 
an open conformation of the iron binding cleft, permissive to iron release (Figure 37A). The C-
lobe aligned with holo-transferrin, showcasing a closed fold of the cleft to retain iron (Figure 
37B). Adoption of the closed conformation in the C-lobe and an open conformation in the N-
lobe provided further evidence that the structure had a single iron atom bound in the C-lobe. 
Although the structure gave us a snapshot of the iron state of the complex at pH 6.5, 
understanding transferrin binding and iron presence at different pH values of the endocytic 
pathway was essential. 
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Figure 34: Human TfR and trypanosome TfR bind a similar surface on Tf. Overlay of the 
structures of human TfR-Tf complex and the trypanosome TfR-Tf complex. Human TfR is 
represented in purple, ESAG6 in blue, ESAG7 in cyan and human Tf in red. 
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Figure 35: Alignment of mammalian transferrins. Protein sequences of mammalian Tfs 
used in binding studies were aligned and variation was highlighted in orange. Residues in 
human Tf that interact with the trypanosome TfR are indicated with a red asterisk and those 
that interact with the human TfR are indicated with a green circle.  
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Figure 36: Structure of human Tf N- and C-lobes bound to trypanosome TfR. The N-lobe 
of human Tf is shown brown, the iron-bound C-lobe is coloured in red and Fe(III) is depicted 
as an orange sphere. The four Tf residues that coordinate iron are shown as a stick 
representation in green in the inset.  
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Figure 37: Comparison of apo- and holo-Tf structures with Tf bound to the trypanosome 
TfR. A, Structure of human apo-Tf (PDB: 2HAU) shown in yellow was superimposed onto the 
structure of human Tf (red) bound to the trypanosome TfR. B, An overlay of diferric human Tf 
(PDB: 3V83) in green and human Tf (red) bound to the trypanosome TfR. 
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5.3.3 Effects of pH on ligand binding 
In light of the similarities in Tf-binding site between the trypanosome TfR and the native TfR, 
a hypothesis was formulated that molecular mimicry may occur. Following iron release from 
the endocytosed human TfR-Tf complex, apo-Tf remains bound at acidic pH. Recycling of the 
complex to the cell surface leads to Tf dissociation as apo-Tf has a low affinity for the human 
TfR at neutral pH (Morgan, 1983). Thus, binding of apo- and holo-Tf to trypanosome TfR was 
investigated by SPR using a pH range that represented the changes in environment during 
endocytosis. Previous studies had shown that the lysosomal pH encountered in bloodstream-
form trypanosomes is 4.8 (McCann et al., 2008), and this increase in acidity was reflected in 
the pH spectrum selected. The sensorgrams showed binding of iron-bound and iron-free 
transferrin to the trypanosome TfR at every pH tested (Figure 38), with dissociation constants 
(KD) remaining in the low nanomolar range (Table 4). At pH 7.4, a three-fold difference in 
affinity was observed between holo- and apo-Tf. While holo-Tf bound Bn2-TfR with a KD of 9.1 
nM, apo-Tf showed weaker binding with a KD of 31 nM (Table 4). While a reduction in binding 
was observed, it was clear that the loss of iron did not abolish Tf binding to the trypanosome 
TfR at neutral pH, indicating that the parasite receptor did not operate in the same way as the 
human receptor. Contrary to previous findings (Maier & Steverding, 1996), low pH did not 
disrupt the TfR-Tf complex. One possibility is that a lower affinity TfR, such as BES1-TfR, may 
facilitate the release of Tf at acidic pH. To test this, a similar experiment was performed by 
biolayer interferometry (BLI) to study the effect of pH on the lower affinity interaction between 
BES1-TfR and bovine Tf. The sensorgrams showed that Tf binding was conserved at low pH 
(Appendix 8). A difference in binding response was observed between two iron states at pH 
7.4, with a reduction in binding observed for apo-Tf compared to holo-Tf. The decrease in 
binding was consistent with the differences in binding responses between Bn2-TfR and human 
Tf in two iron states, measured by SPR at pH 7.4 (Figure 38). The reduction in binding was 
attributed to the differences in Tf conformation depending on the iron state (Figure 37), 
suggesting that these changes were ubiquitous in mammalian Tfs. The open conformation of 
apo-Tf was likely responsible for the weaker affinity observed. At lower pH, binding of bovine 
Tf to BES1-TfR was not disrupted (Appendix 8). While it appeared that holo-Tf showed weaker 
binding compared to apo-Tf as the acidity increased, it was difficult to draw robust conclusions 
as there were discrepancies between the initial baseline signal and kinetic parameters could 
not be determined. However, the data suggest that Tf would remain bound to its receptor 
throughout the endocytic pathway, regardless of the host species or the TfR actively 
expressed.  
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Although we had determined that the trypanosome receptor-transferrin complex does not 
respond to pH in the same way as the native human receptor, the fate of iron remained elusive. 
A decrease in affinity was observed in human holo-Tf binding to Bn2-TfR between pH 7.4 (KD 
= 9.1 nM) and pH 6.5 (KD = 31 nM) (Table 4). The weaker binding of holo-Tf at pH 6.5 closely 
resembled the affinity of apo-Tf at pH 6.5 (KD = 35 nM), suggesting that there may be iron 
release from the TfR-Tf complex between pH 7.4 and pH 6.5. Additional studies would be 
conducted to further elucidate iron release during endosomal progression. 
 
5.3.4 Investigation of iron release by microPIXE 
Particle-induced X-ray emission with a microfocused beam (microPIXE) is a technique 
pioneered by Elspeth Garman and Geoffrey Grime (Garman & Grime, 2005), which allowed 
investigation of iron release in atomic detail (Appendix 9). An identical pH range was selected 
to reflect endocytic conditions and provide a comparison with SPR data. Iron quantification 
was performed to measure the number of iron atoms present in unbound human Tf and human 
Tf bound to Bn2-TfR (Figure 39), providing several observations. First, it is worth noting that 
the starting iron saturation at physiological pH for both free Tf and receptor-bound Tf is ~0.6 
atoms per Tf, which correlated with the reported 30-60% iron saturation of circulating serum 
Tf (Williams & Moreton, 1980) (Eckenroth et al., 2011). Second, in the absence of receptor, Tf 
displayed a dramatic release of iron following a decrease by one pH unit, with a loss of ~80% 
of bound iron. By pH 4.8, almost all iron has been released from Tf, with 0.055 atoms of iron 
remaining per molecule of Tf. In contrast, the fate of iron for receptor-bound Tf was different 
with a reduced amount of iron loss during acidification compared to Tf alone. Approximately 
50% of bound iron was released from the complex between physiological pH and pH 6.5, 
which correlated with previous SPR data suggesting a loss of iron between pH 7.4 and pH 6.5 
(Figure 38). Finally, binding of the trypanosome TfR to human Tf appeared to stall the release 
of iron during transit of the complex through the endosomal lumen. Thus, iron could be 
retained until the complex reached the lysosome. 
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Figure 38: Measurement of human holo- and apo-Tf binding to Bn2-TfR at different pH 
by SPR. Biotinylated TfRs were immobilised and purified Tf was injected in a concentration 
series ranging from 1 µM to 1 nM at pH 7.4, 6.5, 5.5 and 4.8. 
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Table 4: SPR measurement of binding parameters. Kinetic values for interactions between 
immobilised Bn2-TfR and humo holo- and apo-transferrin. Kinetic data for pH 5.5 and pH 4.8 
were not reported due to inaccuracies caused by the low pH buffer. 
TfR pH Transferrin KD(nM) kon(M-1s-1) koff(s-1) 
Bn2 7.4 Human holo-Tf 9.1 2.4 x105 2.2x10-3 
Bn2 7.4 Human apo-Tf 31 1.3x105 4.1x10-3 
Bn2 6.5 Human holo-Tf 41 2.4 x105 9.8x10-3 
Bn2 6.5 Human apo-Tf 35 2.1x105 3.7x10-2 
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Figure 39: Quantification of bound iron by microPIXE. The number of iron atoms bound 
per Tf was measured at each pH value (7.4, 6.5, 5.5 and 4.8) for free human Tf (Transferrin) 
and human Tf bound to the trypanosome TfR (Complex). Mean values of three technical 
replicates were plotted while error bars represent standard deviation.  
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5.3.5 How essential is transferrin? 
Previous studies in chapter 3 and this chapter showed that a low affinity TfR can support 
growth and that the trypanosome TfR does not discriminate between holo- and apo-Tf, which 
prompted questioning of the essentiality attributed to Tf uptake in trypanosomes. To test this, 
bovine Tf was selectively depleted from foetal calf serum (FCS) by affinity chromatography 
using a Bn2-TfR column. Tf was not detected by western blot probed with anti-bovine Tf 
antibody in Tf-depleted FCS (Figure 40). A titration was performed to investigate the sensitivity 
of anti-bovine Tf antibody and low (4.5 nM) concentrations of Tf were detectable (Appendix 
10), indicating that Tf-depleted serum was likely to have sub-nanomolar concentrations of 
bovine Tf. BES1-TfR was shown to bind bovine Tf with a KD of 80 nM (Table 1), which was far 
greater than the concentration of bovine Tf in depleted FCS. Trypanosomes expressing the 
BES1-TfR were cultured in medium containing Tf-depleted FCS and compared to a control 
culture in medium containing FCS. In both groups, cells proliferated without any marked 
differences in growth rates (Figure 40). Cells were cultured for 200 hours, a sufficient amount 
of time to exhaust iron reserves, and the low Tf concentrations (< 1 nM following dilution in 
medium) did not negatively impact cell proliferation.  
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Figure 40: Comparison of growth rates of trypanosomes in FCS and Tf-depleted serum. 
A, Samples containing 10% FCS (1), 10% FCS depleted of Tf and repleted with 3 µM bovine 
Tf (2) and 10% FCS depleted of Tf (3) were analysed by western blot probed with anti-bovine 
Tf antibody. B, Bloodstream form trypanosomes expressing BES1-TfR were grown in medium 
containing FCS (blue) or FCS depleted of Tf (red).   
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5.4 Discussion 
In this study, pH appeared to have little effect on transferrin binding, indicating that receptor-
ligand interactions are likely to be maintained through the endocytic pathway. Furthermore, 
binding of Tf to the trypanosome receptor stalled iron release compared to unbound Tf, with 
some iron shown to remain bound at lysosomal pH. The delayed release of iron observed in 
receptor-bound Tf could indicate an evolutionary advantage conferred by iron retention until 
the lysosome. Iron sequestration until the lysosome may have physiological significance, as 
previous studies have shown that T. brucei mucolipin-like protein (TbMLP), involved in iron 
transport to the cytosol, is located in proximity to the lysosome (Taylor et al., 2013). However, 
release of the remaining iron and the fate of the TfR-Tf complex remains unknown, prompting 
speculation of several possible scenarios. First, the entire complex could be degraded allowing 
iron release, although this is inconsistent with previous reports that the TfR is recycled (Kabiri 
& Steverding, 2001). Second, the entire complex could be recycled to the cell surface, but this 
does not explain how the remaining sequestered iron is released. Third, the receptor and 
ligand could be differentially sorted and embark on separate routes, resulting in Tf proteolysis 
and TfR recycling as suggested in previous studies (Pal et al., 2003). Previous investigations 
have shown that the TfR may have a half-life between 1.5 hours (Schwartz et al., 2005) 
(Tiengwe et al., 2017) and 7 hours (Kabiri & Steverding, 2000), with a cycling time of 11 
minutes (Kabiri & Steverding, 2000), suggesting that the receptor is recycled. However, 
whether the ligand remains bound or the factors involved in receptor-ligand dissociation 
remain to be elucidated and further investigation is required.  
Previous studies have shown that iron is essential for bloodstream form trypanosomes, and 
depletion of iron using the iron chelator deferoxamine resulted in growth inhibition (Breidbach 
et al., 2002). It would be useful to investigate iron metabolism through titration of deferoxamine 
to modulate iron starvation and further understand iron requirements in bloodstream form 
trypanosomes. Tf-depletion studies in section 5.3.5 have shown that uptake of Tf may not be 
essential as proliferation was not affected, which is in contrast to previous findings (Schell et 
al., 1991b). In the study conducted by Schell et al., cell growth was arrested in Tf-depleted 
FCS at 24 hours, with a decline in trypanosome population attributed to cell death observed 
between 24 and 48 hours. The discrepancies were not likely to be due to differences in the 
expressed TfR as both studies used trypanosomes expressing from the BES1 (221) site. 
However, Tf-depletion methods did vary. While Schell et al. immunised rabbits with bovine Tf 
to generate polyclonal antibodies for Tf depletion from FCS, the approach adopted in this 
study (section 5.3.5) relied upon the selectivity of Bn2-TfR for Tf-depletion from FCS. FCS is 
likely to contain lactoferrin, another iron transporter protein which is homologous to Tf. 
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Concentrations of lactoferrin detected in serum were 10-fold lower than Tf in 3-month old 
calves (Tóthová et al., 2016), and may remain at low levels in adults. An alignment of bovine 
Tf and bovine lactoferrin showed that the iron transporter proteins shared 58% amino acid 
identity (Appendix 11). The use of a polyclonal antibody may have resulted in depletion of both 
Tf and lactoferrin as the alignment suggested a likelihood for the presence of shared epitopes. 
It is unclear whether the polyclonal antibody used in 5.3.5 for Tf detection would cross-react 
and recognise lactoferrin, thus making it difficult to comment on whether lactoferrin would be 
present in Tf-depleted serum. If Bn2-TfR selectively depleted Tf and lactoferrin remained in 
the serum, two possibilities could be formulated. Either BES1-TfR does not discriminate 
between the two iron transporter proteins and can bind and endocytose lactoferrin, or 
trypanosomes have evolved an alternative strategy for lactoferrin uptake. If lactoferrin was not 
present in the Tf-depleted serum, it may be possible that trypanosomes can rely on an 
alternative iron source, whether that be through uptake of HpHb in conjunction with an 
uncharacterised pathway for iron extraction from haem, or bloodstream-form trypanosomes 
may have evolved an alternative route for iron uptake.  
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Chapter 6  
 
 
Development of TfR-specific 
monoclonal antibodies using phage 
display 
 
 
 
6.1 Introduction 
Trypanosome populations have inherent capacities to avoid host immune detection by 
switching expression of cell surface proteins. Antibodies that successfully bind prior to 
switching can, at low to medium immunoglobulin titres, be cleared by endocytosis. 
Trypanosomes have remarkable endocytic capacities, a feat that is further enhanced by 
hydrodynamic flow forces that propel large, globular molecules such as antibodies towards 
the flagellar pocket (Engstler et al., 2007). Internalisation of surface bound immunoglobulins 
led to the formulation of the hypothesis that trypanosomes could be specifically targeted and 
killed if a toxin were conjugated to the IgG. This concept was investigated and validated during 
a collaboration involving our laboratory and AstraZeneca, led by MacGregor and Gonzalez-
Munoz. The study was an elegant demonstration of a novel therapeutic strategy that can draw 
upon the body of research conducted in cancer ADC therapeutics by using a related ADC 
scaffold, with the addition of modified specificity to target trypanosomes (MacGregor, 
Gonzalez-Munoz et al., 2019).   
 
 116 
 
6.1.1 Trypanosome receptors as a target for ADC-based 
therapeutics 
The T. b. brucei haptoglobin-haemoglobin receptor was selected as the target for an ADC 
therapeutic for several reasons. First, the receptor is encoded by a single copy gene within 
the genome which will remain expressed during dynamic VSG switching. Second, HpHbR is 
capable of receptor-mediated endocytosis of macromolecules including haptoglobin-
haemoglobin (Mr = 150,000) (Lane-Serff et al., 2014) and the host immune complex TLF1 (Mr 
= 500,000) (Raper et al., 1999). Third, the T. b. brucei HpHbR structure revealed a three-helix 
bundle featuring a rigid 50° kink forming an extensive ligand interaction surface (Lane-Serff et 
al., 2014), which is likely accessible to bivalent IgG binding. Finally, a knockout HpHbR-/- cell 
line was available, as a control, to further validate the specificity of the proof-of-principle study. 
Specificity of the antibody drug conjugate (ADC) was achieved by performing phage display 
with a diverse scFv library. The choice of receptor proved fruitful as the phage display screen 
produced several antibodies that were endocytosed following HpHbR binding. Two antibodies 
were toxin-conjugated and exhibited excellent trypanosome-specific lethality with minimal 
toxicity to human cells. The IC50 concentrations of the ADCs tested in T. b. brucei were ~ 1 
pM while human cell lines tolerated a dose 50,000 times greater, providing a remarkably wide 
therapeutic window (MacGregor, Gonzalez-Munoz et al., 2019). However, there were a few 
drawbacks in the choice of receptor: (i) A low copy number of 200 – 400 molecules per cell 
(Vanhollebeke et al., 2008); (ii) A polymorphism in the human infective T. b. gambiense 
HpHbR leads to reduced efficiency of the ADCs in their current format (personal 
communication);  (iii) Knockout studies show that the receptor is not essential and resistance 
may arise. Together, these formed the premise for an investigation of additional trypanosome 
cell surface receptors as targets for ADCs. The trypanosome transferrin receptor is an 
attractive target as it has a higher copy number of ~ 3,000 receptors/cell (Steverding et al., 
1994) and has, in previous studies, been shown to be essential (Tiengwe et al., 2016).  
Although the TfR is variable, the different sequences are highly conserved and common 
epitopes may be exploitable. Following the previous success of a phage display selection 
screen generating trypanosome-specific antibodies, phage display would be employed to 
raise antibodies against the trypanosome transferrin receptor. BES1-TfR and Bn2-TfR are two 
of the most divergent TfRs in the Lister 427 T. b. brucei strain and would serve as a substrate 
for developing a pan-specific TfR antibody. 
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6.1.2 Origins of phage display 
In addition to the endocytic potential of an ADC-based therapy to target trypanosomes, 
antibodies provide an attractive therapeutic strategy due to their compatibility with the host 
immune system. Phage display offers a high-throughput, in vitro approach for raising specific 
antibodies against a target. Two properties of bacteriophage were harnessed to develop 
‘phage display’: their capacity to express surface proteins and their ability to replicate in 
bacteria. This concept of coupling genotype to phenotype within a virion and achieving clonal 
propagation from E. coli was originally pioneered in the 1990s (Scott & Smith, 1990) 
(McCafferty et al., 1990). Filamentous M13 phage infect E. coli expressing the F-pilus and are 
commonly used in phage display. The variable regions from the light and heavy chains of an 
antibody (Figure 41A) can be engineered in various configurations to form bivalent antigen-
binding fragments (F(ab’)2) (Figure 41B) or monovalent antigen-binding fragments (Fabs) 
(Figure 41C). Additionally, the variable heavy (VH) and variable light (VL) chains can be fused 
with a flexible linker to form a single chain variable fragment (scFv) (Figure 41D). The scFv 
format was initially selected during the origins of phage display for two reasons. First, the 
binding kinetics of an scFv were shown to be equivalent to antigen binding by the parental 
antibody (Ward et al., 1989). Second, scFv can be inserted into a filamentous fd phage vector 
at the N-terminus of the gene III adsorption protein,  and expressed to achieve scFv – protein 
III (pIII) surface display (McCafferty et al., 1990) (Figure 42). Four copies of pIII are typically 
expressed at the surface of each virion and mediate bacterial adhesion. McCafferty and 
colleagues demonstrated that a one million-fold enrichment of anti-lysozyme scFv-expressing 
phage could be achieved after two rounds of purification over a lysozyme-Sepharose column 
(McCafferty et al., 1990). This principle was adapted to soluble and panning selections in 
which antigens are immobilised on beads or a plate surface respectively. Two to four rounds 
of selection are typically performed with library output quantification and diversity monitoring 
to determine the success of the screen. 
 
6.1.3 Filamentous phage properties 
Filamentous phage are used in phage display due to their parasitic, as opposed to lytic, 
infection of bacteria. This results in phage extrusion from E. coli without killing the cells (Marvin 
and Hohn, 1969). The phage single stranded genome is typically replaced with a phagemid 
vector encoding a selectable marker and the scFv-pIII fusion protein under the lacZ promoter. 
The remainder of the genetic material required for virion production is supplied by helper 
phage. M13KO7trp helper phage have been designed to preferentially package phagemid 
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vector DNA over phage DNA, ensuring effective assembly and extrusion of scFv-phages 
rather than helper phage production. Any helper phage DNA that is packaged and extruded 
encodes a trypsin-sensitive motif within the pIII protein that will render the phage non-infective 
following trypsin treatment. 
 
6.1.4 Library generation 
ScFv phage display concomitantly holds a phenotype and genotype by providing an immune 
component display system coupled to its DNA cargo. The success of the technology can be 
underpinned by the size and diversity of the scFv-expressing phage library. The diversity of 
scFv-expressing phage was achieved by building an immune naïve library that harnesses the 
inherent variation of antibodies expressed from lymphocytes. Peripheral blood lymphocytes, 
tonsil B-cells and bone marrow B-cells were collected from 43 non-immunised donors 
(Vaughan et al., 1996). Messenger RNA was isolated and complementary DNA was 
transcribed using random hexamer primers. PCR was performed with specific primers to 
amplify VH and VL chains. PCR fragments were inserted into a phagemid vector with a 
(Gly4Ser)3 linker to connect the two chains. The resulting bone marrow Vaughan (BMV) phage 
library achieved 1.4x1010 individual scFv recombinants. The combined spleen (CS) library was 
created in the same way using splenic and foetal liver B-cells from 20 non-immunised donors 
(Lloyd et al., 2009). BMV and CS phage libraries were pooled to produce a library size of 
9.6x1010 scFv clones.  
 
6.1.5 Phage display principle 
Phage display is performed by incubation of the target receptor with the BMV/CS scFv-
expressing phage library (Figure 43). Following removal of unbound phage, trypsin was added 
to fulfil several functions. First, trypsin-mediated proteolysis released bound phage through 
cleavage of the trypsin-sensitive Myc-tag adjacent to the scFv. Second, removal of the scFv 
fragment revealed pIII, rendering the phage E. coli infective. While library phage retained the 
ability to infect E. coli, they lacked the capacity to replicate the phagemid vector and egress 
from cells. Library phage were supplemented with helper phage to provide the genetic material 
to complete a productive infection and release phage particles. The resulting output population 
was enriched with phage displaying scFv specific to the target receptor.  
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6.1.6 Triage of output phage library 
6.1.6.1 Phage ELISA 
Phage-based enzyme-linked immunosorbent assays (ELISA) provided a high-throughput 
screening method to visualise specificity and triage the enriched output population to remove 
weak or non-specific binders. Each well of a 96-well master plate had a single TG1 colony that 
contained the phagemid vector encoding scFv-pIII. The pIII leader sequence localised pIII to 
the periplasmic space. Insertion of pIII in the outer membrane was refractory to subsequent 
phage infection, preventing superinfection of multiple phages in TG1 cells. To enable helper 
phage superinfection, glucose was added to the medium to mediate lacZ repression and 
prevent scFv-pIII expression. Upon addition of M13KO7trp helper phage, extrusion of scFv-
phage was achieved. 
The phage output raised against either BES1-TfR or Bn2-TfR was subsequently used in a 
phage ELISA to assess interactions with each antigen (Figure 44). A 96-well streptavidin 
assay plate was coated with BES1-TfR or Bn2-TfR. A third streptavidin plate without 
immobilised antigen was used to assess the prevalence of streptavidin binders. Clonally-
extruded scFv-phage from each well of the master plate were added to each well of the 
antigen-coated assay plate. Following a wash step, bound scFv-phage were detected by anti-
M13. HRP-conjugated anti-M13 reacted with TMB to produce a chromogenic substrate. The 
reaction was quenched by the addition of sulfuric acid and absorbance of the chromogen could 
be visualised at 450 nm. The absorbance signal was measured in absorbance units (AU) and 
positively correlated with phage binding. 
 
6.1.6.2 Homogenous time resolved fluorescence  
While phage ELISA served as a first-line indication of the success of a phage display screen, 
its reliability as a quantitative assay was debatable as several shortcomings exist. First, 
expression of phage and display proteins can vary between clones. Second, anti-M13-HRP 
binds pVIII, the most abundant phage coat protein. Phage express ~ 2,700 pVIII copies per 
virion (Newman et al., 1977), resulting in significant signal amplification and difficulties in 
discriminating between weak and strong binders. Homogenous time resolved fluorescence 
(HTRF) can be considered a more reliable screening technique to scrutinise binding as E. coli-
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derived soluble scFv were used to eliminate the complications related to the presence of 
phage.  
HTRF can be used to measure protein-protein interactions based on a combination of the 
fluorescence resonance energy transfer (FRET) principle and time-resolved measurement. 
An energy donor, such as cryptate, was coupled to streptavidin in order to bind the biotinylated 
target receptor (Figure 45). The acceptor fluorophore, XL665, was coupled to an anti-myc 
antibody for specific targeting to the myc-tagged scFv. Upon excitation from a light source, 
emission at 620nm occurred in the absence of proximity between the two fluorophores. 
However, if the scFv binds the target receptor, energy transfer from the donor to the acceptor 
fluorophore resulted in emissions at 665nm. The time resolved concept was derived from the 
occurrence of background short-lived fluorescence following excitation. To avoid interference 
of this signal in the analysis, measurements were taken 50-150 µs after excitation to allow for 
decay of the non-specific signal. Emissions at 665 nm and 620 nm wavelengths were 
measured following the time delay. The signal ratio of 665:620 nm positively correlated with 
the binding response between the scFv and the target receptor. 
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Figure 41: Immunoglobulin engineering schematic. A, Schematic representation of an 
IgG, with heavy chains shown in blue and light chains in violet. B, Representation of a F(ab’)2 
fragment containing the two disulphide bridges in the hinge region to link the heavy chains. C, 
Fab fragment containing a disulphide bond connecting the heavy and light constant regions. 
D, Schematic of an scFv, composed of the variable domains of the light and heavy chain, 
fused by a linker peptide as they do not contain thiols for disulphide linkage.  
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Figure 42: Schematic of the engineered filamentous M13 phage. The abundant pVIII protein forms the coat of the bacteriophage. Four to five 
copies of pIII are located at the anterior tip and mediate E. coli infection. A phagemid vector encodes scFv at the N-terminus of pIII to achieve 
scFv display.
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Figure 43: Schematic of the phage display soluble selection principle. Biotinylated target antigen is incubated with the scFv-phage library 
and binders are isolated by streptavidin bead precipitation. Trypsin digest fulfils the dual function of releasing bound phage and revealing pIII for 
E. coli infection. Helper phage are added to provide the lacking genetic material for virion packaging and extrusion. The resulting output population 
is enriched in phage expressing scFv that bind the target antigen.  
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Figure 44: Schematic of the phage ELISA principle. A, 96-well plates are coated with 
biotinylated target antigen BES1-TfR or Bn2-TfR. B, A single well of a streptavidin-coated 96-
well plate is represented. Biotinylated target antigen is immobilised on the streptavidin surface. 
Phage expressing scFv from clonal E. coli expansion are added and wells containing bound 
scFv-phage are visualised by anti-M13-HRP.  
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Figure 45: HTRF schematic. A, Europium-cryptate, a fluorescent donor that emits at 620 nm, 
is conjugated to streptavidin. B, XL665, an acceptor fluorophore, is conjugated to an anti-Myc-
tag antibody. C, Anti-Myc-XL665 binds scFv via the Myc-tag while SA-Eu-cryptate is 
complexed with biotinylated target antigen. Proximity-induced energy transfer between Eu-
cryptate and XL-665 is achieved upon scFv binding to target antigen, resulting in fluorescence 
emission at 665 nm.  
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6.2 Aims 
The aim of the phage display screen was to isolate antibodies targeting the trypanosome 
transferrin receptor (TfR), and answer several questions surrounding the development of TfR 
monoclonal antibodies (mAbs): 
1. Can a human-derived scFv library be enriched for trypanosome TfR binders? 
2. Can a glycan-rich protein be targeted? 
3. Would in vitro binders function in the context of a dense VSG coat? 
To answer these questions, phage display against BES1-TfR and Bn2-TfR was performed 
and scFv-binders were further triaged and characterised by homogenous time-resolved 
fluorescence (HTRF), SPR and trypanosome uptake assays.  
 
6.3 Results 
6.3.1 Enrichment of BMV/CS library for TfR binders 
Three serial rounds of soluble selections were performed by addition of the BMV/CS library to 
biotinylated BES1-TfR or biotinylated Bn2-TfR. Phage binders were captured with streptavidin 
beads and, following phage infection of E. coli TG1 cells, the library output size could be 
estimated based on the number of TG1 colony forming units (cfu) while the diversity was 
assessed via sequencing of the complimentary determining region 3 (CDR3). The diversity 
typically begins to fall as the output increases, indicating enrichment of a subset of high affinity 
binders. The antigen concentration is decreased during each round of phage display to drive 
the selection of high affinity binders (Figure 46A).  
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Figure 46: Phage display soluble selection outputs and diversity. A, Workflow highlighting 
the selection strategy for each round of selection. B, Table indicating the output library size 
following each round, determined by quantification of E. coli colony forming units. C, Diversity 
of the output library after three rounds of selection.  
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The output figures revealed a low round 1 output with an unusually large enrichment after 
round 2 (Figure 46B). The low round 1 output could be related to the presence of glycans on 
the receptors, resulting in a reduced interaction interface for the scFv-phage due to steric 
hinderance and impaired accessibility. Nevertheless, glycan binders may exist, but the origin 
of the library must be considered. As the library was generated from human lymphocytes, 
many glycan binders could potentially be screened and removed during the B-cell education 
process to avoid self-reactivity. The BES1-TfR and Bn2-TfR were expressed in CHO cells 
which display similar glycans to humans. It is therefore unlikely that a human-derived library 
would be rich in mammalian glycan binders.  
A considerable enrichment was observed after round 2 which, although usual, may indicate a 
plummet in diversity and propagation of dominant scFv-phage within the population. Indeed, 
analysis of the CDR3 sequences after round 3 indicated a low diversity, with 53% of the Bn2-
TfR output population representing unique scFvs, and less than half of the population for 
BES1-TfR (Figure 46C). The library outputs show marginal increases between round 2 and 
round 3 for both TfR variants (Figure 46B). Stabilisation of the library output size and the 
concomitant reduction in diversity could be indicative of a saturated effort in library enrichment 
and thus a fourth round of selection was not performed.  
 
6.3.2 Phage ELISA reveals variant specificity and a lack of cross-
reactivity 
Phage enriched for BES1-TfR binders, referred to as the BES1-TfR output, were screened by 
phage ELISA for binding interactions against the three immobilised targets: BES1-TfR, 
streptavidin and Bn2-TfR. The Bn2-TfR output would be analysed in an identical screen.  
To ascertain the number of hits in each screen, the hit threshold was determined. The average 
signal obtained from the negative control containing phage targeting an irrelevant antigen, 
carcinoembryonic antigen (CEA), was used as a starting point. A hit threshold was determined 
as three-fold the negative control signal. ELISA response signals above the hit threshold were 
considered as positive hits. The BES1-TfR output appeared to be selective for BES1-TfR 
binding. All phage clones gave a positive binding response to immobilised BES1-TfR and 
showed negligible binding to the streptavidin control plate (Figure 47A). Furthermore, the 
BES1-TfR output showed little interaction with immobilised Bn2-TfR, with only two scFv-phage 
clones producing a response above the hit threshold (Figure 47C). On the other hand, the 
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Bn2-TfR output appears to have produced more cross-reactive binders (Figure 47D) in 
addition to specific binding to the enrichment target (Figure 47B). The larger number of cross-
reactive hits generated from the Bn2-TfR library may correlate with the greater diversity of the 
enriched output, as the diverse scFvs may bind a variety of epitopes, increasing the chances 
of targeting shared epitopes.  
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Figure 47: Visualisation of binding by phage ELISA reveals variant specificity and 
infrequent cross-reactivity. A, The BMV/CS library enriched for BES1-TfR binders was 
screened for binding against immobilised BES1-TfR and streptavidin. B, The BMV/CS library 
output selected against Bn2-TfR was tested for Bn2-TfR and streptavidin binding. C, Cross-
reactivity was investigated by testing binding of the BES1-TfR output library to Bn2-TfR. D, 
The Bn2-TfR output library was screened for cross-reactive binding to BES1-TfR.  
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6.3.3 Output triage by HTRF 
Target-specific binding was determined by the following equations:  
𝑅𝑎𝑡𝑖𝑜 =  
𝐸𝑚𝑖𝑠𝑠𝑖𝑜𝑛 𝑎𝑡 665 𝑛𝑚
𝐸𝑚𝑖𝑠𝑠𝑖𝑜𝑛 𝑎𝑡 620 𝑛𝑚
 x 104 
 
%𝛥𝐹 =  
𝑅𝑎𝑡𝑖𝑜𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑅𝑎𝑡𝑖𝑜𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
𝑅𝑎𝑡𝑖𝑜𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
 x100 
 
The background ratio is determined by averaging the ratios produced by a negative control 
anti-CEA scFv against the target of interest. Thus, ΔF is a measure of specific binding obtained 
after the removal of non-specific noise.   
The specificity of the phage selection screen was apparent from the segregation of binders 
depending on the library origin (Figure 48). Samples 1 - 44 represent the scFv library targeting 
BES1-TfR while samples 45 - 88 contain scFv raised against Bn2-TfR. The results corroborate 
previous data from the phage ELISA, revealing a high degree of specificity for each target and 
a lack of cross-reactivity. ELISA data showed a higher number of cross-reactive hits derived 
from the Bn2-TfR library which, coupled with the greater diversity of phage, suggested a 
variety of scFv targeting conserved epitopes. However, the cross-binding hits showed a 
weaker HTRF signal which appears to be sub-detection in HTRF as fewer hits are obtained, 
highlighting the extent of signal amplification in phage ELISA. The increased number of cross-
reactive hits from the Bn2-TfR library is still visible although less marked.  
Although HTRF provides a high-throughput screening method, quantitation can be unreliable 
due to variation in E. coli density, scFv expression and periplasm extraction between samples. 
The results provided a platform for sample triage to select for several types: scFvs that bound 
both receptors and showed promising cross-reactivity, and scFvs that produced a unique 
binding response to BES1-TfR or Bn2-TfR alone. Based on these criteria, six clones were 
further investigated by SPR using immobilised receptor to directly measure the affinities of 
variable antibody fragments. 
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Figure 48: Detection of scFv binding to target antigen by HTRF confirms low cross-
reactivity. The %ΔF indicating the binding response of each scFv with BES1-TfR and Bn2-
TfR is represented as a stacked bar chart. Samples 1 – 44 inclusive contain scFv raised 
against BES1-TfR while samples 45 – 88 were raised against Bn2-TfR.  
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6.3.4 Kinetic analysis 
6.3.4.1 Fab conversion 
The choice of fragment framework was informed by several factors. First, the requirement of 
a single juxtaposed VH and VL domain as opposed to the bivalent format offered by IgG and 
F(ab’)2 (Figure 1A and B). Bivalency promotes avidity, thus making accurate kinetic 
measurements between a single variable domain and an epitope challenging. Fab fragments 
(Figure 41C) and scFv (Figure 41D) offer single domain formats which would enable affinity 
determination. Previous observations from fellow lab members revealed that scFv have the 
propensity to aggregate by forming intermolecular interactions in addition to intramolecular 
interactions, resulting in oligomeric configurations. On the other hand, Fab fragments retain a 
conserved domain from each chain and disulphide bonding maintains pairing between the 
light and heavy chain. Variable domains are cloned into a Fab framework, expressed in CHO 
cells and purified for SPR.  
 
6.3.4.2 Kinetic measurements by SPR 
The binding of Fabs to immobilised BES1-TfR and Bn2-TfR was measured by SPR (Figure 
49).  The majority of the purified Fabs tested showed little to no binding to BES1-TfR. Tbru104, 
109 and 110 did not produce a binding response, while Tbru10 showed a negligible response. 
Two Fabs, Tbru108 and Tbru111, produced a significant response indicative of binding to 
BES1-TfR. However, the determined kinetic values are low due to the rapid off rates, with an 
estimated KD of 1 µM for Tbru108 and 1.4 µM for Tbru111 (Table 5). The Fabs showed a 
greater binding to Bn2-TfR, with the exception of Tbru104 and Tbru105 which did not produce 
a binding response. Tbru108, Tbru109, Tbru110 and Tbru111 Fabs bound Bn2-TfR. The 
highest affinities were observed with Tbru108 and Tbru111 (Table 5), suggesting the potential 
for a pan-specific TfR binding. Nip228 is a negative control antibody commonly used at 
AstraZeneca, targeting 4‐hydroxy‐3‐iodo‐5‐nitrophenylacetic acid (Haqqani et al., 2018). Fab 
fragments of Nip228 did not interact with BES1-TfR although low levels of negligible binding 
were observed with Bn2-TfR. Human holo-Tf was used as a positive control and produced the 
previously observed low affinity binding to BES1-TfR and high affinity binding to Bn2-TfR. A 
positive binding response from Tbru108 and Tbru111 to both TfR variants warranted further 
investigation by conversion into fluorescently-labelled IgGs to visualise binding and uptake in 
trypanosomes.  
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Figure 49: Measurement of Fab binding to target antigen by SPR. Biotinylated BES1-TfR and Bn2-TfR were immobilised and purified Fabs 
were injected in a concentration series ranging from 1000 nM to 62.5 nM.
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Table 5: SPR analysis of binding kinetics. Kinetic values for interactions between soluble Fabs 
and immobilised BES1-TfR or Bn2-TfR. Kinetic data from Fabs that produced a binding 
response were reported; data for low binding responses were not able to be determined.  
 
TfR Transferrin KD(nM) kon(M-1s-1) koff(s-1) 
BES1 Tbru108 1000 2.2 x105 2.2 x10-1 
BES1 Tbru111 1400 7.4x105 1.0 
Bn2 Tbru108 110 1.7x104 1.8x10-3 
Bn2 Tbru109 610 8.2x102 5.0x10-4 
Bn2 Tbru110 800 4.8x102 3.8x10-4 
Bn2 Tbru111 230 3.1x103 7.2x10-4 
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6.3.5 Testing internalisation of anti-TfR mAbs in trypanosomes 
To investigate IgG binding to TfR in live trypanosomes, antibodies were prepared and used in 
uptake assays. Variable regions were reformatted into an IgG1 framework and fluorescently-
labelled (AlexaFluor 488). Antibodies were tested for BES1-TfR binding and uptake by adding 
mAbs to trypanosomes expressing from BES1. Assays were performed in serum-free 
conditions to avoid competition of serum Tf. The addition of FMK, a lysosomal protease 
inhibitor, allowed accumulation of endocytosed protein. Internalisation of Tbru108 and Tbru111 
was compared to fluorescently-labelled bovine Tf uptake and the negative control antibody 
Nip228 (Figure 50). While Tf was internalised, forming a bright spot in the lysosome, mAb 
binding and uptake was not apparent. Neither Tbru108 nor Tbru111 showed accumulation 
within the cell and Nip228 appeared to produce a greater signal inside the cell under the same 
conditions.  
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Figure 50: Testing internalisation of anti-TfR mAbs. Fluorescently-labelled (AlexaFluor 
488) mAbs (Tbru108 and Tbru111) were added to BES1 trypanosomes in serum-free medium. 
Uptake of a negative control antibody (Nip228) and bovine Tf was also visualised.  
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6.4 Discussion 
6.4.1 TfR as a therapeutic target 
The screen has provided further insights into the feasibility of TfR targeting as a successful 
therapeutic strategy. Considering the high concentration of mAb tested (500 nM), it was evident 
that mAbs generated here did not bind BES1-TfR in their current format. It is possible that the 
mAbs may bind a TfR from another expression site and further testing would be required. Low 
output yields obtained in the first round of selection are likely a product of heavily and 
heterogeneously glycosylated antigens which may also account for the low binding response 
of Fabs observed by SPR. The lack of binding and uptake in trypanosomes may be due to 
minor differences in glycosylation profile and composition between CHO cells and 
trypanosomes. In addition, while an IgG format increases avidity through bivalency, the larger 
structure of an IgG may encounter accessibility constraints depending on the location of the 
epitope.  
In light of the high degree of sequence conservation amongst trypanosome TfRs, the lack of 
cross-reactive BES1-TfR and Bn2-TfR binders was the most unexpected outcome. The 
majority of enriched scFv were receptor-specific and only a discrete population was cross-
reactive. Our previous data have shown that conservation is predominantly located in the 
membrane-proximal region of the receptor. Following scFv-phage binding, the immobilisation 
and stringent washing of C-terminally biotinylated receptors on streptavidin beads may have 
resulted in loss of phage bound to the C-terminus due to steric hinderance caused by crowding 
at the surface of the beads. Thus, binders located towards the tip of the receptor would be 
enriched. This coincides with the most polymorphic region of the receptor in which BES1-TfR 
and Bn2-TfR show the greatest disparity.  
Furthermore, the TfR is rich in glycans, with eight predicted N-linked glycosylation sites per 
heterodimer. Due to the inherently variable nature of glycans, it is possible that differences in 
glycosylation profile and composition between BES1-TfR and Bn2-TfR may lead to differences 
in scFv binding. Moreover, while the structure of BES1-TfR is yet to be solved, it is plausible 
that subtle structural differences between variants may confer a loss of cross-reactivity. Finally, 
the shortcomings of the phage display screen provided further evidence to support the 
hypothesis of TfR diversification driven by an immune avoidance strategy. The lack of exposed 
conserved epitopes, coupled with glycan shielding and C-terminal receptor packing to protect 
less diverse regions, are all likely to contribute to immunoglobulin inaccessibility. 
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6.4.2 Future perspectives 
Several strategies could be explored to improve the selection output library, cross-reactivity 
and affinities. First, removal of glycans prior to phage display selections could be considered. 
The TbHpHbR was expressed in E. coli resulting in the absence of glycosylations during the 
phage display trials, without impinging on IgG binding to native, glycosylated HpHbR 
(MacGregor, Gonzalez-Munoz et al., 2019). A crossover of the output libraries during the 
selection process to raise an output concomitantly enriched against both antigens would 
further improve cross-reactivity of the selection library. In vitro affinity maturation could be 
performed to increase the affinities and cross-reactivity of the output library. A third-round 
output enriched for antigen binders can be randomly mutated in the VH and VL using error-
prone PCR to drive the production of higher affinity binders. Finally, a library formatted on a 
smaller framework such as a small fragment peptide library could be tested to achieve greater 
accessibility to conserved epitopes. However, the structure of the receptor has since revealed 
that the TfR is a complex target. The lateral surfaces are protected by the VSG coat and glycan 
shielding, likely rendering the conserved core inaccessible to immunoglobulins (Figure 51). In 
addition, ligand occlusion of the receptor by apo- and holo-Tf, coupled with diversification of 
the regions surrounding the Tf-binding site, will contribute to difficulties in the production of a 
viable pan-specific antibody therapeutic targeting the TfR. 
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Figure 51: Model of the T. brucei surface coat. Surface representation of MITat1.2 (PDB = 
1VSG) homodimers (grey) with TfR heterodimers in blue and cyan. C-terminal domains and 
GPI-anchors are represented as springs to represent flexibility. Glycans are modelled in green 
and Tf is represented in red. The VSG coat and glycans shield lateral surfaces of the TfR, 
while the residues at the tip of the receptor are engaged in ligand binding or have diversified, 
thus complicating the development of a pan-specific TfR therapeutic.  
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Chapter 7  
 
General discussion 
 
 
More than a century since the first reports on what we now know to be antigenic variation in 
trypanosomes (Franke, 1905), progress is still being made to further our understanding of the 
strategies deployed to avoid host detection whilst responding to nutrient requirements. In this 
work, the findings can be summarised and further explored through the following questions.  
 
7.1 How do trypanosomes acquire iron whilst 
avoiding host recognition? 
The trypanosome is an elegant example of an extracellular pathogen that has developed 
multiple strategies to avoid host immune recognition. In contrast to other kinetoplastids (T. 
cruzi and Leishmania spp.) which have a coat rich in glycoconjugates, the T. brucei coat is 
predominantly protein (reviewed by Ferguson, 1997). As the coat assumes the role of the host-
parasite interface, evolutionary adaptations in the coat to avoid host immune detection have 
shaped the genome. While the VSG is central to antigenic variation, the findings presented in 
this thesis suggest that TfR variation may play a supporting role by forming an additional 
degree of variation.  
Trypanosomes were considered to rely primarily on single copy receptors to bind host 
macromolecules, such as the haptoglobin-haemoglobin receptor (HpHbR) to fulfil haem 
requirements (Vanhollebeke et al., 2008) and the factor H receptor (FHR) to mediate protection 
from the host innate immune response and promote insect vector transmission (Macleod et 
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al., 2020). This raises the interesting question of whether single copy receptors elicit an 
immune response. In the case of FHR, expression is low on proliferating bloodstream-form 
cells (< 200 copies per cell) (Macleod et al., 2020), which may confer protection. HpHbR is 
also expressed at low levels (200 to 400 copies per cell), yet the receptor has elicited an innate 
immune response through targeting by trypanosome lytic factor (TLF) (Vanhollebeke et al., 
2008) and can be targeted by an immunoglobulin-based therapy (MacGregor et al., 2019), 
suggesting immunogenicity. Likely in a bid to combat immunogenicity, the trypanosome TfR is 
peculiar as it has evolved a family of receptors for iron acquisition. Understanding how 
trypanosomes orchestrate immune avoidance whilst maintaining a functional Tf-binding site 
was a key focus of the research in this thesis. 
Based on the structure of the receptor and mapping of sequence diversification, it was evident 
that variation was selective due to the preponderance of apical polymorphisms. Further 
experiments produced a number of salient findings relating to the origin of selective variation. 
In the first instance, biophysical analyses complemented with trypanosome growth 
experiments confirmed that high affinity binding of Tf was not necessary for cell proliferation. 
Moreover, the structure of the receptor-ligand complex and investigation of the polymorphic 
regions revealed that ligand binding may not be the determinant for selective variation as the 
binding site was predominantly conserved. In addition, point mutation of one to four residues 
in BES1-TfR produced a considerable increase in Tf binding affinity, suggesting that Tf affinity 
was not the factor driving receptor evolution. Finally, the positioning of glycans to shield 
conserved epitopes suggested that the TfR may be a target of immunoglobulin-mediated 
attack. Thus, a picture emerged in which variation was likely derived from antigenic drift and 
restricted by a requirement for maintenance of Tf binding.  
Investigation of the receptor-ligand complex in different pH conditions revealed Tf remained 
bound to the receptor at lysosomal pH. Moreover, iron was likely to be sequestered in the 
complex during endosomal progression to the lysosome. This finding is compatible with reports 
that a trypanosome iron transporter protein is located in proximity to the lysosome (Taylor et 
al., 2013). The TfR has been shown to undergo recycling, with conflicting reports on TfR half-
life ranging from 1.5 hours (Schwartz et al., 2005) (Tiengwe et al., 2017) to 7 hours (Kabiri & 
Steverding, 2000). Further work is required to fully understand how iron is released from the 
complex and the fate of Tf and TfR thereafter.  
 
 143 
 
7.2 Did the VSG evolve from a TfR? 
Structural determination of the trypanosome TfR revealed striking similarities between the 
receptor and type A VSGs. While it is highly likely that the VSG and TfR evolved from a 
common ancestor, an interesting question in precedence arose. Evolutionary analyses 
suggest that an ancestral procyclic form trypanosome residing in the insect vector predates 
the bloodstream-form trypanosome (Lake et al., 1988). Iron requirements for procyclic form 
cells exceed those of bloodstream-form cells (Stijlemans et al., 2015).  Thus, it is plausible that 
the ancestral parasite had greater requirements for iron during the early stages of adaptation 
to the mammalian host. Over time, bloodstream-form cells have evolved to require less iron 
whilst developing more advanced immune evasion strategies in the form of the VSG coat.  
How have the TfR and VSG evolved since divergence? Much like the VSG, evolution of the 
TfR is centred around diversification of immunogenic surfaces. For the TfR, variation 
stringency is imposed by functional requirements to maintain Tf binding. This is largely 
reminiscent of VSG selection, in which diversification whilst preserving the core structure to 
maintain VSG coat function has shaped evolution of the VSG repertoire. However, one 
interesting distinction was observed. Diversity in the core three-helix bundle is less pronounced 
in the TfR compared to the VSG, which prompted the question of why the TfR core was less 
variable. Conservation mediated by core structural constraints seemed implausible as 
sequence diversity is compatible with three-helix bundle conservation (Blum et al., 1993) 
(Carrington & Boothroyd, 1996), and studies have shown that an N-terminal VSG core fusion 
with a TfR binding site supports Tf binding (Salmon et al., 1997). A conceivable explanation is 
that the conserved core may be testament to the shielding capacities of ESAG6 and ESAG7 
glycans. The ring of five sugars at the periphery of the Tf-binding site favours occlusion of the 
three-helix core, which may have reduced the requirement for variation. In contrast, type A 
VSGs were shown to have one or two glycans per monomer in most cases, with a location 
predominantly towards the membrane proximal base of the VSG (Mehlert et al., 2002). Thus, 
diversity within the core fold of the VSG may be required to protect against an adaptive immune 
response in the absence of glycan shielding. 
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7.3 Is TfR-mediated endocytosis of host Tf 
essential?  
Investigation of TfR-Tf interactions revealed two interesting findings. First, a high affinity 
receptor is not essential for trypanosome growth. Second, TfR can bind both apo- and holo-Tf 
at extracellular pH. If Tf were critical for fulfilment of iron requirements, the expectation is that 
evolution of the TfR repertoire would be centred around the production of high affinity receptors 
or, at the very least, receptors that discriminate between apo- and holo-Tf for selective uptake 
of iron-laden Tf. The evidence produced here suggested that TfR-Tf interactions may not be 
essential and the hypothesis was tested. Trypanosomes cultured in Tf-depleted medium did 
not exhibit a growth phenotype, and the surprising findings warrant further investigation to 
address several questions: 
1. Do trypanosomes rely on uptake of lactoferrin or another iron transport protein to fulfil iron 
requirements in the absence of Tf?  
2. Why is TfR knockdown lethal and does the TfR have an additional function? 
3. Does an alternative iron uptake pathway exist? 
4. Are TfRs or any other proteins upregulated in response to Tf depletion? 
The lack of discrimination between apo- and holo-Tf may be explained by the advantage of 
TfR occupancy, as ligand-bound receptor would provide protection against an adaptive 
immune response. Numerous findings in this thesis suggest that immune avoidance is 
paramount for host persistence and surpasses trypanosome requirements for iron during TfR 
evolutionary selection.  
In conclusion, the work described in this thesis has elucidated one of the complex interactions 
that occurs between host and parasite during infection, offering several key findings. First, the 
future of an antibody therapy targeting the TfR is uncertain and trypanosome efficiency in 
immunoglobulin avoidance may explain the challenges in TfR targeting. Second, 
trypanosomes have a broad host range, yet host promiscuity does not appear to be the 
selective pressure for diversity within the TfR repertoire. Finally, evolution of the TfR is likely 
selected by an advantage conferred in immune avoidance to promote long-term persistence 
in the host. These findings will provide valuable insights for the design of future therapeutics 
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and will further our understanding of the molecular architecture of the trypanosome cell 
surface. 
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Appendices 
 
Appendix 1: List of GeneArt gene constructs. Amino acid sequences of the expression 
constructs, containing the CD33 leader sequence. Linkers, AviTag and His-tag are present 
in ESAG6, and residues mutated in BES1 are shown in pink. ESAG7 contains linker and 
StrepII-tag, with location of primers used for RT-PCR marked in BES1. 
 
BES1 ESAG6 
MPLLLLLPLLWAGALAAAYENKRNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMR
NRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGGSSQFCISVGT
NIPAEYNNLQECFDGIIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFNSLGAENIRGGNGRDGCNLVRTDTDG
VLEGGSVRRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNEVM
NKIKTTVDELAKCIGQKEVELTDDQLYEEFIWETIHRLELSKRVSEQLSLGEEEETILKSNYTAEPVRGPFTVAG
SGSGSGSASGGLNDIFEAQKIEWHEGGHHHHHHHHHH 
 
BES1 ESAG7 
MPLLLLLPLLWAGALAAAYENKRNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMR
NRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGGSSQFCISVGT
NIPAEYNNLQECFDGIIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFSSLGAESIVEQRKNRGCNLMRTADGG
LLKDICLNCNFTWGGGVMNFGSCVAGNLKIKGGEYGDVSSHDVVRWTEDPSKVSIFKDVIRLFARFQEAKNAVMN
KIKTTVDELAKCIGQKEVELTNDQLYEEFEAIQKYLGSGSGSGSWSHPQFEK 
 
Bn2 ESAG6 
MPLLLLLPLLWAGALAAAYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMR
NRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGLAAGRLEEWIFVFAQAAGRSSQFCISVGK
TGPAEYNNLQECFDGTIGPETLYKIEDSRVKESAKTSLQLHEVLSSISFGSLGVKNIRGGNGKDGCNLVRTDTDG
VLEGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNAVV
KKIKTTVDELTKCIGQKEAELTNDQLYEEFIWETINRLELSKRVSEQSAFGEEEETIVKFNYTAEPVRGPFTVAG
AGSGSGSASGGLNDIFEAQKIEWHEGGHHHHHHHHHH 
 
Bn2 ESAG7 
MPLLLLLPLLWAGALAAAYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMR
NRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGGSSQFCISVGT
NIPAEYNNLQECFDGTIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFSSLGAESIVEKGENRGCNLMRTADGG
LLKDVCLNRNFTWGGGVLNFGYCVAGNLKIKGGEYGDVGSHDAVRWTEDPSKVSIFKDVIRLFARFQEVKNAVVK
KIKTTVDELTKCIGQKEAELTNDQLYEEFEVIQKYLWFLGSGSGSWSHPQFEK 
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Appendix 2: List of GeneArt gene constructs. DNA sequences of the expression 
constructs used in this work.  
 
BES1 ESAG6 
ATGCCTCTGCTGCTGCTGCTGCCTCTGCTGTGGGCTGGCGCTCTGGCGGCCGCATACGAGAACAAGCGGAACGCC
CTGAATGCCACCGCCGCCAACAAAGTGTGCGGCCTGAGCACCTACCTGAAGGGAATCGCCCACAGAGTGAACAGC
GAGAGCGCCGTCGTGACCGAGAAGCTGAGCGACCTGAAGATGCGGAGCATCCAGCTGCAGCTGAGCGTGATGCGG
AACAGAGTGCCTAGCGGCGAGCAGGACTGCAAGGACATCCGGACCCTGCTGAAAACCGTGCTGAGAAACGAGTTC
ACCTTCCAGCAGGAACTGGAAGAGATGAGAAACGCCAGCGCCCTGGCCGCTGCCGCTGCTGGAATTGCTGCTGGC
AGACTGGAAGAATGGATCTTCGTGTTCGCCCAGGCCGCAGGCGGCAGCTCCCAGTTCTGTATCAGCGTGGGCACC
AACATCCCCGCCGAGTACAACAACCTGCAGGAATGCTTCGACGGCATCATCGGCCCCGAGACACTGTACAAGATC
GAGGACAGCAGAGTGAAAGAGTCCGCCCAGAAGTCCCTGCAGCTGCACGAGGTGCTGAGCAGCATCAGCTTCAAC
AGCCTGGGCGCCGAGAACATCAGAGGCGGCAATGGCAGAGATGGCTGCAACCTCGTGCGGACCGATACCGACGGC
GTGCTGGAAGGCGGATCTGTGCGGAGACACAACCTGACATGGGGCGGAGGCGTGATGAACTTCGGCAGCTACCAG
AACGGCTCTATGTACGTGGAAGGGGGCGAGTACGGCGACGCCACAGAATATGGCGCTGTGCGGTGGACCGAGGAC
CCCAGCAAGGTGTCCATCTTCAAGGACGTGATCCGGCTGTTCGCCCGGTTCCAGGAAGCCAAGAACGAAGTGATG
AACAAGATCAAGACCACCGTGGACGAGCTGGCCAAGTGCATCGGCCAGAAAGAGGTGGAACTGACCGACGACCAG
CTGTACGAGGAATTCATCTGGGAGACAATCCACCGGCTGGAACTGAGCAAGCGGGTGTCCGAGCAGCTGTCCCTG
GGCGAGGAAGAGGAAACCATCCTGAAGTCCAACTACACCGCCGAGCCCGTGCGGGGACCTTTTACAGTGGCCGGC
TCTGGAAGCGGCTCTGGCTCTGCTAGCGGCGGACTGAACGACATCTTCGAGGCCCAGAAAATCGAGTGGCACGAG
GGCGGACACCACCACCATCACCATCATCACCACCATTGA 
 
BES1 ESAG7 
ATGCCTCTGCTGCTGCTGCTGCCTCTGCTGTGGGCTGGCGCTCTGGCGGCCGCATACGAGAACAAGCGGAACGCC
CTGAATGCCACCGCCGCCAACAAAGTGTGCGGCCTGAGCACCTACCTGAAGGGAATCGCCCACAGAGTGAACAGC
GAGAGCGCCGTCGTGACCGAGAAGCTGAGCGACCTGAAGATGCGGAGCATCCAGCTGCAGCTGAGCGTGATGCGG
AACAGAGTGCCTAGCGGCGAGCAGGACTGCAAGGACATCCGGACCCTGCTGAAAACCGTGCTGAGAAACGAGTTC
ACCTTCCAGCAGGAACTGGAAGAGATGAGAAACGCCAGCGCCCTGGCCGCTGCCGCTGCTGGAATTGCTGCTGGC
AGACTGGAAGAATGGATCTTCGTGTTCGCCCAGGCCGCAGGCGGCAGCTCCCAGTTCTGTATCAGCGTGGGCACC
AACATCCCCGCCGAGTACAACAACCTGCAGGAATGCTTCGACGGCATCATCGGCCCCGAGACACTGTACAAGATC
GAGGACAGCAGAGTGAAAGAGTCCGCCCAGAAGTCCCTGCAGCTGCACGAGGTGCTGAGCAGCATCAGCTTCAGC
AGCCTGGGCGCCGAGAGCATCGTGGAACAGCGGAAGAACCGGGGCTGCAACCTGATGAGAACAGCCGATGGCGGC
CTGCTGAAGGACATCTGCCTGAACTGCAACTTCACCTGGGGCGGAGGCGTGATGAACTTCGGCTCTTGCGTGGCC
GGCAATCTGAAGATCAAGGGCGGCGAGTACGGCGACGTGTCCAGCCATGATGTCGTGCGGTGGACCGAGGACCCC
AGCAAGGTGTCCATCTTCAAGGACGTGATCCGGCTGTTCGCCCGGTTCCAGGAAGCCAAGAACGCTGTGATGAAC
AAGATCAAGACCACCGTGGACGAGCTGGCCAAGTGCATCGGCCAGAAAGAGGTGGAACTGACCAACGACCAGCTG
TACGAGGAATTCGAGGCCATCCAGAAGTACCTGGGCAGCGGCTCTGGCTCCGGATCTTGGAGCCACCCCCAGTTC
GAGAAATGA 
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Bn2 ESAG6 
ATGCCTCTGCTGCTGCTGCTGCCTCTGCTGTGGGCTGGCGCTCTGGCGGCCGCATACGAGAACGAGAGAAACGCC
CTGAATGCCACCGCCGCCAACAAAGTGTGCGGCCTGAGCACCTACCTGAAGGGAATCGCCCACAGAGTGAACAGC
GAGAGCGCCGTCGTGACCGAGAAGCTGAGCGACCTGAAGATGCGGAGCATCCAGCTGCAGCTGAGCGTGATGCGG
AACAGAGTGCCTAGCGGCGAGCAGGACTGCAAGGACATCCGGACCCTGCTGAAAACCGTGCTGAGAAACGAGTTC
ACCTTCCAGCAGGAACTGGAAGAGATGAGGAACGCCTCTGCCCTGGCCGCTGCTGCTGCAGGACTGGCTGCTGGC
AGACTGGAAGAATGGATCTTCGTGTTCGCCCAGGCCGCTGGCAGAAGCTCCCAGTTCTGTATCAGCGTGGGCAAG
ACCGGCCCTGCCGAGTACAACAACCTGCAGGAATGCTTCGACGGCACCATCGGCCCCGAGACACTGTACAAGATC
GAGGACAGCAGAGTGAAAGAGTCCGCCAAGACCTCCCTGCAGCTGCACGAGGTGCTGAGCAGCATCAGCTTTGGC
AGCCTGGGCGTGAAGAACATCAGAGGCGGCAACGGCAAGGACGGCTGCAATCTCGTGCGGACCGATACCGACGGC
GTGCTGGAAGGCGGCAGCCCCACAAGACACAACCTGACATGGGGCGGAGGCGTGATGAACTTCGGCAGCTACCAG
AACGGCTCTATGTACGTGGAAGGGGGCGAGTACGGCGACGCCACAGAATATGGCGCTGTGCGGTGGACCGAGGAC
CCCAGCAAGGTGTCCATCTTCAAGGACGTGATCCGGCTGTTCGCCCGGTTCCAGGAAGCCAAGAACGCCGTCGTG
AAGAAAATCAAGACCACCGTGGACGAGCTGACCAAGTGCATCGGCCAGAAAGAGGCCGAGCTGACAAACGACCAG
CTGTACGAGGAATTCATCTGGGAGACAATCAACCGGCTGGAACTGAGCAAGCGGGTGTCCGAGCAGAGCGCCTTC
GGCGAAGAGGAAGAGACAATCGTGAAGTTCAACTACACCGCCGAGCCCGTGCGGGGACCTTTTACAGTGGCTGGC
GCCGGATCTGGCAGCGGCTCTGCTAGCGGCGGACTGAACGACATCTTCGAGGCCCAGAAAATCGAGTGGCACGAG
GGCGGACACCACCACCATCACCATCATCACCACCATTGA 
 
Bn2 ESAG7 
ATGCCTCTGCTGCTGCTGCTGCCTCTGCTGTGGGCTGGCGCTCTGGCGGCCGCATACGAGAACGAGAGAAACGCC
CTGAATGCCACCGCCGCCAACAAAGTGTGCGGCCTGAGCACCTACCTGAAGGGAATCGCCCACAGAGTGAACAGC
GAGAGCGCCGTCGTGACCGAGAAGCTGAGCGACCTGAAGATGCGGAGCATCCAGCTGCAGCTGAGCGTGATGCGG
AACAGAGTGCCTAGCGGCGAGCAGGACTGCAAGGACATCCGGACCCTGCTGAAAACCGTGCTGAGAAACGAGTTC
ACCTTCCAGCAGGAACTGGAAGAGATGAGGAACGCCTCTGCCCTGGCCGCTGCCGCTGCTGGAATTGCTGCTGGC
AGACTGGAAGAATGGATCTTCGTGTTCGCCCAGGCCGCTGGCGGCAGCTCCCAGTTCTGTATCAGCGTGGGCACC
AACATCCCCGCCGAGTACAACAACCTGCAGGAATGCTTCGACGGCACCATCGGCCCCGAGACACTGTACAAGATC
GAGGACAGCAGAGTGAAAGAGTCCGCCCAGAAGTCCCTGCAGCTGCACGAGGTGCTGAGCAGCATCAGCTTCAGC
AGCCTGGGAGCCGAGAGCATCGTGGAAAAGGGCGAGAACCGGGGCTGCAACCTGATGAGAACAGCCGATGGCGGC
CTGCTGAAGGACGTGTGCCTGAACCGGAACTTCACCTGGGGAGGCGGAGTGCTGAACTTCGGCTATTGCGTGGCC
GGCAATCTGAAGATCAAGGGCGGCGAGTATGGCGACGTGGGCTCTCATGATGCCGTGCGGTGGACCGAGGACCCC
AGCAAGGTGTCCATCTTCAAGGACGTGATCCGGCTGTTCGCCCGGTTCCAGGAAGTGAAGAACGCCGTCGTGAAG
AAAATCAAGACCACCGTGGACGAGCTGACCAAGTGCATCGGCCAGAAAGAGGCCGAGCTGACAAACGACCAGCTG
TACGAGGAATTCGAAGTGATCCAGAAATACCTGTGGTTCCTGGGCAGCGGCTCCGGCTCTTGGAGCCACCCTCAG
TTCGAGAAATGA 
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Appendix 3: Sequence of the Bn2-TfR mutant. Amino acid and DNA sequences of N-
linked glycan mutant used for crystallography. The linkers, AviTag and His-tag are cleavable 
at the TEV-protease cut site. ESAG7 does not contain affinity tags and N-linked glycosylation 
sites were mutated to aspartic acid.  
Bn2 ESAG6 
MPLLLLLPLLWAGALAAAHHHHHHHHHHGGGLNDIFEAQKIEWHEASENLYFQGSGYENERNALDATAANKVCGL
STYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMRNRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRDA
SALAAAAAGLAAGRLEEWIFVFAQAAGRSSQFCISVGKTGPAEYNNLQECFDGTIGPETLYKIEDSRVKESAKTS
LQLHEVLSSISFGSLGVKNIRGGNGKDGCNLVRTDTDGVLEGGSPTRHDLTWGGGVMNFGSYQDGSMYVEGGEYG
DATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNAVVKKIKTTVDELTKCIGQKEAELTNDQLYEEFIWETINR
LELSKRVSEQSAFGEEEETIVKFDYTAEPVRGPFTVAGA 
ATGCCTCTGCTGCTGCTGCTGCCTCTGCTGTGGGCTGGCGCTCTGGCGGCCGCTCACCACCACCATCACCATCAT
CACCACCATGGCGGCGGACTGAACGACATCTTCGAGGCCCAGAAAATCGAGTGGCACGAGGCTAGCGAGAACCTC
TATTTCCAAGGGTCTGGCTACGAGAACGAGAGAAACGCCCTGAATGCCACCGCCGCCAACAAAGTGTGCGGCCTG
AGCACCTACCTGAAGGGAATCGCCCACAGAGTGAACAGCGAGAGCGCCGTCGTGACCGAGAAGCTGAGCGACCTG
AAGATGCGGAGCATCCAGCTGCAGCTGAGCGTGATGCGGAACAGAGTGCCTAGCGGCGAGCAGGACTGCAAGGAC
ATCCGGACCCTGCTGAAAACCGTGCTGAGAAACGAGTTCACCTTCCAGCAGGAACTGGAAGAGATGAGGAACGCC
TCTGCCCTGGCCGCTGCTGCTGCAGGACTGGCTGCTGGCAGACTGGAAGAATGGATCTTCGTGTTCGCCCAGGCC
GCTGGCAGAAGCTCCCAGTTCTGTATCAGCGTGGGCAAGACCGGCCCTGCCGAGTACAACAACCTGCAGGAATGC
TTCGACGGCACCATCGGCCCCGAGACACTGTACAAGATCGAGGACAGCAGAGTGAAAGAGTCCGCCAAGACCTCC
CTGCAGCTGCACGAGGTGCTGAGCAGCATCAGCTTTGGCAGCCTGGGCGTGAAGAACATCAGAGGCGGCAACGGC
AAGGACGGCTGCAATCTCGTGCGGACCGATACCGACGGCGTGCTGGAAGGCGGCAGCCCCACAAGACACAACCTG
ACATGGGGCGGAGGCGTGATGAACTTCGGCAGCTACCAGAACGGCTCTATGTACGTGGAAGGGGGCGAGTACGGC
GACGCCACAGAATATGGCGCTGTGCGGTGGACCGAGGACCCCAGCAAGGTGTCCATCTTCAAGGACGTGATCCGG
CTGTTCGCCCGGTTCCAGGAAGCCAAGAACGCCGTCGTGAAGAAAATCAAGACCACCGTGGACGAGCTGACCAAG
TGCATCGGCCAGAAAGAGGCCGAGCTGACAAACGACCAGCTGTACGAGGAATTCATCTGGGAGACAATCAACCGG
CTGGAACTGAGCAAGCGGGTGTCCGAGCAGAGCGCCTTCGGCGAAGAGGAAGAGACAATCGTGAAGTTCAACTAC
ACCGCCGAGCCCGTGCGGGGACCTTTTACAGTGGCTGGCGCCTGA 
 
Bn2 ESAG7 
MPLLLLLPLLWAGALAAAYENERNALDATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMR
NRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRDASALAAAAAGIAAGRLEEWIFVFAQAAGGSSQFCISVGT
NIPAEYNNLQECFDGTIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFSSLGAESIVEKGENRGCNLMRTADGG
LLKDVCLNRDFTWGGGVLNFGYCVAGNLKIKGGEYGDVGSHDAVRWTEDPSKVSIFKDVIRLFARFQEVKNAVVK
KIKTTVDELTKCIGQKEAELTNDQLYEEFEVIQKYLWFLGS 
ATGCCTCTGCTGCTGCTGCTGCCTCTGCTGTGGGCTGGCGCTCTGGCGGCCGCTTACGAGAACGAGAGAAACGCC
CTGAATGCCACCGCCGCCAACAAAGTGTGCGGCCTGAGCACCTACCTGAAGGGAATCGCCCACAGAGTGAACAGC
GAGAGCGCCGTCGTGACCGAGAAGCTGAGCGACCTGAAGATGCGGAGCATCCAGCTGCAGCTGAGCGTGATGCGG
AACAGAGTGCCTAGCGGCGAGCAGGACTGCAAGGACATCCGGACCCTGCTGAAAACCGTGCTGAGAAACGAGTTC
ACCTTCCAGCAGGAACTGGAAGAGATGAGGAACGCCTCTGCCCTGGCCGCTGCCGCTGCTGGAATTGCTGCTGGC
AGACTGGAAGAATGGATCTTCGTGTTCGCCCAGGCCGCTGGCGGCAGCTCCCAGTTCTGTATCAGCGTGGGCACC
AACATCCCCGCCGAGTACAACAACCTGCAGGAATGCTTCGACGGCACCATCGGCCCCGAGACACTGTACAAGATC
GAGGACAGCAGAGTGAAAGAGTCCGCCCAGAAGTCCCTGCAGCTGCACGAGGTGCTGAGCAGCATCAGCTTCAGC
AGCCTGGGAGCCGAGAGCATCGTGGAAAAGGGCGAGAACCGGGGCTGCAACCTGATGAGAACAGCCGATGGCGGC
CTGCTGAAGGACGTGTGCCTGAACCGGAACTTCACCTGGGGAGGCGGAGTGCTGAACTTCGGCTATTGCGTGGCC
GGCAATCTGAAGATCAAGGGCGGCGAGTATGGCGACGTGGGCTCTCATGATGCCGTGCGGTGGACCGAGGACCCC
AGCAAGGTGTCCATCTTCAAGGACGTGATCCGGCTGTTCGCCCGGTTCCAGGAAGTGAAGAACGCCGTCGTGAAG
AAAATCAAGACCACCGTGGACGAGCTGACCAAGTGCATCGGCCAGAAAGAGGCCGAGCTGACAAACGACCAGCTG
TACGAGGAATTCGAAGTGATCCAGAAATACCTGTGGTTCCTGGGCAGCTGA 
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Appendix 4: List of sequences used for sequence entropy 
calculations 
ESAG6 sequences: 
 
>ACH41858 
MMKFWFVLLALLGKETHAYYENKRNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVM
RNRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGGSSQFCISVG
KHIPAEHGNLQECFDGIIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFNSLGAENIRGGNGRHGCNLVRTDTD
GVLEGGSVRRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNEV
MNKIKTTVDELAKCIGQKEVELTDDQLYEEFIWETIHRLELSKRVSEQLSLGEEEETILKSNYTAEPVRGPFTVA
GSNAAAVHLSVSTAALCFSVLLLGVL 
 
>ACH41863 
MMKFWFVLLALLGKETHAYYENKRNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVM
RNRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGRSSQFCISVG
KHIPAEHGNLQECFDGIIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFNSLGAENIRGGNGRDGCNLVRTDTD
GVLEGGSVRRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNEV
MNKIKTTVDELAKCIGQKEVELTDDQLYEEFIWETIHRLELSKRVSEQLSLGEEEETILKSNYTAEPVRGPFTVA
GSNAAAVHLSVSTAALCFSVLLLGVL 
 
>ACH41864 
MMKFWFVLLALLGKETHAYYENKRNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVM
RNRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGRSSQFCISVG
KHIPAEHGNLQECFDGIIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFNSLGAENIRGGNGRDGCNLVRTDTD
GVLEGGSVRRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNEV
MNKIKTTVDELAKCIGQKEVELTDDQLYEEFIWETIHRLELSKRVSEQLSLGEEEETILKSNYTAEPVRGHFTVA
GSNAAAVHLSVSTAALCFSVLLLGVL 
 
>ACH41855 
MRFLFVLLALLGKKTHAYYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMR
NRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAADGSSQFCISVGT
NIPAEHNNLQECFDGTIGPETLYKIEDSRVKESAKKSLQLHEALSSISFSSLGVKNIRGGNGRDGCNLVRTDTNG
ILNGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFEDLIRLFARFQEAKNAVM
KKIKTTVDELTKCIGQKEAELTNDQIYEEFIWETINRLELSKRMSEQSAFGEEEETILKSNYTAEPVRGPFTGAG
SNTVAVHLSFSTAALCCSVLLLGVL 
 
>ACH41854 
MRFLFVLLALLGKKTHAYYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMR
NRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGLAAGRLEEWIFVFAQAADGSSQFCISVGT
NIPAEHNNLQECFDGTIGPETLYKIEDSRVKESAKKSLQLHEALSSISFSSLGVKNIRGGNGRDGCNLVRTDTNG
ILNGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNAVM
RRIKTTVDELTKCIGQKEAELTNDQIYEEFIWETINRLELSKRMSEQPTLGEEEETILKSNYTAEPVRGPFTGAG
ANTVALHLSVSTAALCCSVLLLGVL 
 
>ACH41849 
MRFWFVLLALLGKETYAYYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMR
NRVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNTSALAAAAAGIAAGRLEEWIFVFAQAAGRSSQFCISVGK
TGPAEYNNLQECFDGTIGPETLYKIEDSRVKESAKTSLQLHEVLSSISFGSLGVKNIRGGNGKDGCNLVRTDTDG
VLEGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTDDPSKVSIFKDVIRLFARFQEAKNAVM
KKIKTTVDELTKCVGQKEAELTNDQLYEEFIWETINRLELSKRVSEQSAFGEEEETIVKFNYTAEPVRGPFTVAG
ANAAAIHLSVSTAALCRSALLLGVL 
 
>ACH41867 
MRFWFVLLAVLGKETYAYYENERNALNATAANKVCALSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMR
NRVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGRSSQFCISTGK
TGPAEYNNLQECFDGTIGPETLYKIEDSRVKESAKTRLLLHEVLSSISFGSLGAENIRGGNGKDGCNLVRTDNNG
ILKGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNAVM
KKIKTTVDELTKCIGQKEAELTNDQIYEEFIWETINRLELSKRVSEQPSLGEEEETILKSNYTAEPVRGPFTGAG
ANTVAVQSSVFTAALCCSALLLGVL 
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>ACH41861 
MRFLFVLLALLGKKTHAYYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSIMR
NRVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGRSSQFCISVGK
TGPAEYNNLQECFDGTIGPETLYKIEDSRVKESAKKSLQLHEVLSSISFGSLGVKNIRGGNGKDRCNLVRTDTDG
VLEGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNAVM
KKIKTTVDELTKCIGQKEAELTNDQLYEEFIWETINRLELSKRVSEQSAFGEEEETIVKFNYTAEPVRGPFTVAG
ANAAAIHLSVSTAALCRSALLLGVL 
 
>ACH41852 
MMRFLFVLLALLRKETHANYYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSV
MRNRVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGLAAGRLEEWIFVFAQAAGGSSQFCISV
GKNIPAEHKNLQECFDGKIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFSSLGAENIRGGNGKDGCNLVRTDN
NGILKGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATPHGTVRWTEDPNKVSIFKDVIRLFARFKEAKNA
VMTKIKTTVDELTKCIGQKEAELTNDQLYEEFIWETINRLELSKRVSEQPSLGEEEETILKSNYTAEPVRGPFTG
AGANTVAVQSSVSTAALCCSVLLFGVL 
 
>ACH41856 
MRFLFVLLALLGKETYAYYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMR
NRVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNTSALAAAAAGLAAGRLEEWIFVFAQAADRSSQFCISVGK
HIAAEHGNLQECFDGTIGPETLYKIEDSRVKESAKTSLQLHEVLSSISFGSLGVKNIRGGNGRDGCNLVRTDTDG
VLEGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNAVM
TKIKTTVDELTKCIGQKEAELTNDQLYEEFIWETINRLELSKRVSEQSAFGEEEETIVKFNYTAEPVRGPFTVAG
ANAAAIHLSVSTAALCRSALLLGVL 
 
>ACH41865 
MRFWFVLLALLGKEIYAYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMRN
RVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAGGRSSQFCISTGKT
GPAEYNNLQECFDGTIGPETLYKIEDSRVKESAKTSLQLHEVLSSISFGSLGVKNIRGGNGRDGCNLVRTDTDGV
LEGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNAVMT
KIKTTVDELTKCIGHKEAELTNDQLYEEFIWETINRLELSKRVSEQSAFGEEEETIVKFNYTAEPVRGPFTVAGA
NAAAIHLSVSTAALCRSALLLGVL 
 
>ACH41859 
MRFLFVLLAVLGKETYAYYENERNALNATAANKVCALSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMR
NRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGLAAGRLEEWIFVFAQAADGSSQFCISVGK
TGPAEYNNLQECFDGTIGPETLYKIEDSRVKESAKTRLLLHEVLSSISFGSLGAENIRGGNGKDGCNLVRTDNNG
ILKGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFKEAKNAVM
TKIKTTVDELTKCIGQKEAELTNDQIYEEFIWETINRLELSKRVSEQPSLGEEEETILKSNYTAEPVRGPFTGAG
ANTVAVQSSVSTAALCCSVLLLGVL 
 
>ACH41866 
MRFLFLLLVLLGKKTHANYYENKRNALNATAANKVCGLSTYLKGIAHRVNGESAVVTEKLSDLKIRSIQLQLSVM
RNRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNTSALAAAAAGIAAGRLEEWIFVFAQAADRSSQFCISVG
KTIPPEHNNLQECFDGTIGPETLYKIEDSRVKESAKKSLQLHEALSSISFGSLGVKNIRGGNGKDGCNLVRTDTD
GILNGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNAV
MKKIKTTVDELTKCTGQKEAELTNDQLYEEFIWETINRLELSKRVSEQSAFGEEEETILKSNYTAEPVRGPFTVA
GSNAVAIHLSVSTAALCRSALLLGVL 
 
>ACH41853 
MRFWLVLLALLGKETYANYYENKRNALNATAANKVCRLSTYLKGIAHRVSSESAVVTEKLSDLKMKSIQLQLSIL
RNRVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGMTSKFCISVG
GSRPAVHDKLQECFDGTIGPETLYKIEDSRVKESAQKSLQLHEALSSISFGSLGVKNIRGGNGMDGCNLVRTDTD
GILAGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTKDPSKVSIFKDVIRLFARFQEAKNAV
MNKIKTTVDELTKCIGHKEAELTDYQLYEEFIWETIHRLELSKRVSEQPSLGEQEETILKSNYTAEPVRGPFTGA
GADAAAIQSSVSTAALCCLALLLGVM 
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>ACH41847 
MRFWFVLLALLGKEIYAYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMRN
RVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGLAAGRLEEWIFVFAQAADRSSQFCISVGKT
IPPEQNNLQECFDGTIGPETLYKIEDSRVKESAKKSLQLHEALSSISFNSLGAESIRGGNGKDGCNLVRTDTDGI
LNGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNAVMK
KIKTTVDELTKCIGQKEAELTNDQLYEEFIWETINRLELSKRVSEQSAFGEEEETIVKFNYTAEPVRGPFTVAGA
NAAAIHLSVSTAALCRSALLLGVL 
 
>ACH41848 
MMKFWFVLLALLGKETHAYYENKRNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVM
RNRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGGSSQFCISVG
TNIPAEYNNLQECFDGIIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFNSLGAENIRGGNGRDGCNLVRTDTD
GVLEGGSVRRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNEV
MNKIKTTVDELAKCIGQKEVELTDDQLYEEFIWETIHRLELSKRVSEQLSLGEEEETILKSNYTAEPVRGPFTVA
GSNTVAVHLSVSTAALCFSVLLLGVL 
 
>ACH41851 
MRFLFVLLALLGKETHANYYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVM
RNRVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGLAAGRLEEWIFVFAQAAGGSSQFCISVG
RTGPAEYNNLQECFDGKIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFSSLGAENIRGGNGKDGCNLVRTDNN
GILKGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATPHGTVRWTEDPNKVSIFKDVIRLFARFKEAKNAV
MTKIKTTVDELTKCIGQKEAELTNDQLYEEFIWETINRLELSKRVSEQPSLGEEEETILKSNYTAEPVRGPFTGA
GANTVAVQSSVSTAALCCSVLLFGVL 
 
>ACH41857 
MMKFWFVLLALLGKETHAYYENKRNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVM
RNRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGRSSQFCISVG
KHIPAEHGNLQECFDGIIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFNSLGAENIRGGNGRHGCNLVRTDTD
GVLEGGSVRRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNEV
MNKIKTTVDELAKCIGQKEVELTDDQLYEEFIWETIHRLELSKRVSEQLSLGEEEETILKSNYTAEPVRGPFTVA
GSNAAAVHLSVSTAALCFSVLLLGVL 
 
>ACH41860 
MRFLFVLLALLGKEIYAYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSIMRN
RVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGLAAGRLEEWIFVFAQAAGRSSQFCISTGKT
GPAEYNNLQECFDGTIGPETLYKIEDSRVKESAKKSLQLHEVLSSISFSSLGVKNIRGGNGKDRCNLVRTDTDGV
LEGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNAVMK
KIKTTVDELTKCIGQKEAELTNDQLYEEFIWETINRLELSKRVSEQSAFGEEEETIVKFNYTAEPVRGPFTVAGA
NAAAIHLSVSTAALCRSALLLGVL 
 
>ACH41862 
MRFLFVLLALLGKKTHAYYKNERNALNATAANKVCALSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMR
NRVPSGEQDCKDISTLLKTVLRNEFTFQQELEEMRNASALAAAAAGLAAGRLEEWIFVFAQAAGRSSQFCISVGK
TIPAEHGDLQECFDGTIGPETLYKIEDSRVKESAKKSLQLHEALSSISFSSLGVKNIRGGNGRDGCNLVRTDTNG
ILEGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFEDVIRLFARFQEAKNEVM
NKIKTTVDELAKCIGQKEVELTDDQLYEEFIWETIHRLELSKRVSEQPSLGEEEETILKSNYTAEPVRGPFTGAG
SNTVAVHLSVSTAALCRSALLLGVL 
 
>ACH41868 
MMRFWFVLLALLGKETYAYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMR
NRVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGLAAGRLEEWIFVFAQAAGGSSQFCISVGK
HIAAEHGNLQECFDGKIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFGSLGVKNIRGGNGRDGCNLVRTDTNG
ILNGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFEDVIRLFARFQEAKNAVM
RRIKTTVDELTKCIGQKEAELTNDQIYEEFIWETIHRLELSKRVSEQPSLGEEEETILKSNYTAEPVRGPFTGAG
SNTVAVHLSVSTAALCCLALLLGVL 
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>CAQ57275 (BES1) 
MMKFWFVLLALLGKETHAYYENKRNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVM
RNRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGGSSQFCISVG
TNIPAEYNNLQECFDGIIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFNSLGAENIRGGNGRDGCNLVRTDTD
GVLEGGSVRRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNEV
MNKIKTTVDELAKCIGQKEVELTDDQLYEEFIWETIHRLELSKRVSEQLSLGEEEETILKSNYTAEPVRGPFTVA
GSNTVAVHLSLFTAALCCSALLLGVL 
 
>CAQ57298 
MMKFWFVLLALLGKETHAYYENKRNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVM
RNRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGRSSQFCISVG
KHIPAEHGNLQECFDGIIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFNSLGAENIRGGNGRHGCNLVRTDTD
GVLEGGSVRRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNEV
MNKIKTTVDELAKCIGQKEVELTDDQLYEEFIWETIHRLELSKRVSEQLSLGEEEETILKSNYTAEPVRGPFTVA
GSNAAAVHLSVSTAALCFSVLLLGVL 
 
>CAQ57310 
MRFWFVLLALLGKEIYAYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMRN
RVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGLAAGRLEEWIFVFAQAADRSSQFCISVGKT
IPPEQNNLQECFDGTIGPETLYKIEDSRVKESAKKSLQLHEALSSISFNSLGAESIRGGNGKDGCNLVRTDTDGI
LNGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNAVMK
KIKTTVDELTKCIGQKEAELTNDQLYEEFIWETINRLELSKRVSEQSAFGEEEETIVKFNYTAEPVRGPFTVAGA
NAAAIHLSVSTAALCRSALLLGVL 
 
>CAQ57333 
MMKFWFVLLALLGKETHANYYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSV
MRNRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGGSSQFCISV
GTNIPAEYNNLQECFDGTIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFNSLGAENIRGGNGRDGCNLVRTDT
DGVLEGGSVRRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNE
VMNKIKTTVDELAKCIGQKEVELTDDQLYEEFIWETIHRLELSKRVSEQLSLGEEEETILKSNYTAEPVRGPFTG
AGSNKVAVHLSVSTAALCFSVLLLGVL 
 
>CAQ57361 
MMRFLFVLLALLGKETHAYYENKRNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVM
RNRVPSGEQDCKDIRTLLKTVLRNEFTFQQELKEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGGSSQFCISVG
TNIPAEYNNLQECFDGIIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFNSLGAENIRGGNGRDGCNLVRTDTD
GVLEGGSVRRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNEV
MNKIKTTVDELAKCIGQKEVELTNDQLYEEFIWETIHRLELSKRVSEQLSLGEEEETILKSNYTAEPVRGPFTVA
GSNTVAVHLSVSTAALCFSALLLGVL 
 
>CAQ57373 
MRFLFVLLALLGKETHANYYENERNALNATAANKVCALSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSIM
RNRVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEVRNASALAAAAAGLAAGRLEEWIFVFAQAGGRSSQFCISTG
KTGPAEYNNLQECFDGTIGPETLYKIEDSRVKESAKTRLLLHEVLSSISFSSLGAENIRGGNGKDGCNLVRTDNN
GILKGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNAV
MTKIKTTVDELTKCIGQKEAELTNDQLYEEFIWETINRLELSKRVSEQPSLGEEEETILKSNYTAEPVRGPFTGA
GANTVAVQSSVSTAALCCSALLLGVL 
 
>CAQ57403 
MRFLFVLLALLGKEIYAYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSIMRN
RVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGLAAGRLEEWIFVFAQAAGRSSQFCISTGKT
GPAEYNNLQECFDGTIGPETLYKIEDSRVKESAKKSLQLHEVLSSISFSSLGVKNIRGGNGKDRCNLVRTDTDGV
LEGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNAVMK
KIKTTVDELTKCIGQKEAELTNDQLYEEFIWETINRLELSKRVSEQSAFGEEEETIVKFNYTAEPVRGPFTVAGA
NAAAIHLSVSTAALCRSALLLGVL 
 
>CAQ57408 
MRFLFVLLALLGKETHANYYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVM
RNRVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGLAAGRLEEWIFVFAQAAGGSSQFCISVG
RTGPAEYNNLQECFNGKIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFSSLGAENIRGGNGKDGCNLVRTDNN
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GILKGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATPHGTVRWTEDPNKVSIFKDVIRLFARFKEAKNAV
MTKIKTSVDELTKCIGQKEAELTNDQLYEEFIWETINRLELSKRVSEQPSLGEEEETILKSNYTAEPVRGPFTGA
GANTVAVQSSVSTAALCCSVLLFGVL 
 
 
>CAQ57419 
MMRFWFVLLALLGKETYAYYENERNALNATAANKVCALSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVM
RNRVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAADGSSQFCISVG
RTGPAEYNNLQECFDGKIGPETLYKIEDSRVKESVQKSLQLHEVLSSISFGSLGVKNIRGGNGRDGCNLVRTDTN
GILNGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFEDVIRLFARFQEAKNAV
MRRIKTTADELTKCIGQKEAELTNDQIYEEFIWETIHRLELSKRVSEQPSLGEEEETILKSNYTAEPVRGPFTGA
GSNTVAVHLSVSTAALCCSVLLLGVL 
 
>CAQ57428 
MMRFWFVLLALLGKETYAYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMR
NRVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGLAAGRLEEWIFVFAQAAGGSSQFCISVGK
HIAAEHGNLQECFDGKIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFGSLGVKNIRGGNGRDGCNLVRTDTNG
ILNGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFEDVIRLFARFQEAKNAVM
RRIKTTVDELTKCIGQKEAELTNDQIYEEFIWETIHRLELSKRVSEQPSLGEEEETILKSNYTAEPVRGPFTGAG
SNTVAVHLSVSTAALCCLALLLGVL 
 
>CAQ57442 
MRFLFVLLALLGKKTHAYYKNERNALNATAANKVCALSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMR
NRVPSGEQDCKDISTLLKTVLRNEFTFQQELEEMRNASALAAAAAGLAAGRLEEWIFVFAQAAGRSSQFCISVGK
TIPAEHGDLQECFDGTIGPETLYKIEDSRVKESAKKSLQLHEALSSISFSSLGVKNIRGGNGRDGCNLVRTDTNG
ILEGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFEDVIRLFARFQEAKNEVM
NKIKTTVDELAKCIGQKEVELTDDQLYEEFIWETIHRLELSKRVSEQPSLGEEEETILKSNYTAEPVRGPFTGAG
SNTVAVHLSVSTAALCRSALLLGVL 
 
>CAQ57453 
MRFWFVLLAVLGKETYAYYENERNALNATAANKVCALSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMR
NRVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGRSSQFCISTGK
TGPAEYNNLQECFDGTIGPETLYKIEDSRVKESAKTRLLLHEVLLSISFGSLGAENIRGGNGKDGCNLVRTDNNG
ILKGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNAVM
KKIKTTVDELTKCIGQKEAELTNDQIYEEFIWETINRLELSKRVSEQPSLGEEEETILKSNYTAEPVRGPFTGAG
ANTVAVQSSVFTAALCCSALLLGVL 
 
>CAQ57480 
MRFWFVLLALLGKEIYAYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMRN
RVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGLAAGRLEEWIFVFAQAAGRSSQFCISVGKT
GPAEYNNLQECFDGTIGPETLYKIEDSRVKESAKTSLQLHEVLSSISFGSLGVKNIRGGNGKDGCNLVRTDTDGV
LEGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNAVVK
KIKTTVDELTKCIGQKEAELTNDQLYEEFIWETINRLELSKRVSEQSAFGEEEETIVKFNYTAEPVRGPFTVAGA
NAAAIHLSVSTAALCRSALLLGVL 
 
>CAD21457 (Bn2) 
MRFWFVLLALLGKEIYAYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMRN
RVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGLAAGRLEEWIFVFAQAAGRSSQFCISVGKT
GPAEYNNLQECFDGTIGPETLYKIEDSRVKESAKTSLQLHEVLSSISFGSLGVKNIRGGNGKDGCNLVRTDTDGV
LEGGSPTRHNLTWGGGVMNFGSYQNGSMYVEGGEYGDATEYGAVRWTEDPSKVSIFKDVIRLFARFQEAKNAVVK
KIKTTVDELTKCIGQKEAELTNDQLYEEFIWETINRLELSKRVSEQSAFGEEEETIVKFNYTAEPVRGPFTVAGA
NAAAIHLSVSTAALCRSALLLGVL 
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ESAG7 sequences: 
 
>CAQ57274 (BES1) 
MMKFWFVLLALLGKETHAYYENKRNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVM
RNRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGGSSQFCISVG
TNIPAEYNNLQECFDGIIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFSSLGAESIVEQRKNRGCNLMRTADG
GLLKDICLNCNFTWGGGVMNFGSCVAGNLKIKGGEYGDVSSHDVVRWTEDPSKVSIFKDVIRLFARFQEAKNAVM
NKIKTTVDELAKCIGQKEVELTNDQLYEEFEAIQKYLGSL 
 
>CAQ57296 
MMKFWFVLLALLGKETHAYYENKRNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVM
RNRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGGSSQFCISVG
KHIPAEHGNLQECFDGIIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFSSLGAESIVEQGENRGCNLMRTADG
GLLKDICLNCNFTWGGGVMNFGSCVAGNLKIKGGEYGDVSSHDVVRWTEDPSKVSIFKDVIRLFARFQEAKNAVM
NKIKTTVDELAKCIGQKEVELTNDQLYEEFEAIQKYLGSL 
 
>CAQ57297 
MMKFWFVLLALLGKETHAYYENKRNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVM
RNRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGGSSQFCISVG
KHIPAEHGNLQECFDGIIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFSSLGAESIVEQGENRGCNLMRTADG
GLLKDICLNCNFTWGGGVMNFGSCVAGNLKIKGGEYGDVSSHDVVRWTEDPSKVSIFKDVIRLFARFQEAKNAVM
NKIKTTVDELAKCIGQKEVELTNDQLYEEFEAIQKYLGSL 
 
>CAQ57309 
MRFWFVLLALLGKEIYAYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMRN
RVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAADGSSQFCISVGKH
IPPEHKNLQECFDGTIGPETLYKIEDSRVKESAKKSLQLHEALSSISFSSLGAESIVEQRKNRGCNLMRTAYGGL
LKDFCLNRNFTWGGGVMNFGSCVAGNLKIEGGEYGDVGSHDAVRWTEDPSKVSIFKDVIRLFARFQEVKNAVMKK
IKTTVDELTKCIGQKEAELTNDQLYEEFEAIQKYLWFL 
 
>CAQ57332 
MMKFWFVLLALLGKETHANYYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSV
MRNRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGGSSQFCISV
GTNIPAEYNNLQECFDGTIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFSSLGAESIVEQRKNRGCNLMRTAD
GGLLKDICLNCNFTWGGGVMNFGSCVAGNLKIKGGEYGDVSSHDVVRWTEDPSKVSIFKDVIRLFARFQEAKNAV
MNKIKTTVDELAKCIGQKEVELTNDQLYEEFEAIQKYLGSL 
 
>CAQ57345 
MMKFWFVLLALLGKETHANYYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSV
MRNRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGGSSQFCISV
GTNIPAEYNNLQECFDGTIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFSSLGAESIVEQRKNRGCNLMRTAD
GGLLKDICLNCNFTWGGGVMNFGSCVAGNLKIKGGEYGDVSSHDVVRWTEDPSKVSIFKDVIRLFARFEEAKNAV
MNKIKTTVDELAKCIGQKEVELTNDQLYEEFEAIQKYLGSL 
 
>CAQ57346 
MMKFWFVLLALLGKETHANYYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSV
MRNRVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGGSSQFCISV
GTNIPAEYNNLQECFDGTIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFSSLGAESIVEQRKNRGCNLMRTAD
GGLLKDICLNCNFTWGGGVMNFGSCVAGNLKIKGGEYGDVSSHDVVRWTEDPSKVSIFKDVIRLFARFQEAKNAV
MNKIKTTVDELAKCIGQKEVELTNDQLYEEFEAIQKYLGSL 
 
>CAQ57360 
MMRFLFVLLALLGKETHAYYENKRNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVM
RNRVPSGEQDCKDIRTLLKTVLRNEFTFQQELKEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGGSSQFCISVG
TNIPAEYNNLQECFDGTIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFSSLGAESIVEQRKNRGCNLMRTADG
GLLKDICLNCNFTWGGGVMNFGSCVAGNLKIKGGEYGDVSSHDVVRWTEDPSKVSIFKDVIRLFARFQEAKNAVM
NKIKTTVDELAKCIGQKEVELTNDQLYEEFEAIQKYLGSL 
 
 
 
 
 156 
 
>CAQ57402 
MRFWFVLLALLGKEIYAYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSIMRN
RVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAADRSSQFCISVGKH
IAAEHGNLQECFDGTIGPETLYKIEDSRVKESAKKSLQLHEALSSISFSSLGAESIIERNEDRGCNLMRTADGGL
LKDVCLNRNFTWGGGVLNFGYCVAGNLKIKGGEYGDVGSHDAVRWTEDPSKVSIFKDVIRLFARFQEAKNAVMKK
IKTTVDELTKCIGQKEAELTNDQIYEEFEAIQKYLGFL 
 
>CAQ57407 
MMRFWFVLLALLGKETYAYYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVM
RNRVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAADMTSQFCISVG
KNIPAEHKNLQECFNGKIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFSSLGAESIVERRENRGCNLMRTGRG
GLLKDVCLNRNFTWGGGVMNFGSCVAGNLKIKGGEYDDVSSHDEVRWTEDPSKVSIFKDVIRLFARFKEAKNAVM
KKIKTTVDELTKCIGQKEAELTNDQLYEEFEAIQKYLGFGKME 
 
>CAQ57420 
MMRFWFVLLALLGKETYAYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMR
NRVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGLAAGRLEEWIFVFAQAADRSSQFCISVGK
TIPAEHGDLQECFDGKIGPETLYKIEDSRVKESAKKSLQLHEALSSISFSSLGAENIVEQRKNRGCNLMRTAYGG
LLKDVCLNRNFTWGGGVMNFRSCVAGNLKIEGGEYGDVGSHDAVRWTEDPSKVSIFKDVIRLFARFQEAKNAVMK
KIKTTVDELTKCIGQKEAELTNDQLYEEFEAIQKYLGFL 
 
>CAQ57429 
MMRFWFVLLALLGKKTHAYYENERNALNATAANKVCGLSTYLKGVAHRVNSESAVVTEKLSDLKMRSIQLQLSVM
RNRVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGLAAGRLEEWIFVFAQAADRSSQFCISVG
KHIAAEHGNLQECFDGTIGPETLYKIEDSRVKESAQKSLQLHEALSSISFSSLGAENIVEKGENRGCNLMRTAYG
GLLEGICLNRNFTWGGGVMNFGSCVAGNLEIKGGEYGDVSSHDAVRWTEDPSKVSIFKDVIRLFARFQEAKNAVM
RRIKTTVDELTKCIGKKEAELTNDQIYEEFEAIQKYLGFL 
 
>CAQ57441 
MRFLFVLLALLGKKTHAYYKNERNALNATAANKVCALSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMR
NRVPSGEQDCKDISTLLKTVLRNEFTFQQELEEMRNASALAAAAAGLAAGRLEEWIFVFAQAADRSSQFCISVGK
HIAAEHGDLQECFDGTIGPETLYKIEDSRVKESAKKSLQLHEALSSISFSSLGAENIVEKGENRGCNLMRTADEG
LLKDVCLNRNFTWGGGVLNFGYCVAGNLKIKGGEYGDVGSHDAVRWTEDPSKVSIFKDVIRLFARFQEAKNEVMN
KIKTTVDELAKCIGQKEVELTDDQLYEEFEAIQKYLGFL 
 
>CAQ57452 
MRFWFVLLALLGKETHAYYYENKRNALNATAANKVCALSTYLKGIAHRVNSESAVVTEKISDLKMRSIQLQLSIM
RNRVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGRSSQFCISVG
KTIPAEHGDLQECFDGTIGPETLYKIEDSRVKESAKKSLQLHEALSSISFSSLGAENIVEKGENRGCNLMRTADE
GLLKDVCLNRNFTWGGGVMNFGYCVAGNLKIKGGEYGDVSSHDAVRWTEDPSKVSIFKDVIRLFARFQEAKNAVM
TKIKTTVDELTKCIGQKEAELTNDQIYEEFEAIQKYLGFL 
 
>CAQ57467 
MRFWFVLLALLGKEIYAYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSIMRN
RVPSGEKDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGMSSQFCISVGKT
IPAEHGDLQECFDGTIGPETLYKIEDSRVKESAKKSLQLHEALSSISFSSLGAESIVEKGENRGCNLMRTADGGL
LKDVCLNRNFTWGGGVLNFGYCVAGNLKIKGGEYGDVGSHDAVRWTEDPSKVSIFKDVIRLFARFQEVKNAVVKK
IKTTVDELTKCIGQKEAELTNDQLYEEFEVIQKYLWFL 
 
>CAD21456 (Bn2) 
MRFWFVLLALLGKEIYAYENERNALNATAANKVCGLSTYLKGIAHRVNSESAVVTEKLSDLKMRSIQLQLSVMRN
RVPSGEQDCKDIRTLLKTVLRNEFTFQQELEEMRNASALAAAAAGIAAGRLEEWIFVFAQAAGGSSQFCISVGTN
IPAEYNNLQECFDGTIGPETLYKIEDSRVKESAQKSLQLHEVLSSISFSSLGAESIVEKGENRGCNLMRTADGGL
LKDVCLNRNFTWGGGVLNFGYCVAGNLKIKGGEYGDVGSHDAVRWTEDPSKVSIFKDVIRLFARFQEVKNAVVKK
IKTTVDELTKCIGQKEAELTNDQLYEEFEVIQKYLWFL 
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Appendix 5: Size exclusion high performance liquid chromatography. Elution 
profiles of Bn2 ESAG6/6 homodimers (Bn2 6/6) (Mr = 87,000) and ESAG7/7 (Mr = 74,000) 
homodimers (Bn2 7/7) were investigated separately. Incubation of ESAG6 with ESAG7 (Bn2 
6/6 + 7/7) (Mr = 81,000) did not result in the formation of a novel peak indicating the formation 
of heterodimers. 
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Appendix 6: Data collection and refinement statistics for crystal structures. 
Data collection Non-glycosylated TfR Glycosylated TfR  
Space group 
C121 C121  
Cell dimensions    
    a, b, c (Å) 163.49, 108.11, 115.00 128.18, 117.87,134.55  
    α, β, γ () 90.0, 128.74, 90.0 90.0, 111.5, 90.0  
Wavelength (Å) 
1.000 1.000  
Resolution (Å) 46.3 – 2.75 (2.80 - 2.75) 39.6 – 34.2 (3.48 – 3.42)  
Total Observations 134161 (7123) 83799 (4432)  
Total Unique 40238 (2045) 25075 (1291)  
Rpim (%) 
6.0 (62.8) 3.3 (67.3)  
Rmerge (%) 
9.3 (99.9) 4.9 (116.3)  
Rmeas (%) 
11.1 (118.3) 5.9 (126.2)  
CC1/2 
0.991 (0.553) 0.988 (0.692)  
I/(I) 
9.1 (1.2) 11.6 (1.1)  
Completeness (%) 
98.9 (99.8) 99.0 (99.5  
Multiplicity 3.3 (3.5) 
3.3 (3.4)  
Wilson B factor (Å2) 59.95 
152.06  
    
Refinement    
Reflections 
38216 25066  
Rwork / Rfree 
18.3/23.3 21.1/24.1  
Number of residues    
    Protein 
    Sugar 
    Fe(III) 
    water 
1288 
0 
1 
38 
1288 
12 
1 
0 
 
 
R.M.S. deviations    
    Bond lengths (Å) 0.01 0.01  
    Bond angles () 1.21 1.22  
Ramachandran plot 
   
    Favoured (%) 
93.6% 94.4%  
    Allowed (%) 
6.3% 5.5%  
    Outliers (%) 
0.1% 0.1%  
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Appendix 7: Alignment of eight mammalian TfRs. 
 
mouse       MMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNSHVEMKLAADEEENADNNMKAS---VR 57 
rat         MMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNSHVEMKLAADEEENADSNMKAS---VR 57 
pig         MMDQARSAFSSLFGGEPLSYTRFSLARQVDGDNSHVEMKLAADEEENVDSNTRSNHIGVA 60 
cow         MMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNSHVEMKLAADEEENVDSNMRGNQTSIA 60 
goat        MMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNSHVEMKLAADEEENVDSNMRGNQTSIT 60 
horse       -MDQARSAFSNLFGGAPLSYTRFSLARQVDGDNSHVEMKLAVDEEENVDNNVRSNHASLT 59 
human       MMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNSHVEMKLAVDEEENADNNTKAN---VT 57 
rabbit      MMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNSHVEMKLAVDEEENVENNVRAN---VA 57 
             *********.**** *************************.*****.:.* :..   :  
 
mouse       KPKRFNGRLCFAAIALVIFFLIGFMSGYLGYCKRVEQKEECVKLAETEETDKSE--TMET 115 
rat         KPKRFNGRLCFATIAVVIFFLIGFMIGYLGYCKRVEQKEECVRLAEAEEADKSE--NDET 115 
pig         KPKRLNGYVCYGIIAVITFFLIGFMIGYLAYCKRVESKTDCKTLVPTEPSETEETETFEA 120 
cow         KPKRLNGYVCYGIIAVIVFFLIGFMIGYLGYCRRVES-QDCGKEAGTQPSCPEETETFES 119 
goat        KPKRLNGYICYGIIAVIIFFLIGFMIGYLGYCKRVEPQGDCGKEAGTQPSCPEETEAFEP 120 
horse       KPKRFNGSFCYAVIAVIIFFLIGFMIGYLGYCKRVEPKSECGRSGDSKEIE--GTEPPET 117 
human       KPKRCSGSICYGTIAVIVFFLIGFMIGYLGYCKGVEPKTECERLAGT-ESP--VR--EEP 112 
rabbit      KPKRCNGTLCYAMVAIIIFFLIGFMIGYLGNCKRVEQKAECESVAGT-EVE--QSENAEP 114 
            **** .* .*:. :*:: ******* ***. *: **   :*     :           *  
 
mouse       -EDVPT-SSRLYWADLKTLLSEKLNSIEFADTIKQLSQNTYTPREAGSQKDESLAYYIEN 173 
rat         -EYVPK-SSRLFWADLKTLLSEKLNSIEFTDIIKQLSQNTYTPREAGSQKDENLAYYIEN 173 
pig         E-NFPQ-TPRLFWADLKILLSKGLDTTDFTRTIKMLNE-DYAPREAGSQKDESLGFFIEN 177 
cow         EEQLPG-VPRIFWADLKSTLSGKLDAVDFARAIKMLNENSYVPREAGSEKDTSLAFFIEN 178 
goat        EEQLPG-VPRIFWADLKSTLSDRLDAVDFTRAIKMLNENSYVPREAGSQKDSSLAFYIES 179 
horse       EEYFPETPSRLLWTDLRTMLSERLTATEFTNTIKRLNGNSYVPREAGSQKDESLAFFIEN 177 
human       GEDFPA-ARRLYWDDLKRKLSEKLDSTDFTGTIKLLNENSYVPREAGSQKDENLALYVEN 171 
rabbit      EEDLPVIPPRLYWEDLRTMLSEKLDTTDFTSTIRQLNENSYIPREAGSQNDENLASFVEN 174 
               .*    *: * **:  **  * : :*:  *: *.   * ******::* .*. ::*. 
 
mouse       QFHEFKFSKVWRDEHYVKIQVKSSIGQNMVTIVQS--NGNLDPVESPEGYVAFSKPTEVS 231 
rat         LFHDFKFSKVWRDEHYVKIQVKNSVSQNLVTI-NS--GSNIDPVEAPEGYVAFSKAGEVT 230 
pig         QFREFKLSKVWHDEHFVKIQVKGSNAENSVTLVNTDSNSLVYPVESPEGYVAYSKATTVT 237 
cow         QLQDCKLGKVWHDEHFIKIQVKGSSQNSVSIVSTSGNGSQAYPVESPEGYVAYSKAATVT 238 
goat        QLRDYKLDKVWHDEHFVKIQVKGSSQNSVSIVSTSGDGSQAYSVENPEGYVAYSKAATVT 239 
horse       QFREFKLNKVWRDEHFVKIQVKGSNAQSSVTVVN-GSGDMISLVENPTGYVAYSKATTVT 236 
human       QFREFKLSKVWRDQHFVKIQVKDSA-QNSVIIVD-KNGRLVYLVENPGGYVAYSKAATVT 229 
rabbit      KFRDFKLSKVWHDEHFVKIQVKDSA-QNSVIIVN-KNSEAPDLVENPMGYVAYSKATTVT 232 
             ::: *:.***:*:*::*****.*  :.   :     .     ** * ****:**   *: 
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mouse       GKLVHANFGTKKDFEELSYSVNGSLVIVRAGEITFAEKVANAQSFNAIGVLIYMDKNKFP 291 
rat         GKLVHANFGTKKDFEELNYSVNGSLVIVRAGKITFAEKVANAQSFNAIGVLIYMDRNTFP 290 
pig         GKLIFANFGTKKDFEDLKMPVNGSLVIVRAGKITFAEKVANAQSLDAIGVLIYMDRANFP 297 
cow         GKLVHANFGTKQDFEDLNMPVNGSLVIVRAGKISFAEKVANAESLNAIGVLIYMDYSKYP 298 
goat        GKLVHANFGTKQDFEDLNMPVNGSLVIVRAGKITFAEKVANAERLNAIGVLIYMDHSKFP 299 
horse       GKLVHANFGTKEDYEALSYPVNGSLVIVRAGEITFAQKVANAESLNAVGVLIYMDQAKFP 296 
human       GKLVHANFGTKKDFEDLYTPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFP 289 
rabbit      GKLIHANFGTKKDFEDLNSPVNGSIVIVRAGEITFAEKVANAESLNAIGMLIYMDQMKFP 292 
            ***:.******:*:* *   ****:******:*:**:*****: ::*:*:*****  .:* 
 
mouse       VVEADLALFGHAHLGTGDPYTPGFPSFNHTQFPPSQSSGLPNIPVQTISRAAAEKLFGKM 351 
rat         VVEADLQFFGHAHLGTGDPYTPGFPSFNHTQFPPSQSSGLPSIPVQTISRAAAEKLFKNM 350 
pig         IINADVPVFGHAHLGTGDPYTPGFPSFNHTQFPPSQSSGLPNIPVQTISRAGAEKLFGNM 357 
cow         IVNANLPVFGHAHLGTGDPYTPGFPSFNHTQFPPSQSSGLPNIPVQTITRAGAEKLFQNM 358 
goat        IVNANLPVFGHAHLGTGDPYTPGFPSFNHTQFPPSQSSGLPNIPVQTISRAGAERLFQNM 359 
horse       IVNANLPVFGHAHLGTGDPYTPGFPSFNHTQFPPSQSSGLPNIPVQTISRAAAEALFANM 356 
human       IVNAELSFFGHAHLGTGDPYTPGFPSFNHTQFPPSRSSGLPNIPVQTISRAAAEKLFGNM 349 
rabbit      IVKADLPLFGHAHLGTGDPYTPGFPSFNHTQFPPSQSSGLPNIPVQTISREAAEKLFGNM 352 
            :::*:: .***************************:*****.******:* .** ** :* 
 
mouse       EGSCPARWNIDSSCKLELSQNQNVKLIVKNVLKERRILNIFGVIKGYEEPDRYVVVGAQR 411 
rat         EGNCPPSWNIDSSCKLELSQNQNVKLTVNNVLKETRILNIFGVIKGYEEPDRYIVVGAQR 410 
pig         EQDCPLTWRTDFPCKLVSSPSKNVKLTVNNVLKEIKILNIFGVIKGFEEPDRYVIVGAQR 417 
cow         EGDCPRIWGTDSSCKLVSSQDKNVKLSVNNVLKEIRILNVFGVIKGFEEPDRYVIVGAQR 418 
goat        QGDCPSTWGTDSSCKLVSSQDKNVKLSVNNVLKEIRIFNVFGVIKGFEELDRYIIVGAQR 419 
horse       KGDCPSSWKTDSSCRLEFPGDKNVKLTVNNELKEIRIFNVFGVIKGFEEPDRYVVIGAQR 416 
human       EGDCPSDWKTDSTCRMVTSESKNVKLTVSNVLKEIKILNIFGVIKGFVEPDHYVVVGAQR 409 
rabbit      EGACPSEWQTDSTCRLQSSQNKNVKLTVNNVLKEARILNVFGVIKGFEEPDRYIVVGAQR 412 
            :  **  *  *  *::    .:**** *.* *** :*:*:******: * *:*:::**** 
 
mouse       DALGAGVAAKSSVGTGLLLKLAQVFSDMISKDGFRPSRSIIFASWTAGDFGAVGATEWLE 471 
rat         DAWGPGVA-KSSVGTGLLLKLAQVFSDMISKDGFRPSRSIIFASWTAGDYGAVGATEWLE 469 
pig         DAWGPGA-AKSSVGTSLLLNLAQILSDMVIKGQFKPSRSIVFASWSAGDFGAIGATEWLE 476 
cow         DAWGPGA-AKSSVGTSLLLTLARILSDMVLKGQFKPSRSIVFASWSGGDFGAVGATEWLE 477 
goat        DAWGPGA-AKSSVGTSLLLTLARILSDMVLKGQFKPSRSIVFASWSGGDFGAVGATEWLE 478 
horse       DAWGPGA-AKSSVGTALLLELARIFSDMVSKGGFKPSRSIVFASWGAGDFGAIGATEWLE 475 
human       DAWGPGA-AKSGVGTALLLKLAQMFSDMVLKDGFQPSRSIIFASWSAGDFGSVGATEWLE 468 
rabbit      DAWGPGA-AKSSVGTALLLELARMFSDMVLKGGFKPSRSIIFASWSAGDFGAIGATEWLE 471 
            ** * *.  **.***.*** **:::***: *. *:*****:**** .**:*::******* 
 
mouse       GYLSSLHLKAFTYINLDKVVLGTSNFKVSASPLLYTLMGKIMQDVKHPVDGKSLYRDSNW 531 
rat         GYLSSLHLKAFTYINLDKVVLGTSNFKVSASPLLYTLMGKIMQDVKHPIDGKYLYRDSNW 529 
pig         GYLSSLHLKAFTYINLDKAVLGTSNFKVSASPLLYSLIEKMMQDVKNPVTGQSLYRDSNW 536 
cow         GYLSSLHLKAFTYINLDKAVVGTTNFKVSASPLLYSLIEKIMKDVKHPLNGLSLYRDSNW 537 
goat        GYLSSLHLKAFTYINLDKAVVGTTNFKVSASPLLYSLIEKIMKDVKHPLTGLSLYRDSNW 538 
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horse       GYLSSLHLKAFTYINLDKAVLGAKNFKVSASPLLYSLIEKTMQEVKHPVTGLSLYRDSNW 535 
human       GYLSSLHLKAFTYINLDKAVLGTSNFKVSASPLLYTLIEKTMQNVKHPVTGQFLYQDSNW 528 
rabbit      GYLSSLHLKAFTYINLDKAVLGTTNFKVSASPLLYKLIEKTMQDVKHPVTGMSLYQDSNW 531 
            ******************.*:*:.***********.*: * *::**:*: *  **:**** 
 
mouse       ISKVEKLSFDNAAYPFLAYSGIPAVSFCFCEDADYPYLGTRLDTYEALTQKVPQLNQMVR 591 
rat         ISKIEELSLDNAAFPFLAYSGIPAVSFCFCEDEDYPYLGTKLDTYEILIQKVPQLNQMVR 589 
pig         INKVEKLSFDDAAFPFLAYSGIPAVSFCFCEDTDYPYLGTTMDTYDVLSKRVPQLNRMAR 596 
cow         ISKVQKLSLDNAAFPFLAYSGIPAVSFCFCEDTDYPYLGTPMDTYETLNREVPQLNRVAR 597 
goat        ISKVKKLSLDNAAFPFLAYSGIPAVSFCFCEDTDYPYLDTPMDTYETLNGQVPQLNRVAR 598 
horse       INKVEKLSFDNAAFPFLAYSGIPALSFCFCEDTEYPYLGTTMDTYEVLSQNVPELSRLTR 595 
human       ASKVEKLTLDNAAFPFLAYSGIPAVSFCFCEDTDYPYLGTTMDTYKELIERIPELNKVAR 588 
rabbit      VNKVEKLSFDNAAFPFLADSGIPSLSFWFCEDTDYPYLGTTFDTYGMLIQKIPQLNKMAR 591 
             .*:::*::*:**:**** ****::** **** :****.* :***  *  .:*:*.::.* 
 
mouse       TAAEVAGQLIIKLTHDVELNLDYEMYNSKLLSFMKDLNQFKTDIRDMGLSLQWLYSARGD 651 
rat         TAAEVAGQFIIKLTHDIELTLDYEMYNSKLLSFMKDLNQFKADIKDMGLSLQWLYSARGD 649 
pig         AAAEVAGHLVIKLTIDFELNLNYEMYNDKILSFVREMNQFRVDIREMGLSLQWLYSARGD 656 
cow         AAAEVAGQLVIKLTHGVELNLNYEMYNDEILRFVKEMNLFRADIRDMGLNMQWLYSARGD 657 
goat        AAAEVAGQLVMKLTHGVELDLNYEMYNDEILRFVKEMNLFRADIRDMGLNMQWLYSARGD 658 
horse       AAAEVAGQLLIKLSYDVELNLNYDMYNDKILSFVKDMNQFRADIKEMGLNLQWLYSARGD 655 
human       AAAEVAGQFVIKLTHDVELNLDYERYNSQLLSFVRDLNQYRADIKEMGLSLQWLYSARGD 648 
rabbit      AAAEVAGQFMIKLTHDAELNLDYEMYNNKILSFVRELNQYRAYIKELGLNLQWLYSARGD 651 
            :******::::**: . ** *:*: **.::* *::::* ::. *:::**.:********* 
 
mouse       YFRATSRLTTDFHNAEKTNRFVMREINDRIMKVEYHFLSPYVSPRESPFRHIFWGSGSHT 711 
rat         YFRATSRLTTDFHNAEKTNRFVMREINDRIMKVEYHFLSPYVSPRESPFRHIFWGSGSHT 709 
pig         FFRATSRLTSDYRNVETRDKFVMREINDRIMKVEYHFLSPYVSPRESPFRHIFWGSGSHT 716 
cow         FFRATSRLTTDYKNAEKTDRSVMREINDRIMKVEYHLLSPYVSPREFPFRHIFWGSGSHT 717 
goat        FFRATSRLTTDYKNAEKTDRSVMREINDRIMKVEYHLLSPYVSPREFPFRHIFWGSGSHT 718 
horse       FFRATSRLTTDYKNAERANRVVMREINDRIMKVEYHFLSPYVSPRESPFRHIFWGSGSHT 715 
human       FFRATSRLTTDFGNAEKTDRFVMKKLNDRVMRVEYHFLSPYVSPKESPFRHVFWGSGSHT 708 
rabbit      FFRATSRLTTDFKNAEITNRFVMREINDRIMKVEYHFLSPYVSPRESPFRHIFWGSGSHT 711 
            :********:*: *.*  :: **:::***:*:****:*******:* ****:******** 
 
mouse       LSALVENLKLRQKNITAFNETLFRNQLALATWTIQGVANALSGDIWNIDNEF 763 
rat         LSALVENLRLRQKNITAFNETLFRNQLALATWTIQGVANALSGDIWNIDNEF 761 
pig         LSALVEHLKLRQKNSSAFNQTLLKNQLALATWTIQGAANALSGDIWDIDNEF 768 
cow         LSALLEHLKLRKKNNGAFNQTLLENQLALATWTIQGAANALSGDIWDIDNEF 769 
goat        LSALLEHLKLRKKLNGAFNQTLLENQLALATWTIQGAANALSGDIWDIDNEF 770 
horse       LSALLEHLKLRQKNSGAFNETLLRNQLALATWTIQGAANALSGDIWDIDNEF 767 
human       LPALLENLKLRKQNNGAFNETLFRNQLALATWTIQGAANALSGDVWDIDNEF 760 
rabbit      LSALLENLNLRQKNNGAFNETLLRNQLALATWTIQGAANALSGDIWDIDNEF 763 
            * **:*:*.**::   ***:**:.************.*******:*:***** 
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Appendix 8: Biolayer interferometry measurement of binding between BES1-TfR 
and bovine Tf. Biotinylated BES1-TfR was immobilised on a streptavidin biosensor and 
binding of bovine Tf was measured for different iron states and at different pH values. 
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Appendix 9: Quantification of elements present in Tf and TfR-Tf complex at 
different pH by microPIXE. The photon emissions associated with each element (sulphur, 
chloride, potassium and iron) were measured and counts per channel were plotted. Sulphur 
measurements were used in conjunction with the number of sulphurs present in the protein 
sequence to extrapolate the quantity of iron. 
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Appendix 10: Measurement of bovine anti-Tf antibody sensitivity. Serial dilution of 
FCS was performed to test the detection limit of the antibody by western blot, with estimated 
concentrations reported above each lane in nM. The Tf-depleted serum sample (S) was also 
analysed by western blot. 
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Appendix 11: Alignment of bovine lactoferrin and transferrin protein 
sequences. 
 
 
Identity:     403/693 (58.2%) 
Similarity:   515/693 (74.3%) 
 
lactoferrin        1 --------CTISQPEWFKCRRWQWRMKKL--GAPSITCVRRAFALECIRA     40 
                             ||||..|..||..::..:.::  ..|.::||::...::||:| 
transferrin        1 DPERTVRWCTISTHEANKCASFRENVLRILESGPFVSCVKKTSHMDCIKA     50 
 
lactoferrin       41 IAEKKADAVTLDGGMVFEACRDPYKLRPVAAEIYGTKESPQTHYYAVAVV     90 
                     |:..:|||||||||:|:||...|..|:||.||.:|||::||||||||||| 
transferrin       51 ISNNEADAVTLDGGLVYEAGLKPNNLKPVVAEFHGTKDNPQTHYYAVAVV    100 
 
lactoferrin       91 KKGSNFQLDQLQGRKSCHTGLGRSAGWIIPMGILRPYLSWTESLEPLQGA    140 
                     ||.::|:|::|:|:|||||||||||||.|||..|  |....:..|.:|.| 
transferrin      101 KKDTDFKLNELRGKKSCHTGLGRSAGWNIPMAKL--YKELPDPQESIQRA    148 
 
lactoferrin      141 VAKFFSASCVPCIDRQAYPNLCQLCKGEGENQCACSSREPYFGYSGAFKC    190 
                     .|.|||||||||.|:.::|.|||||.|:|.::||||:.|||||||||||| 
transferrin      149 AANFFSASCVPCADQSSFPKLCQLCAGKGTDKCACSNHEPYFGYSGAFKC    198 
 
lactoferrin      191 LQDGAGDVAFVKETTVFENLPEKADRDQYELLCLNNSRAPVDAFKECHLA    240 
                     |.:|||||||||.:|||:|||...||..|||||.:|:|..||.::||:|| 
transferrin      199 LMEGAGDVAFVKHSTVFDNLPNPEDRKNYELLCGDNTRKSVDDYQECYLA    248 
 
lactoferrin      241 QVPSHAVVARSVDGKEDLIWKLLSKAQEKFGKNKSRSFQLFGSPPGQRDL    290 
                     .|||||||||:|.||||:||:||:.|||.|||:|..:||||.||.| :|| 
transferrin      249 MVPSHAVVARTVGGKEDVIWELLNHAQEHFGKDKPDNFQLFQSPHG-KDL    297 
 
lactoferrin      291 LFKDSALGFLRIPSKVDSALYLGSRYLTTLKNLRETAEEVKAR-YTRVVW    339 
                     ||||||.|||:||||:|..||||..|:|.|:||||:.....:: ...|.| 
transferrin      298 LFKDSADGFLKIPSKMDFELYLGYEYVTALQNLRESKPPDSSKDECMVKW    347 
 
lactoferrin      340 CAVGPEEQKKCQQWSQQSGQNVTCATASTTDDCIVLVLKGEADALNLDGG    389 
                     ||:|.:|:.||.:||..||..:.|.||..|::||..::||||||::|||| 
transferrin      348 CAIGHQERTKCDRWSGFSGGAIECETAENTEECIAKIMKGEADAMSLDGG    397 
 
lactoferrin      390 YIYTAGKCGLVPVLAENRKSSKHSSLDCVLRPTEGYLAVAVVKKANEGLT    439 
                     |:|.|||||||||||||.|:...|   |...|.:|||||||||.::..:. 
transferrin      398 YLYIAGKCGLVPVLAENYKTEGES---CKNTPEKGYLAVAVVKTSDANIN    444 
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lactoferrin      440 WNSLKDKKSCHTAVDRTAGWNIPMGLIVNQTGSCAFDEFFSQSCAPGADP    489 
                     ||:|||||||||||||||||||||||:.::..:|.||||||..||||:.. 
transferrin      445 WNNLKDKKSCHTAVDRTAGWNIPMGLLYSKINNCKFDEFFSAGCAPGSPR    494 
 
lactoferrin      490 KSRLCALCAGDDQGLDK-CVPNSKEKYYGYTGAFRCLAEDVGDVAFVKND    538 
                     .|.|||||.|.::|..| |||||.|:|||||||||||.|. |||||||:. 
transferrin      495 NSSLCALCIGSEKGTGKECVPNSNERYYGYTGAFRCLVEK-GDVAFVKDQ    543 
 
lactoferrin      539 TVWENTNGESTADWAKNLNREDFRLLCLDGTRKPVTEAQSCHLAVAPNHA    588 
                     ||.:||:|.:...|||||.:|:|.:||.||||||||:|::||||..|||| 
transferrin      544 TVIQNTDGNNNEAWAKNLKKENFEVLCKDGTRKPVTDAENCHLARGPNHA    593 
 
lactoferrin      589 VVSRSDRAAHVKQVLLHQQALFGKNGKNCPDKFCLFKSETKNLLFNDNTE    638 
                     ||||.|:|..|:::|..||..|||:..:|...||||:|.:|:|||.|:|: 
transferrin      594 VVSRKDKATCVEKILNKQQDDFGKSVTDCTSNFCLFQSNSKDLLFRDDTK    643 
 
lactoferrin      639 CLAKLGGRPTYEEYLGTEYVTAIANLKKCSTSPLLEACAFLTR    681 
                     |||.: .:.||:.|||.:||.|:.||::||||.|||||.|... 
transferrin      644 CLASI-AKKTYDSYLGDDYVRAMTNLRQCSTSKLLEACTFHKP    685 
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Appendix 12: List of primer sequences (5’-3’) used in this project. 
 
Primers used for sequencing the mammalian expression vector (pDest12) and the scFv used 
for phage display.  
pDest12 forward GCTGCCTCTGCTGTGGGCTG 
pDest12 reverse GTCACACCACAGAAGTAAGG 
scFv forward GATTACGCCAAGCTTTGGAGC 
scFv reverse CTCTTCTGAGATGAGTTTTTG 
 
 
Primers used to add an N-terminal TEV protease site to Bn2 ESAG6 and remove affinity tags 
from Bn2 ESAG7. Primers for multi site-directed mutagenesis to convert N-linked glycosylation 
sites to aspartic acid are also listed. Fw = forward and Rv = reverse.  
Bn2 ESAG6 N-
terminal TEV Fw 
GCACGCTAGCGAGAACCTCTATTTCCAAGGGTCTGGCTACGAGAACGAGAGAAACGC 
Bn2 ESAG6 C-
terminal stop Rv 
GCACGCTAGCTTATCAGGCGCCAGCCACTGTAAAAG 
 
Bn2 ESAG7 Fw GCACGCGGCCGCATACGAGAACGAG 
 
Bn2 ESAG7 C-
terminal stop Rv 
GCACGCTAGCTTATCAGCTGCCCAGGAACCACAGG 
 
Bn2 N26D Fw GAACGCCCTGGATGCCACCGCCGCCAACAAAG 
 
Bn2 N110D Fw GGAACTGGAAGAGATGAGAGACGCCAGCGCCCTGGCC 
 
Bn2 ESAG6 
N235D Fw 
GCAGCCCCACAAGACACGACCTGACATGGGGCGG 
 
Bn2 ESAG7 
N234D Fw 
GGACGTGTGCCTGAACCGGGACTTCACCTGGGGAGG 
 
Bn2 ESAG6 
N250D Fw 
GGCAGCTACCAGGACGGCTCTATGTACGTGGAAGGGGGCG 
 
Bn2 ESAG6 
N360D Fw 
GGAAGAGACAATCGTGAAGTTCGACTACACCGCCGAGCCCGTG 
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Primers for site-directed mutagenesis in BES1-TfR. Residues are numbered according to the 
crystal structure (Bn2-TfR). 
BES1 ESAG6 G139R forward CGTGTTCGCCCAGGCCGCAGGCCGCAGCTCCCAGTTCTGTATCAGC 
BES1 ESAG6 G139R reverse GCTGATACAGAACTGGGAGCTGCGGCCTGCGGCCTGGGCGAACACG 
BES1 ESAG7 S246Y forward GGAGGCGTGATGAACTTCGGCTATTGCGTGGCCGGCAATCTGAAG 
BES1 ESAG7 S246Y reverse CTTCAGATTGCCGGCCACGCAATAGCCGAAGTTCATCACGCCTCC 
BES1 ESAG7 I229V forward GATGGCGGCCTGCTGAAGGACGTCTGCCTGAACTGCAACTTCACC 
BES1 ESAG7 I229V reverse GGTGAAGTTGCAGTTCAGGCAGACGTCCTTCAGCAGGCCGCCATC 
BES1 ESAG7 C233R forward CTGCTGAAGGACGTCTGCCTGAACCGCAACTTCACCTGGGGCGG 
BES1 ESAG7 C233R reverse CCGCCCCAGGTGAAGTTGCGGTTCAGGCAGACGTCCTTCAGCAG 
 
 
Primers used for BES1-TfR RT-PCR. 
BES1 ESAG6 ESAG7 forward CACTCTTGAAAACAGTATTG 
BES1 ESAG6 reverse TCTCTTTGACAGCTCCAATC 
BES1 ESAG7 reverse TAGYACTTTTGTATTGCCTC 
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